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Preface
The Health Systems in Transition (HiT) series consists of country-based reviews that provide a detailed description of a health system and of reform and policy initiatives in progress or under development in a 
specific country. Each review is produced by country experts in collaboration 
with the Observatory’s staff. In order to facilitate comparisons between 
countries, reviews are based on a template, which is revised periodically. The 
template provides detailed guidelines and specific questions, definitions and 
examples needed to compile a report.
HiTs seek to provide relevant information to support policy-makers and 
analysts in the development of health systems in Europe. They are building 
blocks that can be used to:
• learn in detail about different approaches to the organization, financing 
and delivery of health services and the role of the main actors in 
health systems;
• describe the institutional framework, process, content and implementation 
of health care reform programmes;
• highlight challenges and areas that require more in-depth analysis;
• provide a tool for the dissemination of information on health systems and 
the exchange of experiences of reform strategies between policy-makers 
and analysts in different countries; and
• assist other researchers in more in-depth comparative health 
policy analysis.
Compiling the reviews poses a number of methodological problems. In many 
countries, there is relatively little information available on the health system and 
the impact of reforms. Due to the lack of a uniform data source, quantitative 
data on health services are based on a number of different sources, including 
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the World Health Organization (WHO) Regional Office for Europe’s European 
Health for All database, data from national statistical offices, Eurostat, the 
Organisation for Economic Co-operation and Development (OECD) Health 
Data, data from the International Monetary Fund (IMF), the World Bank’s 
World Development Indicators and any other relevant sources considered useful 
by the authors. Data collection methods and definitions sometimes vary, but 
typically are consistent within each separate review.
A standardized review has certain disadvantages because the financing 
and delivery of health care differ across countries. However, it also offers 
advantages because it raises similar issues and questions. HiTs can be used to 
inform policy-makers about experiences in other countries that may be relevant 
to their own national situations. They can also be used to inform comparative 
analysis of health systems. This series is an ongoing initiative and material is 
updated at regular intervals.
Comments and suggestions for the further development and improvement 
of the HiT series are most welcome and can be sent to info@obs.euro.who.int.
HiTs and HiT summaries are available on the Observatory’s web site (http://
www.healthobservatory.eu).
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Abstract
This analysis of the French health system reviews recent developments in organization and governance, health financing, health care provision, health reforms and health system performance. The French population 
has a good level of health, with the second highest life expectancy in the 
world for women. It has a high level of choice of providers, and a high level of 
satisfaction with the health system. However, unhealthy habits such as smoking 
and harmful alcohol consumption remain significant causes of avoidable 
mortality. Combined with the significant burden of chronic diseases, this has 
underscored the need for prevention and integration of services, although these 
have not historically been strengths of the French system.
Although the French health care system is a social insurance system, it 
has historically had a stronger role for the state than other Bismarckian social 
insurance systems. Public financing of health care expenditure is among 
the highest in Europe and out-of-pocket spending among the lowest. Public 
insurance is compulsory and covers the resident population; it is financed by 
employee and employer contributions as well as increasingly through taxation. 
Complementary insurance plays a significant role in ensuring equity in access. 
Provision is mixed; providers of outpatient care are largely private, and hospital 
beds are predominantly public or private non-profit-making.
Despite health outcomes being among the best in the European Union, social 
and geographical health inequities remain. Inequality in the distribution of 
health care professionals is a considerable barrier to equity. The rising cost of 
health care and the increasing demand for long-term care are also of concern. 
Reforms are ongoing to address these issues, while striving for equity in 
financial access; a long-term care reform including public coverage of long-term 
care is still pending.
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Executive summary
Introduction
The French Republic is made up of metropolitan France in western Europe (the mainland plus Corsica) and a collection of overseas islands and territories on other continents. France is the second most populous 
country in the European Union (EU; Union Européenne) after Germany, and 
has the fifth largest economy in the world.
The overall state of health in France is mixed. On the one hand, overall 
indicators show that the health of the population is good. French average life 
expectancy at birth is now over 80 years (82.4 years, compared with the EU 
average of 80.6) and for women is the second highest in the world (85.6 years). 
Moreover, older people remain in better health than in many other European 
countries. However, France suffers from a high rate of premature male deaths 
from accidents and unhealthy habits such as smoking and harmful alcohol 
consumption, which are the most common causes of avoidable mortality 
in France. France also has health inequalities across socioeconomic and 
geographical groups that are wider than in most other European countries. 
These inequalities are the result not only of risk factors but also of disparities 
in access to health services.
Organization and governance
Although the basic form of the French health care system is social insurance 
on the Bismarckian model, the French health care system has historically 
had a more centralized character with a stronger role for the state than other 
social insurance systems. This is illustrated by the single public payer and 
the increasing importance of tax-based revenue for financing health care, 
bringing the French system closer to the state-run national health services on 
the Beveridge model. Statutory health insurance (SHI; assurance maladie), 
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through various schemes, covers the resident population. Which scheme applies 
depends mainly on where people work; the schemes do not compete. Delivery 
of care is mixed, including private, fee-for-service (FFS; rémunération à l’acte) 
physicians, public hospitals, private non-profit-making hospitals and private 
profit-making hospitals.
Management of the health system is split between the state and SHI. Since 
the mid-1990s, reforms have aimed to devolve power from the national to the 
regional level, in particular for planning. Regional institutions were created to 
represent the main stakeholders: SHI schemes, the state, health professionals 
and public health actors. However, to improve the system’s governance, 
responsiveness to needs and efficiency, the 2009 Hospital, Patients, Health and 
Territories (HPST) Act (Loi No. 2009–879 du 21 juillet 2009 portant réforme 
de l’hôpital et relative aux patients, à la santé et aux territoires) merged most 
of these institutions into a single regional health agency (agence régionale de 
santé; ARS). Cutting across the traditional boundaries of health care, public 
health and health and social care sectors, the ARS aims to ensure that health 
care provision meets the needs of the population by improving links between 
ambulatory and hospital sectors, and between health and social care sector 
services, while keeping within national health expenditure limits.
With increasing health care expenditure and an increasing deficit of SHI (and 
corresponding increase in tax financing), the role of the state in planning and 
regulation has increased since the mid-1990s. At the regional level, the ARSs 
coordinate ambulatory and hospital care for the population as well as health and 
social care for the elderly and the disabled through a regional strategic health 
plan (Plan stratégique régional de santé; PSRS) based on population needs. 
This is a first attempt at regional planning of the ambulatory care sector.
In general, in the ambulatory care sector, patients pay providers directly and 
are reimbursed by SHI, although there are exceptions for the most expensive 
care as well as for households with low incomes; currently 35% of ambulatory 
payment is paid directly from the insurer to the provider. Quality of care is 
regulated at the national level. Hospitals must undergo a certification process 
every four years but there is no formal recertification or relicensing process 
for health professionals. However, doctors, pharmacists, dentists and midwives 
are required to undertake lifelong learning through continuing professional 
development (développement professionnel continu; DPC).
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Financing
Health care expenditure in France has grown more rapidly than the economy as 
a whole for many years (with the exception of the period 1997–2000), and faster 
than in neighbouring countries (with the exception of the United Kingdom); 
it rose from 10.4% of gross domestic product (GDP; produit intérieur brut) 
in 1995 to 11.6% in 2013. This is well above the EU average of 9.5%, and in 
Europe, second only to the Netherlands. From 1996, SHI annual expenditure 
has been capped by the national ceiling for health insurance expenditure 
(Objectif National des Dépenses d’Assurance Maladie; ONDAM). However, 
this ceiling was exceeded nearly every year until 2010; since then, the ceiling 
has been underspent as cost-containment measures have intensified. In 1996, a 
specific agency for managing social security debt was established, funded by 
a dedicated tax (amounting to 0.5% of income).
Just over three-quarters of total health care expenditure is publicly funded 
(77%; just above the EU average of 76%), principally through SHI. The 
proportion of costs covered by SHI varies across goods and services: from 
15% for drugs with low medical benefit (service medical rendu; SMR) to 80% 
for inpatient care. However, there are several conditions for which patients 
are exempted from paying a part of the costs, such as chronic conditions or 
pregnancy after the fifth month. Additional co-payments that are not allowed 
to be covered by voluntary health insurance (VHI; assurance complémentaire) 
have been created with the aim of reducing demand and thus SHI expenditure.
SHI resources mainly come from income-based contributions from 
employers and employees (including retirees). Since 1998, as a result of 
attempts to broaden the social security system’s financial base, employees’ 
payroll contributions have been almost fully replaced by a dedicated tax called 
the “general social contribution” (contribution sociale généralisée; CSG) based 
on total income rather than only on earned income, as was previously the case. 
Additional revenue comes from specific taxes such as taxes on potentially 
harmful consumption (tobacco, alcohol) and taxes on pharmaceutical companies.
VHI provides complementary insurance, such as for co-payments and better 
coverage for medical goods and services that are poorly covered by SHI. It 
finances 13.8% of total health expenditure and covers more than 90% of the 
population. Over recent decades, VHI has gained a significant role in ensuring 
equity in access and financing health care. Since 2000, publicly financed 
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complementary universal health coverage (couverture maladie universelle 
complémentaire; CMU-C) has been offered to those on lower incomes; it covers 
7% of the population.
Even after complementary insurance, out-of-pocket (OOP; reste à 
charge) payments from patients themselves account for 7.5% of total health 
expenditure. This raises issues of equity in access and financing, although this 
figure remains well below the EU average for OOP payments of 16.1% of total 
health expenditure.
Funding for long-term care (soins de longue durée) for the elderly and 
disabled is partly provided by a dedicated fund, the National Solidarity Fund 
for Autonomy (Caisse Nationale de Solidarité pour l’Autonomie; CNSA). This 
was created in 2004 following a heat-wave crisis in the summer of 2003 in 
which around 15 000 elderly people died. Its resources come from SHI and 
the “solidarity and autonomy contribution” (contribution solidarité pour 
l’autonomie) that is generated from the revenue equivalent to one unpaid 
working day ( journeé de solidarité). Local authorities increasingly also fund 
long-term care, as do individuals themselves.
Hospital acute care and hospitalization at home (hospitalisation à domicile; 
HAD), providing care equivalent to hospital care but in the patient’s own home, 
are paid by a diagnosis-related group (DRG; groupe homogène de malades) 
method under the medical activity-based payment system (tarification à 
l’activité; T2A). Self-employed professionals are paid on a FFS basis. Tariffs 
are negotiated between SHI and representatives of health professionals and 
approved by the Ministry in charge of Health, although extra-billing by 
doctors above that tariff is allowed in some cases. Pay-for-performance (P4P; 
rémunération à la performance) financial incentives to improve quality and 
efficiency of doctors’ practices were implemented through individual contracts 
with general practitioners (GPs; médecin généraliste ou omnipraticien).
Physical and human resources
Non-profit-making hospitals make up 61% of the total (35% public and 26% 
private sector) and 39% were private hospitals operated on a profit-making basis, 
a higher share of profit-making hospitals than in most other developed health 
systems. Two nationwide capital investment plans have been launched since 
the early 2000s in order to improve quality and safety standards. In December 
2013, the French Government also signed an agreement with the European 
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Investment Bank to finance public and private hospital construction and 
renovation projects under the Hospital of the Future Programme (programme 
Hôpital Avenir), amounting to €1.5 billion over three years. The ARSs are 
responsible for overseeing capital investment and purchasing major medical 
equipment. The availability of imaging units relative to population size is 
lower than the averages for Organisation for Economic Co-operation and 
Development (OECD) countries; particular questions have been raised about 
the number and distribution of magnetic resonance imaging (MRI; imagerie 
par resonance magnétique) units.
Following the general trend in European countries, the number of acute care 
hospital beds has been steadily declining since the mid-1990s. In 2013, it was 
3.45 beds per 1000 population (slightly below the EU average of 3.56). This 
was achieved partly by changing acute beds into rehabilitation and long-term 
care units (Unités de Soins de Longue Durée), as well as the development of 
day surgery and HAD.
About 5.3% of the French population works in the health care sector. France 
has similar levels of doctors and nurses to other European countries (319 doctors 
and 1000 nurses per 100 000 population, compared with 347 doctors and 850 
nurses for the EU as a whole). However, health care professionals are not spread 
equally across the country. The Parisian and the southeastern regions (Île-de-
France and Provence–Alpes–Côte-d’Azur) have the highest density of health 
care personnel, followed by the other southern regions, while the northern and 
eastern regions suffer from a lack of health care professionals. The problem is 
particularly acute with respect to specialist doctors, for which there is an eight-
fold difference between lowest and highest density regions.
Workforce forecasting and planning of educational capacity is mostly made 
at the national level, through a limit on the number of students trained each 
year (the numerus clausus) that is intended to prevent shortages or oversupply 
of health professionals. However, this does not regulate the geographical 
distribution of medical professionals, as self-employed professionals are free 
to choose where they practise. In order to address the resulting disparities 
in the distribution of medical professionals, there has been increasing 
experimentation in transfer of tasks from medical to other professionals such 
as nurses and development of incentives for attracting health professionals to 
underserved areas.
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Provision of services
Public health responsibilities are divided between many actors at the national 
and local level. At national level, the key bodies are the French Institute for 
Public Health Surveillance (Institut National de Veille Sanitaire; InVS) and 
the National Institute for Prevention and Health Education (Institut national de 
prévention et d’éducation pour la santé; INPES), which is involved in managing 
health crises and informing the population.
Primary and secondary health ambulatory care is provided by self-employed 
doctors, dentists and medical auxiliaries (including nurses and physiotherapists) 
working in their own practices, and, to a lesser extent, by salaried staff in 
hospitals and health centres. From the late 1990s, GPs have taken on a major 
role in the coordination of care through a semi-gatekeeping system that provides 
incentives to people to visit their GP prior to consulting a specialist.
France is the third largest European producer of pharmaceutical products; 
the French population is also among the largest consumers of pharmaceutical 
drugs, consuming 22% more than neighbouring countries. Drugs are dispensed 
by self-employed pharmacists, while the price of drugs is set administratively 
for all drugs covered by SHI.
Acute medical care is mainly provided by public hospitals, which account for 
nearly two-thirds of acute medical care capacity (67% of medical beds and 50% 
of day-care beds) and are responsible for 65% of full-time episodes and 42% of 
day-care episodes. Private profit-making hospitals tend to specialize in a small 
number of technical procedures for which there are profit opportunities, such as 
invasive diagnostic procedures (e.g. endoscopy or coronary angiography), and 
surgical procedures that can be performed routinely within a short stay with a 
predictable length. Public hospitals perform a much wider range of surgeries 
than profit-making hospitals, including the most complex procedures.
As in many other European countries, mental health care policy in France 
during the second half of the 20th century was inf luenced by a general 
movement towards community-based organization of mental health care 
services – the so-called “deinstitutionalization” process. The vast majority of 
care in the psychiatric sector is ambulatory, with 77% of patients over the 
course of a year treated exclusively on an outpatient basis.
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Recent reforms
The main objectives of the reforms to the health care system since 2010 were 
to improve governance and increase transparency of the system, to contain 
SHI expenditure without damaging equity in financial access, to increase 
geographical equity in access to care, and to meet the needs of vulnerable 
populations particularly by ensuring access to care for frail elderly individuals 
(personnes agées en risque de perte d’autonomie) and by decreasing social 
health inequities.
One of the major changes has been a move towards more transparency in the 
system, particularly with respect to conflicts of interest of experts that came to 
light in the “Mediator” (benfluorex) scandal. This anti-diabetes drug remained 
on the French market until 2009 despite mounting evidence of side-effects 
that led other countries to ban it as early as 1997. An investigation suggested 
weaknesses in the regulatory system for drugs, including a structural and 
cultural conflict of interest on the part of the regulatory agency because of its 
institutional cooperation with the pharmaceutical industry. The main objectives 
of the subsequent reforms were to restore confidence in the administrative 
decision-making process for health products, particularly drugs; to provide 
greater transparency and reduce the influence of the pharmaceutical industry on 
experts and treating physicians; and to strengthen drug safety and surveillance.
Cost-containment measures have focused particularly on drug expenditure, 
with a tendency to de-list drugs with insufficient SMR. However, despite 
an announcement by the Minister in charge of Health that all drugs with 
an insufficient SMR would be de-listed or reviewed if coverage was to be 
maintained, the measure has not been implemented. Tight control of drug prices 
also continued with the adoption of economic evaluation. However, formal 
assessment of how this tool has affected prices is not yet available.
In order to preserve equity, controlling the level of OOP payments has 
been one of the major policy issues in recent years. Two main tools have been 
employed: expansion of complementary insurance to a larger share of the 
population and restrictions on the level of extra-billing by doctors (although this 
has been only marginally effective so far). The development of P4P schemes for 
doctors was also aimed at increasing the efficiency of the system.
To improve geographical access to care, there have been successive attempts 
to encourage doctors to move to underserved areas. Financial incentives (both 
negative and positive) have proved ineffective. Instead, initiatives focusing on 
improving the workplace quality of life of doctors have flourished at the local 
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level, such as providing infrastructure, reducing start-up costs and enabling 
holiday cover. In addition, new methods of health care organization through 
task transfer and the use of information technologies such as tele-health have 
been encouraged since 2010.
The increasing demand for long-term care remains a major concern in 
the government’s plan. However, despite strong government support, public 
coverage of long-term care for the elderly to achieve greater equity in access 
remains one of the main challenges of the system.
Assessment of the health care system
The French health care system has long enjoyed the reputation of being one of 
the best in the world, combining universal health coverage (Couverture Maladie 
Universelle; CMU) with a generous supply of health services. This reputation 
comes in large part from success in meeting its goals of full coverage, access 
without waiting lists, patient choice and satisfaction. The combination of a 
basic universal public health insurance system and voluntary complementary 
private insurance (which provides reimbursement for co-payments required 
by the public system as well as coverage for medical goods and services that 
are poorly covered by the public system) results in low OOP costs and high 
medical care utilization. France’s average life expectancy of over 80 years is in 
part testament to the strong combination of good health care and good public 
health policies in France.
Despite these positives, there are also some shortcomings, especially when 
considering efficiency and socioeconomic inequalities in health outcomes and 
inequities in access to health care. Major problems include lack of coordination 
between the hospital sector, the ambulatory care sector and the health and social 
care sector, in particular in caring for patients with chronic diseases. France 
has also been slow in developing preventive care and intersectoral policies. 
However, major efforts have been undertaken in the last five years to address 
these issues.
France is among the OECD countries for which public financing of health 
care expenditure is the highest and OOP spending is the lowest. The high level 
of health expenditure has become increasingly significant at a time when the 
public system is facing chronic deficits, and improving allocative and technical 
efficiency is a major concern in order to ensure the financial viability of the 
system. Measures implemented since 2010 have been particularly effective in 
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achieving SHI cost-containment and financing fairness, as reflected by the fact 
that the ONDAM has not been exceeded since 2010 while maintaining stability 
in the percentage of OOP expenditure over the same period.
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1. Introduction
The French Republic is situated in western Europe. It is a unitary state with administrative subdivisions, including five overseas departments (départements) and seven overseas territorial authorities. Its strong 
executive branch is headed by the president, who appoints a prime minister to 
lead the government, which is, in turn, accountable to the bicameral parliament. 
France is the second most populous country in the EU and has the fifth largest 
economy in the world.
The overall picture of the state of health in France contains apparent 
contradictions. On the one hand, indicators such as life expectancy, disability-
free life expectancy and healthy life expectancy show that the health of the 
population is good. The French average life expectancy is now over 80 years 
and is the second highest in the world for women. The French population is 
ageing but not as a result of decreasing fertility as in other European countries. 
Indeed, France has the second highest fertility rate in the EU. Moreover, older 
people remain in better health than in many other European countries. The 
main causes of death in France are cancer, cardiovascular diseases, accidents 
and diseases of the respiratory system. However, France compares well with 
regard to cardiovascular diseases, while its relative position with respect to 
mortality caused by alcoholism, cirrhosis and cancer of the cervix is improving. 
On the other hand, France suffers from a high rate of premature male deaths 
from accidents and unhealthy habits such as smoking and harmful alcohol 
consumption, which are the most common causes of avoidable mortality in 
France. Additionally, France has long-reported health inequalities across 
socioeconomic and geographic groups that are wider than in most other 
European countries. These inequalities result not only from risk factors but 
also from disparities in access to health services.
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1.1 Geography and sociodemography
The French Republic comprises metropolitan France, located in western 
Europe (the mainland plus Corsica), and a collection of overseas islands and 
territories on other continents. The five overseas departments (French Guyana, 
Guadeloupe, Martinique, Mayotte and Réunion) are an integral part of the 
French Republic and subject to the same laws and regulations, although local 
adjustments are possible. The other overseas territories (French Polynesia, Saint 
Barthélemy, Saint Martin, Saint Pierre and Miquelon, Wallis and Futuna, New 
Caledonia and the French Southern and Antarctic Lands) are also part of France 
but have differing legal status.
Metropolitan France is bordered from north to east and south by Belgium, 
Luxembourg, Germany, Switzerland, Italy, Monaco, Andorra and Spain 
(Fig. 1.1). Its geography is varied, from coastal plains in the north and west to 
mountain ranges in the south-west (the Pyrenees) and the south-east (the Alps), 
including Mont Blanc, the highest point in western Europe at 4810 m (15781 ft). 
The climate is temperate.
Fig. 1.1
Map of France
Source: CIA, 2009.
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On 1 January 2013, the French population totalled 63.7 million inhabitants 
in metropolitan France and 2.1 million inhabitants in the five overseas 
departments (INSEE, 2013a). It is the second most populous country in the EU 
after Germany. Table 1.1 shows the most recent demographic indicators.
Table 1.1 
Trends in demographic and socioeconomic indicators for metropolitan France, 
1980–2014 (selected years)
1980 1990 1995 2000 2005 2010 2014
Total population (millions) 53.7 56.5 57.7 58.8 60.9 62.7 66.2
Population, female (% of total) 51.2 51.3 51.4 51.5 51.6 51.6 51.0
Population aged 0–19 years (% of total) 30.6 27.8 26.1 25.6 25.0 24.5 24.4a
Population aged ≥ 60 years (% of total) 17.0 19.0 20.0 20.6 20.9 22.8 24.0a
Population aged ≥ 75 years (% of total) 5.7 6.8 6.1 7.2 8.1 8.9 9.2a
Population growth (average annual growth rate) 0.4 0.5 0.4 0.7 0.8 0.5 0.5b
Population density (average per km2) 100.83 106.65 108.72 111.22 115.36 118.74 121.00
Fertility rate, total (births per woman) 1.9 1.8 1.7 1.9 1.9 2.0 1.9a
Birth rate, crude (per 1,000 people) 14.9 13.4 12.6 13.1 12.7 12.8 12.2a
Death rate, crude (per 1,000 people) 10.2 9.3 9.2 9.0 8.6 8.6 8.8a
Age dependency ratio (% of working population) 57.0 51.0 54.0 54.0 54.0 54.0 59.0
Percentage population urban 73.3 74.1 74.9 76.9 81.5 85.2 79.0
Proportion of single-person households 24.6 27.1 na 31 32.8 33.6c na
School enrolment, tertiary  
(% gross tertiary enrolment)
25.0 37.0 50.0 54.0 55.0 57.0 60.0
Sources: INSEE, 2013a; World Bank, 2015.
Notes: a 2013 data; b 2012 data; c 2009 data; na: Not available.
Metropolitan France covers an area of about 552 000 km2, and with an 
average population density of 119/km2 it ranks 12th in the EU. However, average 
density conceals considerable variations; half of the population lives in just over 
10% of this territory, while large areas remain sparsely populated. By 2012, 86% 
of the population lived in urban areas, with the greatest growth in outer suburbs 
and rural areas surrounding towns, rather than in the city centres. Nonetheless, 
the population of rural areas has grown 1.5 times faster than urban areas over 
the past ten years (Brutel & Levy, 2012).
Historically, French immigration policy has been characterized by a tradition 
of welcome, assimilation and integration of foreigners. However, recent laws 
have imposed stricter conditions for family reunification and asylum. In 
2008, an estimated 5.3 million immigrants (born in a foreign country) resided 
in France, representing 8.3% of the population (INSEE, 2012b). Individuals 
born in Algeria, Morocco and Tunisia accounted for 30% of France’s 
immigrant population.
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France is ethnically heterogeneous, counting more than a hundred different 
ethnic groups within its territory. The government does not gather data 
on ethnicity, although ad hoc surveys may be used to estimate the level of 
discrimination in access to schools, housing or the labour market. A 2008 
survey found that approximately 15% of the French population (10 million) 
had an origin other than French (INED, 2010).
While the government does not maintain statistics on religious adherence, 
a 2008 demographic survey showed France to be multidenominational: 43% 
Roman Catholic, 8% Muslim, 2% Protestant, 0.5% Orthodox, 0.5% Jewish, 
0.5% Buddhist and 0.5% other (INED, 2010). Nearly 45% of the population 
aged 18–50 years declared themselves agnostic or atheist.
Among the EU Member States as of 2013, France has the second highest 
fertility rate (2.02 births per woman in 2010 and 1.97 in 2013) (see Table 1.1). 
The French population is ageing because of increasing life expectancy but not 
because of declining fertility rates as in other European countries. The baby 
boom after the Second World War will exacerbate this trend in the medium 
term, and people aged over 75 years are expected to constitute 15.6% of the 
population by 2050, compared with 9.2% in 2011 (Vasselle, 2011).
Just over 70% of the French population has attained upper secondary 
education (INSEE, 2013a). In 2011, nearly 60% of the population in the five-year 
age group following secondary school was enrolled in higher education 
(Table 1.1).
1.2 Economic context
France is the fifth largest economy in the world and the second largest in 
Europe. Thanks to its overseas departments and territories, France has the 
second largest exclusive economic zone in the world in terms of area, second 
only to that of the United States.
In 2014, the GDP of France exceeded €2 trillion (Table 1.2). The per capita 
GDP was €27 643 in 2012, ranking 11th among EU27 countries. The budget 
deficit was 4.8% of GDP in 2012 compared with 5.3% in 2011 and 7.1% in 2010.
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Table 1.2 
Macroeconomic indicators, 1980–2014, selected years
1980 1990 1995 2000 2005 2014
GDP (€, millions) 444 706 1 032 780 1 196 181 1 439 603 1 718 047 2 132 449
GDP, PPP (current international 
US$, millions) 
522 735 1 000 996 1 200 881 1 533 008 1 860 700 2 571 970
GDP per capita (€, base 2005) 18 733.8 22 459.6 23 367.0 26 127.1 27 288.6 27 643.7a
GDP per capita, PPP (current 
international US$) 
8 071.3 17 764.2 20 143.2 23 707.0 27 288.6 38 847.0
GDP average annual growth rate 
for previous 10 years (%)
1.6 2.6 2.0 3.7 1.8 0.0
Public expenditure (% of GDP) na na 47.2 44.6 46.1 57.5
Cash surplus/deficit (% of GDP) −0.3 −2.5 −5.5 −1.5 −2.9 −4.8a
Tax burden (% of GDP) na na 18.8 23.2 22.4 21.3b
Public debt (% of GDP) 20.7 35.2 55.5 55.7 66.8 95.6
Value added in industry (% of GDP) 32 27 25 23 21 19
Value added in agriculture  
(% of GDP)
5 4 3 3 2 2
Value added in services (% of GDP) 63 69 72 74 77 79
Labour force (total in millions) 22.7 23.2 23.1 25.1 25.8 25.8b
Unemployment, total  
(% of labour force)
5.3 7.9 10.0 8.5 8.9 9.8
Poverty rate (%)c 14.2d 13.8 14.5e 13.6 13.1 13.9a
Income inequality (Gini coefficient) na na na na 0.3 0.3a
Real interest rate 0.9 7.6 6.8 5.0 4.8f 3.3b
Official exchange rate per US$ 
(French francs 1980–1995; 
€ 2000–2012)
4.2 5.4 4.9 0.9 1.2 1.3a
Sources: European Central Bank, 2013; INSEE, 2013a, 2015a,b; World Bank, 2015.
Notes: a 2012 data; b 2011 data; c Population at risk of poverty provided by the National Institute of Statistics and Economic Studies 
follows Eurostat’s definition as the number of people who have an equivalized disposable income below the risk-of-poverty threshold, 
which is set at 60% of the national median equivalized disposable income (after social transfers); d 1979 data; e 1996 data; f 2004 data; 
na: Not available; PPP: Purchasing power parity. 
In 2011, 25.8 million people (56.5% of the metropolitan population) were 
active in the labour market (Table 1.2). Women represented 47.7% of the 
country’s workforce, and their participation in the labour market has increased 
dramatically in recent decades. Between 2008 and 2009, unemployment 
increased by 23% (from 7.4% to 9.1%), reflecting the effect of the economic 
crisis. Since then, the rate has continued to climb despite a slight dip in 2011 to 
9.2%, reaching 9.8% in 2014 (INSEE, 2015b).
In the past 25 years, the structure of employment has moved away from 
agriculture (which today accounts for only 2.9% of the workforce) and 
manufacturing and construction (currently 20.9% of the workforce) towards 
the commercial and services sectors, which now employ 19.5 million people 
(75.8% of the workforce) (INSEE, 2013a). In 2012, 14% of the population was 
below the poverty level, defined as 60% of median income. Income differs 
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across the population: the income ratio of the richest 10% and the poorest 10% 
was 3.6 in 2011, and the Gini index was 0.3 in 2012 (Table 1.2). In comparison 
with other European countries, income is more equally distributed than in 
Spain, the United Kingdom or Italy, but less so than in Sweden and Germany 
(Eurostat, 2013).
1.3 Political context
The institutions of the French Republic are governed by the 1958 Constitution, 
which ushered in the Fifth Republic and strengthened the role of the executive 
branch (the president of the Republic and the prime minister) relative to 
the parliament.
The president is elected by direct universal suffrage for a five-year term. The 
government, led by a prime minister nominated by the president, develops and 
guides policy implementation. The prime minister is accountable to parliament, 
which exercises legislative power and is made up of the National Assembly and 
the Senate. The National Assembly has 577 deputies elected by direct universal 
suffrage. Voting takes place based on a single majority vote (i.e. voting for 
one deputy only) in two rounds, within the framework of constituencies of 
variable size (one deputy for approximately 100 000 inhabitants). The National 
Assembly’s session is five years but can be shortened if the president decides 
to dissolve the National Assembly, as has happened five times since the 
inauguration of the Fifth Republic. The Senate consists of 348 senators who are 
elected for nine years by indirect universal suffrage through an electoral college 
consisting of elected officials in each department. One-third of its membership 
is renewed every three years. The method of polling, the senators’ term of 
office and the fact that the Senate cannot be dissolved give the Assembly a high 
degree of political stability.
The French administration has become more decentralized since the late 
1980s, a substantial change from its long tradition of centralizing policies. 
There are three decentralized levels of administration: the municipality, 
the department and the region. These three levels are both administrative 
constituencies of the state and decentralized local communities run by locally-
elected assemblies. They have their own separate areas of responsibility in 
which they are autonomous. However, the state defines the competencies of 
each level of administration.
The 36 681 municipalities form the basic structure of France’s administrative 
organization; 80% of municipalities have fewer than 1000 inhabitants. They are 
run by municipal councils elected for six years by direct universal suffrage. The 
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mayor is both the elected authority of the municipality and the representative 
of the state within the territory of the municipality. Municipalities oversee 
local activities, and their responsibilities are extensive in the economic and 
social sectors.
The 101 departments, 96 in metropolitan France and five overseas, are 
territorial communities with elected local assemblies (general councils; conseil 
généralaux) that has responsibility in the areas of health and social care and the 
financing and provision of lower secondary education (collèges). The prefect 
(préfet) represents the state’s authority within the department. The departments 
are grouped into 27 regions, 22 in metropolitan France and five overseas, which 
constitute administrative authorities for planning and development. A 2014 
administrative reform will reduce the number of metropolitan regions to 13, 
effective 1 January 2016. Each region has an elected assembly (the Regional 
Council, conseil régional). Regional jurisdiction mainly concerns planning, 
development, economic development, vocational training and upper secondary 
educational institutions (lycées).
Configuration of the current government
The current President of the Republic, François Hollande, was elected in May 
2012, and he appointed Jean-Marc Ayrault as Prime Minister. Manual Valls 
replaced Ayrault as Prime Minister following the March 2014 municipal 
elections, and his government is composed of 16 ministers. The June 2012 
election of deputies resulted in a National Assembly with a slim left-wing 
majority: 51.5% (297) of the deputies are affiliated with left-wing parties, 
including 48.53% (280) from the president’s Socialist Party (Parti Socialiste).
Laws and regulations
France is a civil law country whose laws and regulations (acts, ministerial 
decrees, administrative orders) are broken down into more than 60 codes by 
subject area. The codes that are directly related to health care are the social 
security code (code de la sécurité sociale), the mutual societies code (code de 
la mutualité), the public health code (code de la santé publique) and the social 
action and families code (code de l’action sociale et des familles). However, 
health care also falls under rules in other codes, such as the labour code (code 
du travail) and the commercial insurance code (code des assurances).
Application of the health laws in the French overseas territories varies. For 
example, French Polynesia and New Caledonia are autonomous with respect 
to health matters, while Saint Pierre and Miquelon and Wallis and Futuna rely 
on the French national health authorities.
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For major reforms and annual decisions affecting the social security budget, 
health care laws are enacted by legislation (acts) after discussion in parliament. 
Following enactment, decrees (décrets) are issued by the prime minister. 
When specified in acts, some decrees must be assessed by the Council of State 
(Conseil d’Etat). Lower level regulations such as administrative orders (arrêtés) 
are signed by the relevant minister.
France and international organizations
France is a founding Member State of the EU. France also belongs to numerous 
international organizations, including the United Nations, the World Health 
Organization (WHO), the European Economic Area (EEA; Espace économique 
européen), the OECD, the World Trade Organization, the North Atlantic Treaty 
Organization and the Council of Europe. France has signed several treaties 
with direct or indirect impact on health, including the General Agreement on 
Tariffs and Trade (accord général sur les tarifs douaniers et le commerce) and 
the European Convention on Human Rights.
1.4 Health status
The overall picture of the state of health in France contains apparent 
contradictions. On the one hand, indicators such as life expectancy and healthy 
life-years (années de vie en bonne santé) show that the health of the population 
is good (Fig. 1.2 and Table 1.3).
In terms of international comparisons, women live longer and older 
people remain in better health than in many European countries. France 
also compares well with respect to cardiovascular diseases, and its relative 
position regarding mortality caused by alcohol, cirrhosis and cervical cancer is 
improving. However, France suffers from a high rate of premature male deaths 
from accidents, smoking and harmful alcohol consumption (HCSP, 2013). The 
world age-standardized death rate for all cancers is higher among French men 
(152.62) than for men in Germany, Spain, Italy and the United Kingdom and 
lower among women (79.87) than for women in these same countries, except 
for Spain (Malvezzi et al., 2013). 
Life expectancy at birth in France is increasing steadily, by three months per 
year for men and by two months per year for women. The gap between male and 
female life expectancy remains high, although it is narrowing (Table 1.3). Life 
expectancy is lower in the overseas departments than in metropolitan France 
by one year for men and two years for women. In 2013, the expected healthy 
life-years for both men and women exceeded the EU28 averages both at birth 
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(63 for men and 64 for women in France and 61.4 for men 61.5 for women in 
the EU28) and at age 65 (9.8 for men and 10.7 for women in France and. 8.5 for 
men and 8.6 for women in the EU28) (Eurostat, 2015).
Fig. 1.2 
Health status indicators, France versus the OECD average 
Source: OECD, 2013.
Table 1.3 
Mortality and longevity indicators, 1980–2013, selected years
1980 1990 1995 2000 2005 2010 2013
Life expectancy at birth, total (years) 74.9 77.6 77.8 79.3 79.9 81.1 82.4
Life expectancy at birth, male (years) 70.8 73.4 73.4 75.3 76.7 78.2 79.0
Life expectancy at birth, female (years) 79.1 81.8 81.8 82.8 83.8 85.3 85.6
Total mortality rate, adult male (per 1,000) 196 168 156 138 127 116 109a
Total mortality rate, adult female (per 1,000) 85 69 65 61 57 54 52a
HLY at age 65, men na na 7.6 7.7 8.5 9.0 9.8
HLY at age 65, women na na 8.4 8.6 9.7 9.8 10.7
HLY at birth, men na na 60.0 60.1 62.3 61.8 63.0
HLY at birth, women na na 62.4 63.2 64.6 63.4 64.4
Sources: INSEE, 2013a; Eurostat, 2015; World Bank, 2015.
Notes: a 2012 data; HLY: Healthy life-years; na: Not available.
In 2010, the main causes of death in France were cancer (28.2% of deaths), 
cardiovascular diseases (26.4%), accidents (external causes) (6.9%), nervous 
system disorders (6%) and chronic respiratory diseases (5.9%) (Table 1.4).
Female life expectancy
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Male life expectancy
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Infant mortality, 2012Potential years of
life lost, all causes,
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Potential years of
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males, 2009
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Table 1.4 
Main causes of death, metropolitan France, 1980–2010, selected years
Causes of deatha 1980 1990 1995 2000 2005 2010
Communicable diseases
All infectious and parasitic diseases 
(A00–B99)
6 920 
(1.3%)
9 598 
(1.8%)
12 472 
(2.4%)
10 537 
(2.0%)
9 853 
(1.9%)
10 718 
(2.0%)
Tuberculosis  
(A15–A19)
1 954 
(0.4%)
1 383 
(0.3%)
1 119 
(0.2%)
1 085 
(0.2%)
846 
(0.2%)
583 
(0.1%)
Sexually transmitted infections (A50–A64) na na na 7 4 3
HIV/AIDS (B20-B24) 0 
(0%)
2 738 
(0.5%)
4 696 
(0.9%)
998 
(0.2%)
817 
(0.2%)
452 
(0.1%)
Noncommunicable diseases
Circulatory diseases (I00–I99) 203 659 
(37.4%)
173 729 
(33.2%)
170 886 
(32.3%)
161 330 
(30.5%)
149 273 
(28.4%)
142 456 
(26.4%)
Among which:
  Ischaemic heart disease (I20–I25) 50 278 
(9.2%)
48 961 
(9.4%)
46 711 
(8.8%)
45 068 
(8.5%)
40 383 
(7.7%)
35 324 
(6.5%)
  Cerebrovascular diseases (I60–I69) 67 462 
(12.4%)
48 407 
(9.2%)
43 448 
(8.2%)
38 308 
(7.2%)
33 797 
(6.4%)
31 639 
(5.9%)
Malignant neoplasms (C00–C97) 123 659 
(22.8%)
137 448 
(26.3%)
142 245 
(26.9%)
143 263 
(27.2%)
148 511 
(28.3%)
152 209 
(28.2%)
Among which:
  Colon cancer (C18) 9 677 
(1.8%)
11 424 
(2.2%)
12 342 
(2.3%)
11 784 
(2.2%)
12 265 
(2.3%)
12 457 
(2.3%)
  Cancer of larynx, trachea, bronchus 
and lung (C32–C34)
21 111 
(3.9%)
24 573 
(4.7%)
26 231 
(5.0%)
26 621 
(5.0%)
29 267 
(5.6%)
30 772 
(5.7%)
  Breast cancer (C50) 8 489 
(1.6%)
10 269 
(2.0%)
10 861 
(2.1%)
11 032 
(2.1%)
11 481 
(2.2%)
11 922 
(2.2%)
  Cervical cancer (C53) 973 
(0.2%)
786 
(0.2%)
762 
(0.1%)
684 
(0.1%)
730 
(0.1%)
736 
(0.1%)
Diabetes (E10–E14) 7 030 
(1.3%)
6 451 
(1.2%)
6 421 
(1.2%)
10 779 
(2.0%)
11 262 
(3.1%)
10 679 
(2.0%)
Mental and behavioural  
disorders (F00–F99)
7 972 
(1.5%)
12 896 
(2.5%)
13 246 
(2.5%)
17 305 
(3.3%)
17 052 
(3.2%)
17 929 
(3.3%)
Chronic respiratory diseases (J00–J99) 33 308 
(6.1%)
38 000 
(7.3%)
40 039 
(7.6%)
35 613 
(6.7%)
34 992 
(6.7%)
31 927 
(5.9%)
Digestive diseases (K00–K93) 35 548 
(6.5%)
26 998 
(5.2%)
26 049 
(4.9%)
23 651 
(4.5%)
23 118 
(4.4%)
23 378 
(4.3%)
External causes
Transport accident (V01–V99) 11 122 
(2.0%)
10 084 
(1.9%)
8 166 
(1.5%)
7 346 
(1.4%)
5 224 
(1.0%)
3 926 
(0.7%)
Suicide (X60–X84) 10 368 
(1.9%)
11 354 
(2.2%)
11 760 
(2.2%)
10 806 
(2.0%)
10 673 
(2.0%)
10 334 
(1.9%)
Ill-defined and unknown causes 
of mortality (R95–R99)
15 676 
(2.9%)
11 344 
(2.2%)
10 323 
(2.0%)
12 553 
(2.4%)
12 857 
(2.4%)
21 692 
(4.0%)
Total 544 421 
(100%)
523 569 
(100%)
529 370 
(100%)
528 763 
(100%)
525 663 
(100%)
539 083 
(100%)
Source: Epidemiology Centre on the Medical Causes of Death, 2013.
Notes: a Categories from ICD-10 (WHO, 2015); HIV/AIDS: human immunodeficiency virus/acquired immunodeficiency syndrome; 
na: Not available.
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However, these death rates differ between men and women, with women’s 
death rates being systematically lower. Lung cancer deaths in women increased 
dramatically between 2000 and 2008, ref lecting an increase in smoking 
behaviour in women, which commenced later than it did in men (Binder-
Foucard et al., 2013). The incidence of diabetes has steadily increased since 
2000, while hospitalizations for myocardial infarction and ischaemic heart 
disease have diminished (Table 1.5).
Table 1.5 
Morbidity and factors affecting health status, 2000–2008, selected years
Diseases 2000 2005 2008
Men Women Total Men Women Total Men Women Total
Diabetes (SIR) 121.5 106.3 236.0 143.0 113.7 270.0 154.0a 121.0a 286.0a
Cancer (SIR) 351.7 234.9 na 396.1 248.8 na 362.6b 252c na
Myocardial infarction (raw 
hospitalization rate/100,000)
146.1 52.7 95.0 128.0 47.0 83.7 120.4 43.2 78.7
Stroke (SIR) 169.2 112.8 137.1 163.8 109.6 133.3 162.9 110.3 133.5
Ischemic heart disease 
(hospital discharges/100,000)
75.7 29.8 49.4 61.7 24.4 40.39 49.7c 18.8c 32.1c
Sources: Fagot-Campagna et al., 2010; de Peretti et al., 2012ab; Binder-Foucard et al., 2013.
Notes: a 2006 data; b 2012 data; c 2009 data; na: Not available; SIR: Standardized incidence rate per 100,000.
Social and geographical inequalities in health remain substantial (Fig. 1.3). 
All indicators show higher mortality rates in the northern part of France (from 
Brittany in the west to Alsace in the east), and in regions located on an axis from 
the north-east to Auvergne in the centre of the country. Along this axis, the 
higher rates of mortality concern all causes of death, whereas in the northern 
crescent (Brittany, Normandy, Nord-Pas-de-Calais and Alsace), risk factors 
such as alcohol consumption explain some of the higher mortality. Alcohol and 
tobacco use are not independent of socioeconomic status and are often higher 
in poorer regions affected by higher unemployment and other socioeconomic 
indicators (INPES, 2013).
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Fig. 1.3
Life expectancy at birth in metropolitan France by region, 2011 
Source: INSEE, 2012a. 
Notes: France: 31.4 million men and 33.5 million women. M: Men; W: Women; 1: Alsace; 2: Aquitaine; 3: Auvergne; 4: Burgundy 
5: Brittany; 6: Centre; 7: Champagne-Ardenne; 8: Corsica; 9: Franche-Comté; 10: Île de France; 11: Languedoc-Rousillon; 12: Limousin; 
13: Lorraine; 14: Midi-Pyrennées; 15: Nord-Pas-de-Calais; 16: Normandy (Basse); 17: Normandy (Haute); 18: Loire Valley; 19: Picardy; 
20: Poitou-Charentes; 21: Provences-Alpes-Côte d’Azur; 22: Rhône-Alpes.
Lifestyle factors affecting health status
Tobacco and alcohol, respectively, are the first and second most common causes 
of avoidable mortality. Tobacco was estimated to cause 73 000 attributable 
deaths (59 000 men and 14 000 women) in 2004 (Hill, 2012) and alcohol to 
cause 49 000 deaths in 2009 (Guérin et al., 2013). A number of tobacco and 
alcohol control policies based on regulation of publicity and sales as well as 
taxes have been implemented with the goal of decreasing consumption.
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A tobacco ban initially in public places and workplaces was progressively 
implemented in France (Act of 31 December 1970, Act of 9 July 1976, Act of 
10 January 1991, Act of 21 July 2009). Since 1 January 2008, the tobacco ban 
has been extended to bars, pubs, restaurants, hotels, casinos and nightclubs. 
Individuals not respecting this ban may be fined from €68 to a maximum 
of €450 (Ministerial Circular of 29 November 2006). After a decrease in the 
prevalence of daily smokers between 2000 and 2005, smoking prevalence 
increased from 27.3% in 2005 to 29.1% in 2010, the first significant increase 
since the 1991 Evin Law prohibited smoking in most enclosed public places 
(Beck et al., 2010). By comparison, the 2012 EU27 average percentage of daily 
smokers was 28% (Danet, 2012). Two subpopulations are responsible for this 
increase between 2005 and 2010: women (increasing from 23.3% to 26%) 
and unemployed persons (from 44% to 50.8%). Nonetheless, the emergence 
and increasing popularity of electronic cigarettes in recent years appears to 
be reversing this trend. In 2013, cigarette sales declined 7.6% according to 
the French Observatory on Drugs and Addictions (L’observatoire français des 
drogues et des toxicomanies; OFDT) (OFDT, 2014).
The alcohol industry is a powerful economic sector in France, and wine 
constitutes a particularly important cultural reference. The 1991 Evin Law 
imposed a partial ban on alcohol advertising and permitted advertising requires 
the following health warning: “alcohol abuse is dangerous for your health”. The 
2009 HPST Act increased the legal drinking age to 18, banned open bars and set 
limits on the sale of alcoholic beverages in petrol stations. Alcohol is the most 
consumed psychoactive substance in France, with 9.7 million regular users, 
corresponding to 21% of the population (OFDT, 2010). In 2012, annual alcohol 
consumption was 11.8 litres per inhabitant aged over 15 years (INSEE, 2013a). 
Despite a steady decrease over the last 50 years, this number remains higher 
than the target of 11.5 litres set by the 2004 Public Health Act (Danet, 2012). It is 
important to note that indicators such as average consumption do not reveal the 
extent of harmful use of alcohol. In 2010, nearly a quarter of adults aged 18 to 
75 indicated that they had engaged in risky drinking behaviours (Danet, 2012).
Socioeconomic health inequalities
France has long reported health inequalities across socioeconomic groups that 
are wider than in most other European countries. These inequalities are more 
pronounced for men than for women, with working-class individuals having 
a significantly higher risk of death before age 65 than managers. At age 35, a 
male labourer has a 13% risk of dying before age 65, while the risk for a male 
manager is 6% (Blanpain, 2011).
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The French trends in improving health status, as reflected by the increase 
in life expectancy and the decrease in infant mortality, have not been equally 
beneficial across socioeconomic groups, with the greatest improvement 
being observed among the wealthiest. For example, life expectancy at 35 is 
seven years lower for working class men and three years lower for working 
class women compared with managers (Danet, 2012). These inequalities also 
exist when morbidities or risk factors such as obesity are examined (Table 1.6).
Table 1.6 
Social inequalities in health and access to care between workers and managers 
in France, 2010
Average number 
diseases declared
Obesity (% 
population)
Dental problems 
(% population)
Access to dental 
care in the last 
2 years 
(% population)a
Workers 2.9 15.2 44.0 63.9
Managers 2.5 6.3 29.4 82.3
Sources: Dourgnon, Guillaume & Rochereau, 2012; Clavet, Moisy & Chardon, 2013; OECD, 2013.
Note: a 2009 data.
These social health inequalities result not only from risk factors such as 
alcohol and tobacco consumption but also from differences in access to health 
care that seem to increase over time. In 2012, 26% of the population reported 
having forgone health care in the last 12 months for financial reasons (Célant, 
Guillaume & Rochereau, 2014). This inequity in access is concentrated in a 
limited number of goods and services for which OOP expenditure by patients is 
the highest. Dental health care is of great concern (18% of the population aged 
18–64 years have forgone dental health care in the last 12 months), followed 
by eye care (10%) (Célant, Guillaume & Rochereau, 2014). Forgoing health 
care increases inversely with the level of income: people in the lowest income 
quintile (under €926 a month) are nearly three times more likely to forgo care 
than people in the highest income quintile (more than €2120 a month) (Célant, 
Guillaume & Rochereau, 2014).
Recent immigrants have lower health status than individuals who were 
born in France. This is partly explained by lower socioeconomic status, lower 
complementary VHI coverage and by the economic level of the country of 
origin. Immigrants also have lower access to health care, with greater barriers 
for specialist visits than for visits to GPs (Berchet & Jusot, 2011, 2012). Several 
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public policies have been implemented since the late 1990s to address these 
issues, mainly focused on improving access to health care, but to date they have 
not shown significant results (see section 2.2).
Sexually transmitted diseases and human immunodeficiency virus
In recent years, there has been a growth in sexually transmitted diseases. The 
number of gonorrhoea infections has risen steadily since 1996, reflecting 
an increase in risky sexual behaviours, and there is growing concern about 
antibiotic resistance (Nguyen et al., 2011). There has also been a steady increase 
in the number of Chlamydia infections in recent years, particularly among 
young women (Goulet et al., 2011). The evolution in the number of cases of 
syphilis has been marked by phases: a rapid increase between 2000 and 2002, 
followed by relative stability between 2003 and 2006, a significant increase in 
2007 and a 12% decrease between 2007 and 2009 (Bouyssou et al., 2011). In 
the early 2000s, the Paris region saw the greatest share of cases, but over time, 
the epidemic has spread to other regions. Over this 10-year period, the majority 
of cases (83%) were in homosexual men. France is a low endemic country for 
the hepatitis B virus, with incidence of acute symptomatic cases estimated at 
1/100 000 inhabitants (Antona et al., 2011).
In 2012, the estimated incidence of human immunodeficiency virus (HIV; 
virus de immunodéficience humaine) infection was 6400 new infections 
(100 million inhabitants) increasing to 7500 when the estimated proportion 
of undiagnosed cases was included (Ndawinz et al., 2011; Cazein et al., 2014). 
The prevalence of undiagnosed HIV infection is estimated at 28 800 (450/
million population) (Deuffic-Burban & Costagliola, 2006). Heterosexual 
transmission accounted for 56% of new infections in 2012, with three-quarters 
of these infections in people coming from sub-Saharan African countries. 
Transmission was 1% among injecting drug users, reflecting risk-reduction 
policies put into place over the past 20 years. In contrast to overall incidence, 
which has remained stable since 2007, the incidence among homosexual men 
increased 39% between 2003 and 2012 (Cazein et al., 2014), accounting for 42% 
of new infections in 2012. There are geographical disparities, with higher HIV 
infection rates in the Parisian area and overseas departments (Danet, 2012).
By the end of 2012, a total of 88 000 cases of the acquired immunodeficiency 
syndrome (AIDS; syndrome de immunodéficience acquise) and 47 000 related 
deaths had been recorded in France since the beginning of the epidemic. After 
reaching a peak of 5800 cases a year in 1996, the AIDS incidence decreased 
dramatically to 2300 cases per year in 1998, following the increased use of 
antiretroviral drugs. Since then, AIDS incidence has decreased at a slower rate, 
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falling to about 1500 cases per year in 2012. The male:female ratio decreased up 
to 2004 and has remained constant since then at around 2.2:1. France remains 
one of the western European countries with a relatively high rate of AIDS; 
however, it is lower than other European countries such as Portugal and Spain 
(WHO Regional Office for Europe, 2012).
Dental health and immunization
Oral health estimated by the average number of decayed, missing or filled teeth 
at age 12 is 1.2 in France (2006), which is the same level as in Belgium, Italy 
and Spain, but not as good as in the United Kingdom and Germany, each of 
which reported 0.7 in 2005 (OECD, 2009).
One of the measures for improvement of health status in France is the 
national immunization programme (see section 5.1). Only three immunizations 
are obligatory for the general population: tetanus, diphtheria and poliomyelitis; 
however, many others are recommended depending on age (Houssin, 2010). 
Vaccination coverage varies with the type of vaccination and age. One of the 
public health objectives of the 2004 Public Health Act was to reach at least 
95% coverage rate at appropriate ages by 2008; this target has been partly 
met (Guthmann, Fonteneau, & Lévy-Bruhl, 2012). Weaknesses remain, with 
insufficient coverage in teenagers and a low rate of uptake of the measles and 
hepatitis B vaccinations in children (HCSP, 2010).
Maternal and child health
With regard to reproductive health, the overall French situation is generally 
good. The average age of women at first childbirth increased from 29.3 years 
in 2001 to 30.1 years in 2011. In that same period, the number of adolescents 
giving birth decreased to 34 per 1000 women aged 15–19 (Table 1.7).
Table 1.7 
Maternal, child and adolescent health indicators, 1980–2010, selected years
Indicators 1980 1990 1995 2000 2005 2010
Adolescent birth rate (per 1,000 women 15–19 years) 89 44 39 39 37 34 (p)a
Termination of pregnancy (abortion) rate (per 1,000 women) 13.2 14.6 13.1 14.2 15.1 15.7
Neonatal mortality (per 1,000 births) 5.8 3.6 3.0 2.9 2.5 2.5
Postneonatal mortality rate (per 1,000 live births) 4.3 3.8 2.0 1.6 1.3 1.1
Infant mortality rate (per 1,000 live births) 10.0 7.3 4.9 4.4 3.6 3.3a
Under-5 mortality rate (per 1,000 live births) 12.0 9.0 7.0 5.0 5.0 4.0b
Maternal mortality rate (per 100,000 live births) 12.9 10 9.2 6.8 5.8 8.9
Perinatal and neonatal mortality rate (per 1,000 births)d 10.2 6.1 4.8 0.8 3.8 3.9c
Sources: Eco-Santé, 2013; INSEE, 2013a.
Notes: a 2012 data; b 2011 data; c 2008 data; d The apparent strong growth in perinatal mortality/stillbirth rates reflects legislative 
changes to criteria for intrauterine deaths and stillborn. Therefore, these definitional differences mean that it is not possible to compare 
France with other countries (see definitions, perinatal mortality in OECD health data (OECD, 2013); (p): Provisional data. 
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In terms of contraception, oral contraceptives remain the most popular form 
of birth control, used by 55.5% of women aged 15–49 in 2010. However, 7.7% 
of women at risk for an unplanned pregnancy stated that they used no form of 
contraception. From age 15, minors have free access to contraceptives covered 
by SHI with a prescription and free and anonymous access to emergency 
contraception without a prescription. Between 2000 and 2010, the proportion of 
sexually active women aged 15–49 who indicated that they had used emergency 
contraception increased from 9% to 24% (Danet, 2012).
Abortion is legal on demand in France up to 12 weeks following conception. 
Terminations at later stages require certification by two physicians that the 
abortion is necessary to prevent grave permanent injury to the woman’s 
physical or mental health, that the woman’s life is at risk or that the child will 
suffer from a particularly severe illness that is considered incurable. Despite the 
growing use of contraception and the availability of emergency contraception, 
the voluntary abortion rate has not fallen (Table 1.7). Since 2000, 5–6% of 
the total number of abortions was among women under age 18. Drug-induced 
abortions accounted for half of the total abortions (Danet, 2012).
In 2010, the French number of neonatal deaths per 1000 births was 2.5 
(Table 1.7), the same as the EU27 average. Mortality rates have diminished for 
each age group, except for infant mortality, which remained stable at 3.3 per 
1000 live births in 2012. In the overseas departments, infant mortality is more 
than two times that of metropolitan France. After a significant decrease in 2005, 
maternal mortality has once again increased, and in 2010 the rate was 8.9 deaths 
per 100 000 births (Table 1.7). A 2011 ministerial circular directed the ARSs to 
make the reduction of avoidable maternal deaths a priority.
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2. Organization and governance
The French health care system is of a mixed type, structurally based on a Bismarckian approach with Beveridge goals reflected in the single public payer model, the current increasing importance of tax-based revenue for 
financing health care and strong state intervention. SHI, under various schemes, 
currently covers almost 100% of the resident population. The delivery of care 
is shared among private FFS physicians, public hospitals, private non-profit-
making hospitals and private profit-making hospitals. In addition to the health 
care sector and the social sector, there is a health and social care sector, known 
as the “third” sector (le secteur médico-social), which provides care and services 
to elderly and disabled people.
Jurisdiction in terms of health policy and regulation of the health care system 
is divided among the state (parliament, government), SHI and, to a lesser extent, 
local authorities, particularly at the regional level. However, trends in the reforms 
since the mid-1990s have attempted to devolve a greater remit in governance 
and health policy decision-making, in particular in the area of planning, to 
the regional level. Several regional institutions were created to represent the 
main stakeholders – SHI schemes, the state, health professionals and public 
health actors – at the regional level. However, with the aim of achieving better 
governance of the system at the regional level, better responsiveness to needs 
and higher efficiency, the 2009 HPST merged most of these institutions into 
a single “one-stop shop”, the ARS. Cutting across the traditional boundaries 
of health care, public health and health and social care sectors, the ARS has 
responsibility for ensuring that health care provision meets the needs of the 
population by improving articulation between ambulatory, hospital and health 
and social care sectors, while respecting national health expenditure objectives.
Planning and regulation involve negotiations among provider representatives 
(hospitals and health professionals); the state, represented by the ministries 
in charge of health and in charge of the budget and public accounts; and SHI. 
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The outcome of these negotiations is translated into administrative decrees 
and laws passed by the parliament and collective agreements signed by SHI 
and health professionals’ representatives. These include the Public Health Act 
(Loi relative à la politique de santé publique), Social Security Finance Act (Loi 
de financement de la sécurité sociale) and other reform acts. In the context 
of increasing health care expenditure and the increasing deficit of SHI, the 
role of the state in planning and regulation has increased since the mid-1990s. 
Responsibility for capacity planning is shared by the central and the regional 
levels. At the regional level, the ARSs coordinate ambulatory and hospital care 
for the population as well as health and social care for the elderly and the 
disabled through the PSRS, which is based on population needs. Each sector’s 
planning process must comply with the PSRS. This is a first attempt at regional 
planning of the ambulatory care sector.
Providers are paid by SHI, but patients may have to pay the provider and 
claim reimbursement by SHI afterwards (e.g. for GP visits). The statutory tariffs 
are set through negotiations between providers and SHI and are approved by the 
Ministry in charge of Health. Quality of care is regulated at the national level. 
Hospitals must undergo a certification process every four years but there is no 
formal recertification or relicensing process for health professionals. However, 
doctors, pharmacists, dentists and midwives are required to follow lifelong 
learning activities through professional continuous development. 
2.1 Overview of the health system
The French health care system is structurally based on a Bismarckian approach, 
with goals of universality and solidarity that have led to an increasingly 
Beveridge style of system. SHI currently covers almost 100% of the resident 
population. Jurisdiction over health policy and regulation of the health care 
system (Fig. 2.1) is divided among:
• the state: the parliament and the government, specifically the Ministry 
in charge of Health;
• SHI; and
• local communities to a lesser extent, particularly at the regional level.
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Fig. 2.1 
Overview of the health system in France, 2014 
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Delivery of care is shared among private, independent physicians, public 
hospitals, private non-profit-making hospitals and private profit-making 
hospitals. Alongside the health care sector and the social sector, there is a 
combined health and social care sector, the “third sector”, that provides care 
and supportive services to elderly and disabled people.
2.2 Historical background
The present system of social security, including SHI, was established after the 
Second World War. Prior to this, health and social care were largely provided 
through mutual benefit associations. The statutory system first emerged with 
the 1930 Act on Social Insurance, which created a system of compulsory 
protection paid for by employers for employees whose earnings fell below a 
certain level. Coverage encompassed five areas: illness, maternity, disability, 
old age and death. By 1939, two-thirds of the French population was covered 
for illness by mutual benefit associations, with free choice of the organization 
providing coverage. The creation of SHI in 1945 within the social security 
system changed the role of these associations, which either disappeared or 
became providers of VHI (see section 3.3.2).
Social security consists of compulsory protection, with four branches 
covering health, work-related illness and injuries, retirement and family. SHI is 
the branch of social security covering health (disease, maternity, incapacity and 
death) and is funded by contributions from both employers and employees, with 
benefits provided in cash and in-kind. While the founders of the social security 
system, largely inspired by the Beveridge report in the United Kingdom, aimed 
to ensure uniform rights for all, this was opposed by certain social–professional 
groups that already benefited from insurance coverage with more favourable 
terms. Several of them succeeded in maintaining their particular systems, 
which were transformed into small SHI schemes. However, today, three main 
SHI schemes cover 95% of the population (see section 2.3.5).
Initially, SHI covered workers and their families only. However, the principle 
of expanding coverage to the whole population had been raised as early as 1945 
but was only put into practice in stages (for more details, see section 2.2 in 
Chevreul et al., 2010).
The shift from an employment-based system towards the CMU system was 
nearly achieved with the 1999 Universal Health Coverage Act (Loi No. 99–641 
du 27 juillet 1999 portant création d’une couverture maladie universelle), which 
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instituted a residency-based right to SHI coverage and created the CMU Fund 
(Fonds CMU; see section 3.2) to provide free public coverage for individuals 
whose incomes fall below a certain level; individuals above this threshold who 
are not entitled to SHI on an occupation basis must pay a share of their income 
to be covered on a voluntary basis by SHI. Undocumented immigrants are not 
eligible for access through CMU. However, those who have lived in France 
for at least three months are eligible for free coverage under the state medical 
assistance (aide médicale de l’état; AME) (see section 3.3.1). In parallel, from 
the late 1990s, funding methods on the beneficiary side have shifted from 
an earned income-based social contribution to an earmarked tax, the CSG 
(see section 3.3.1).
2.3 Organization
The current institutional organization of the health system is the result of the 
will of the founders of the social security system to create a single block system, 
guaranteeing uniform rights for all. Health insurance in France, therefore, 
has always been more concentrated and uniform than in other Bismarckian 
systems. Another key difference is that the French SHI has never really had the 
management responsibilities accorded to SHI regimes and funds such as those 
in the German health care system. The state rapidly took responsibility for the 
financial and operational management of SHI (e.g. setting premium levels and 
the prices of goods and services), and nowadays management responsibilities 
are shared between the state and SHI.
2.3.1 The parliament
The parliament has control over the health care system and its resources. It 
has control over health policy priorities by passing public health acts. The 
first Public Health Act was passed in 2004 (Loi No. 2004–806 du 9 août 2004 
relative à la politique de santé publique) and a new one is expected in late 2015. 
The parliament has control over resources by passing an annual Social Security 
Finance Act. This Act is proposed by the government, based on the reports of 
(1) the Auditor’s Office (Cours des comptes), which is an independent public 
body responsible for monitoring state and social security bodies, to ensure 
adequate control over and proper use of public funds; (2) the High Council 
for the Future of Health Insurance (Haut conseil pour l’avenir de l’assurance 
maladie; HCAAM); (3) the High Council for Public Health (Haut conseil de 
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la santé publique; HCSP); and (4) the National Health Conference (Conférence 
nationale de santé) (the last three advisory bodies are described in section 2.3.7). 
This Act on Social Security Finance:
• sets a projected target (ceiling) for health insurance spending for the 
following year (ONDAM);
• approves a report on trends in policy for health and social security; and
• contains new provisions concerning benefits, regulation and measures to 
reach the target.
The parliament also approves the revenue side of the budget based on the 
contribution rates for employers, beneficiaries and employees, and specific 
earmarked taxation proposed by the government.
The government, however, retains the leading role in proposing both public 
health acts and the annual Social Security Finance Act to the parliament and in 
writing the by-laws and decrees that result from the acts passed.
2.3.2 Ministry in charge of Health
The Ministry in charge of Health is the central level of the Administration of 
Health and Social Affairs (Administration sanitaire et sociale). It comprises 
four directorates, which have the following responsibilities:
• General Directorate of Health (Direction générale de la santé), which 
oversees health policy;
• General Directorate of Health Care Supply (Direction générale de 
l’organisation des soins), which manages the human and capital resources 
of the entire health care system;
• Directorate of Social Security (Direction de la sécurité sociale), which 
is responsible for the policies, governance and financing of the social 
security system, including preparation of the annual Social Security 
Finance Act passed by the parliament; and
•  General Directorate for Social Policy (Direction générale de la cohésion 
sociale), which is responsible for health and social care for elderly, 
disabled or vulnerable people.
Depending on the government in place, the Ministry in charge of Health 
may have a different name; it will include the four directorates or fewer and 
each of the directorates will be the responsibility of one or more ministers. This 
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depends on the political power of the minister who is in charge of health. Since 
2014, the Ministry in charge of Health also has responsibility for social affairs 
and women rights.
The Ministry in charge of Health is responsible for preparing and 
implementing government policy in the areas of public health and organization 
and financing of the health care system in the frame of the Public Health 
Act. It controls a large part of the regulation of health care expenditure 
based on the overall framework established by the parliament. Its specific 
responsibilities include:
• allocating the budgeted expenditure among the different sectors (hospitals, 
ambulatory care, mental health care, social and health sector for disabled) 
and, with respect to hospitals, among the different regions;
• deciding on the number of medical students to be admitted to medical 
school each year (numerus clausus), the number of hospital beds 
and the amount of heavy medical equipment, including expensive 
medical technologies;
• setting the lump sum tariffs for public and private hospitals under the 
T2A system;
• approving the agreements signed between SHI and unions representing 
self-employed health care professionals;
• setting the prices of drugs and devices on the basis of proposals from 
the National Health Authority (Haute Autorité de Santé; HAS) ad 
hoc committees;
• establishing safety standards in hospitals; and
• defining priority areas for national programmes.
At the regional level, the Administration of Health and Social Affairs is 
represented by the ARSs (see section 2.4), which are not directly under the 
supervision of the Ministry in charge of Health but fall under the administrative 
supervision of the National Steering Council (Conseil national de pilotage; 
CNP), which is composed of delegates of the ministries in charge of health and 
in charge of public accounts and social security, the SHI and the CNSA.
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2.3.3 Subordinate agencies/arm’s length bodies
The Ministry in charge of Health relies upon a number of health agencies, 
which are under its supervision, and other public bodies in the development and 
implementation of policies for which it is responsible. Some of these agencies 
are part of the public health prevention and health safety surveillance network 
(see section 5.1.1).
French Biomedicine Agency (Agence de la biomédecine). This is a public 
organization operating in four key areas of human biology and medicine: 
assisted reproductive technologies; prenatal and genetic diagnosis; embryo 
and stem cell research; and the procurement and transplant of organs, tissues 
and cells.
French National Agency for Medicines and Health Products Safety (Agence 
nationale de sécurité du médicament et des produits de santé; ANSM). The 
ANSM is the competent authority for all safety decisions taken concerning 
health products from their manufacturing to their marketing. It carries out four 
core missions: (1) scientific evaluation, (2) laboratory oversight and advertising 
regulation, (3) inspection of industrial sites, and (4) information for health 
professionals. The ANSM also coordinates vigilance activities relating to all 
relevant products. This Agency, successor to the French Health Products Safety 
Agency (Agence Française de Sécurité Sanitaire des Produits de Santé), was 
created in the wake of the scandal over Mediator, an anti-diabetes drug that 
remained on the French market until 2009 despite mounting evidence of serious 
side-effects that led other countries to ban it as early as 1997 (see section 6.1).
French Blood Agency (Etablissement français du sang). This is the 
single operator for blood transfusions in France, and its mission is to ensure 
the availability and the safety of red blood cells, platelets and plasma 
throughout France.
InVS. The Institute is responsible for surveillance and alert in all domains 
of public health. Its mandates include monitoring and permanent observation 
of population health conditions, health surveillance and health alerts, including 
the safety of products intended for human use.
INPES.  The Institute is in charge of implementing policies in matters of 
prevention and health education within the government’s public health policy 
framework. It also has in its remit management of emergency or exceptional 
situations having serious consequences on the health of the general population.
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Health Emergency Preparedness and Response Agency (L’Établissement 
de préparation et de réponse aux urgences sanitaires; EPRUS). The Agency 
was created to respond to serious health threats in France, as well as around the 
world, by facilitating the organization and deployment of health personnel in 
the event of a major health crisis. EPRUS maintains a corps of health reservists, 
including working and retired health professionals as well as students at the 
end of their studies, who are prepared to intervene on the ground in France or 
abroad. It also manages France’s strategic pharmaceutical stock.
French Agency for Food, Environmental and Occupational Health Safety 
(Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et 
du travail; ANSES). The ANSES evaluates risks in food, the environment and 
workplaces through monitoring, alert, research and investigation. It was created 
in July 2010 by the fusion of the French Agency for Health Safety, Environment 
and Labour (Agence française de sécurité sanitaire de l’environnement et du 
travail) and the Food Safety Agency (Agence française de sécurité sanitaire 
des aliments).
Radioprotection and Nuclear Safety Institute (Institut de Radioprotection et 
de Sécurité Nucléaire; IRSN). The IRSN was created in 2002 and is under the 
joint authority of the ministries of the environment, health, industry, research 
and defence. The IRSN’s field of expertise covers all of the risks related to 
ionizing radiations used within industry and medicine, as well as natural 
radiation rays.
Agency for Information on Hospital Care (Agence technique de l’information 
sur l’hospitalisation). The Agency manages the information systematically 
collected from all hospital admissions and used for hospital planning 
and financing.
National Agency to Support the Performance of Health and Health and 
Social Care Institutions (Agence nationale d’appui à la performance des 
établissements de santé et médico-sociaux; ANAP). The ANAP provides 
advice and support to health and social care organizations for internal 
reorganization plans; when facing financial difficulties for asset management; 
for merger and acquisition programmes; for assessment, audit and expertise 
of strategic plans, with a particular focus on buildings, equipment and the 
information systems; and for audits of performance. ANAP is also required to 
provide support to the ARSs (see section 2.4) and to the Ministry in charge of 
Health in monitoring the performance of health and social care organizations 
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and in the strategic planning of health care provision and delivery. The 
development of tools to monitor and improve the performance of hospitals and 
social care organizations is also in the remit of ANAP.
National Agency for the Quality Assessment of Health and Social Care 
Organizations and Services (Agence nationale de l’évaluation de la qualité 
des établissements et services sociaux et médico-sociaux). The remit of the 
Agency is to promote an environment of “empathic treatment” (bientraitance) in 
health and social care, which encompasses the promotion of patient rights and 
the development of preventive measures to avoid mistreatment, in particular in 
vulnerable populations such as elderly, disabled people, children, adolescents 
and socially excluded people. It produces practice guidelines for the health and 
social care sector and evaluates organizations and services.
National Institute for Cancer (Institut National du Cancer; INCa). This is 
the national health and scientific agency for oncology and it provides expertise 
in the field of cancer and scientific programming, evaluation and financing of 
projects. It mainly provides expertise in the field of treatment and develops 
clinical guidelines, monitors and finances research and development in cancer 
and contributes to continuing medical education in the field of cancer.
The merger of three of these health agencies has been proposed as part of 
the planned 2015 Health Reform Law (projet loi de santé 2015, see section 6.2): 
InVS (public health surveillance), INPES (education and prevention) and 
EPRUS are to be absorbed into a National Institute for Prevention, Surveillance 
and Public Health Intervention.
2.3.4 Independent health authority
The HAS is an independent public body with financial autonomy to bring 
together within a single entity a number of activities designed to improve the 
quality and the efficiency of patient care. The HAS remit is diverse, ranging 
from assessment of drugs, medical devices and procedures to publication of 
guidelines and accreditation of health care organizations and certification 
of doctors. It is mandated by law to carry out specific missions on which it 
reports to the government and the parliament. It liaises closely with government 
health agencies, SHI funds, research organizations, unions of health care 
professionals and patients’ representatives. Its agenda is defined by a board of 
eight directors designated by the presidents of the French Republic, the National 
Assembly, the Senate and the Economic and Social Council. The HAS board 
provides governance. Each board member heads a specialist committee and is 
responsible for a specific mission or specific aspects of a mission. It has recently 
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been considered too independent in terms of defining its work programme 
and, therefore, not responding appropriately to the need of the government 
and the state for more guidance concerning the efficiency of the system. The 
planned 2015 Health Reform Law (see section 6.2) is, therefore, considering a 
change in the strategic governance of HAS to ensure that it will respond more 
appropriately to public needs.
2.3.5 SHI
SHI is composed of several schemes, which cover virtually the entire population. 
Individuals and their families are affiliated with a scheme based on their 
employment status and remain in this scheme in retirement. Working people 
have no choice regarding the scheme in which they are enrolled and may not 
opt out of coverage except in certain cases (e.g. expatriates and employees of 
international corporations or institutions). Consequently, there is no competition 
among the schemes. Non-working people are automatically enrolled in the 
general scheme.
The three main schemes and beneficiaries in 2011 are as follows:
The general SHI scheme (Caisse nationale d’assurance maladie des 
travailleurs salariés; CNAMTS) covers employees in commerce and industry 
and their families (57 million beneficiaries accounting for 88% of the population) 
and individuals eligible for CMU basic coverage (2.2 million beneficiaries, 
3.4% of the population).
The agricultural SHI fund (Mutualité Sociale Agricole) covers farmers and 
agricultural employees and their families (3.4 million beneficiaries, 5.1% of 
the population).
The SHI scheme for self-employed people (régime social des independents) 
covers artisans and self-employed people (with the exception of self-employed 
agricultural workers), including professionals such as lawyers and independent 
health professionals (4 million beneficiaries, 6% of the population).
The schemes are represented by the National Union of Health Insurance 
Funds (Union Nationale des Caisses d’Assurance Maladie; UNCAM) in 
negotiations with health care providers.
Each of the three major health insurance schemes is made up of a national 
health insurance fund and local structures corresponding to the degree of 
geographical distribution involved.
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Smaller schemes cover just over two million people, also on an employment-
related basis. Several are linked to the general scheme, including those for 
local and national civil servants, doctors working under state health agreements, 
students and military personnel. Other schemes, such as those for miners, 
employees of the national railway company, the clergy, seamen and the 
national bank, function autonomously. For historical reasons, people from the 
Alsace and Moselle regions benefit from their own scheme, which offers better 
coverage with higher contribution rates.
2.3.6 Professional organizations
There are two types of professional organizations: professional associations or 
chambers (conseil de l’ordre) and trade unions. For most medical specialties, 
both an association and a union exist. Professional associations or chambers 
for doctors, pharmacists, dentists, midwives, physiotherapists and nurses are 
concerned with medical ethics and the supervision of professional practice. The 
association is responsible for all matters pertaining to the scientific activities 
of a specialty, including developing guidelines and ensuring compliance with 
annual DPC requirements, while the union is in charge of the negotiations 
between the professionals and SHI over fees and other matters affecting practice. 
In addition to their professional organizations and unions, health professionals 
may also join any of the trade unions that exist to represent workers in all fields 
of industry and services.
Trade union representation is fragmented, not only because of the existence 
of different professions but also through differences in status, for example, 
between salaried and self-employed professionals. In addition to “vertical” 
unions, which represent interests at the national level, “horizontal” unions have 
developed at the departmental level. There are five unions for self-employed 
doctors that are considered representative and competent to sign fee agreements 
with SHI. Because of this diversity, the unions’ positions on government 
measures may differ. Only 15–20% of physicians in private practice are union 
members (Borgetto, 2008).
At the national level, an umbrella organization represents all health care 
professionals in private practice, the National Union of Health Professionals 
(Union Nationale des Professions de Santé). It sets the agenda for negotiations 
between health professionals and SHI and VHI (see section 3.3.4). Similarly, at 
regional level, regional unions of health professionals (Unions Régionale des 
Professionnels de Santé) negotiate with the ARSs (see section 2.4).
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Moreover, physicians working in public hospitals pay a membership fee 
to the National Union of Hospital Physicians (Syndicat des Praticiens des 
Hôpitaux Publics). This organization provides financial assistance in case of 
illness, which has resulted in membership of almost 100%.
Fragmentation of professional representation is not exclusive to doctors. For 
example, the 4000 private laboratories that carry out analyses for outpatients 
have four representative organizations, resulting mainly from divisions among 
large laboratories and small local units.
Hospitals are represented by different organizations, depending on their 
status (public, private non-profit-making or private profit-making). Finally, 
pharmaceutical manufacturers and producers of medical devices each have 
their own union.
2.3.7 The policy formulation process
The Ministry in charge of Health has substantial control over the health system, 
although reforms at both the regional and the national levels have challenged its 
traditional role. For example, at the regional level, the regional health authorities 
(see section 2.4) have public health and health care planning and financing 
responsibilities within their remit; at the national level, the HAS independently 
assesses technologies, hospitals, professionals and the basic benefit package 
(see section 2.3.4).
The policy agenda is set by the Ministry in charge of Health through acts 
approved by the parliament that define health targets pursuant to the objectives 
of the Public Health Act. However, this is done jointly with the Ministry in 
charge of Finance and Public Accounts with respect to the annual Social 
Security Finance Act, which deals with the collection of revenues and delivery 
of health services.
Policy formulation is undertaken with the help of several advisory 
committees such as the HCAAM, the National Health Conference and the HCSP.
HCAAM is an independent committee that publishes an annual report on 
the situation of the health care system. Members are representatives of all 
stakeholders and a few experts selected by the Ministry in charge of Health 
to provide detailed figures and policy forecasts as well as policy proposals to 
ensure the sustainability and fairness of the system.
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The National Health Conference brings together representatives of the 
health professions, health care facilities, the Regional Conference on Health 
and Autonomy (Conférence régionale de la santé et de l’autonomie; CRSA) 
and other experts, to discuss and define health care priorities at the national 
level. The strategy is mainly implemented through the regional health projects 
(projets régionaux de santé; PRS), through which the PSRS is developed by 
the ARSs in consultation with the stakeholders who participate in the CRSAs 
on health and autonomy (see section 2.4).
The HCSP is composed of numerous independent public health experts 
and volunteers appointed by the minister intuitu personae and a share of 
representatives of various subordinate health agencies. It provides guidance 
regarding public health problems and issues related to the organization of 
health care. It undertakes regular overviews of the population’s health status, 
prepares general analyses and forecasts of public health problems, contributes 
to the definition of public health objectives (objectifs de santé publique) and 
makes proposals for strengthening preventive measures. It can also be consulted 
on specific questions concerning the organization of treatment, and in that 
context, it can set up working groups to produce reports on issues and formulate 
proposals. It also monitors the health target objectives of the Public Health Act 
and suggests new objectives.
2.4 Decentralization and centralization
Regional level
The general philosophy underlying decentralization in France reflects a marked 
reluctance to reduce central control over policy and finance, and as a result, it 
has mainly come in the form of deconcentration. The creation of the ARSs in 
2010 changed the regional landscape by merging seven regional institutions (see 
section 2.4 in Chevreul et al., 2010) into a single regional entity traversing the 
traditional boundaries of health care, public health and health and social care 
for elderly and disabled people.
The 26 ARSs are responsible for ensuring that the provision of health care 
services meets the needs of the population by improving the coordination 
between the ambulatory and hospital sectors and health and social care sector 
services, while respecting the ONDAM (see section 3.3.3). They are also 
responsible for implementing regional health policy in relation to occupational 
health services, mother and child health protection services (protection 
maternelle et infantile; PMI), and university and school health services.
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The ARSs monitor the regional health status of the population, ensure 
that hygiene rules are respected, participate in prevention and patient health 
education and assess health professionals’ education. They also carry out SHI 
regional programmes, notably in risk management. They authorize the creation 
of new health services and social and health services for the elderly and disabled. 
In the environment and health sector, they oversee water and air quality.
The CRSAs inform the ARSs’ directors about regional issues, including 
health care and social service needs. Moreover, the ARSs are advised by two 
commissions for coordination of public policies that contain representatives of 
the state, general councils and other local authorities, as well as local SHI fund 
representatives. One is dedicated to prevention, school health, occupational 
health and PMI. The other is dedicated to health and social care for elderly and 
disabled persons.
The ARSs are subsidiaries of the state under the auspices of the ministers 
in charge of health, social security, the elderly and disabled. However, they 
are autonomous bodies, and their directors, appointed by the Ministry in 
charge of Health, have extended autonomy with respect to SHI and CNSA 
budget management and capacity planning in the region. The Surveillance 
Council (Conseil de surveillance), headed by the regional prefect, is in charge 
of approving the budgets and expenses of the ARS and providing opinions 
on the PRS, the main regional capacity planning tool. In order to implement 
national policies at the regional level, services of the state do not communicate 
directly with the ARSs but rather are approved first by the CNP, which passes 
orders on to the ARSs. The National Steering Council contains representatives 
of SHI, CNSA and the ministries in charge of health, social security and the 
elderly and disabled.
This organization, by increasing delegation to the ARSs, has sometimes led 
to coherence problem between regional policies and national health policies to 
meet the cost-containment constraints and improve health services delivery and 
the objectives of the triennial agreement on objectives and management between 
SHI and the state (Convention d’objectifs et de gestion; see section 2.8.1). 
The planned 2015 Health Reform Law (see section 6.2) has recommended 
establishing a contract between SHI and ARSs at the regional level.
Institutions at the department level
Each ARS covers several departments. The ARS is represented in each 
department by a local delegation (délégation territoriale de l’agence regionale 
de santé) that is responsible for implementing the ARS’s regional policies and 
supporting local actors.
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Several health and social services that are not under the remit of the 
ARSs come under the jurisdiction of the General Council (see section 1.3). 
These include:
• health and social care institutions and services for elderly and disabled 
people (nonmedical facilities come under the authority of the general 
councils, who supervise and finance them through social assistance 
budgets, while facilities combining social and medical services come 
under the joint supervision of the state and the general councils);
• social welfare and work programmes supporting individuals with low 
incomes, elderly and disabled people in institutions and financing of 
home assistance;
• protection of children, particularly through the management of PMI 
centres, which offer consultations and free health care;
• prevention of certain diseases, such as tuberculosis, sexually transmitted 
diseases and cancer; and
• public health and hygiene (environmental health, sanitation, etc.), in 
conjunction with municipalities.
2.5 Planning
2.5.1 Capacity / capital planning
Health services are provided by office-based physicians and hospitals. Office-
based physicians are self-employed. Ownership of hospitals is divided among 
government (public hospitals); non-profit-making organizations that are 
linked to the public sector and tend to be owned by foundations, religious 
organizations or mutual-insurance associations; and private profit-making 
hospitals, ownership of which is increasingly concentrated in large international 
groups. Responsibility for planning health system resources and capacity is 
shared by the Ministry in charge of Health and the 26 ARSs. The goal of this 
partial devolution of the planning function is to enable regional authorities to 
meet the health needs of the population more appropriately.
Hospitals
Other corporate actors, such as the hospital federations (see section 2.3.6) 
and public representatives, also participate in the planning process and may 
play an important role during consultations. The regulatory framework for 
hospitals applies equally to public, private non-profit-making and private 
profit-making providers.
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Planning largely takes place at the regional level, involving the CRSA and 
the ARSs. The Ministry in charge of Health has a stewardship role, establishing 
a catalogue of health services that the regions must incorporate in their plans 
based on a national assessment of needs and (sometimes politically driven) 
priorities. The strategy is mainly implemented through a regional health 
organization plan (Schema Régional d’Organisation de soins; SROS) developed 
by the ARSs in consultation with the stakeholders (including the Ministry in 
charge of Health) who participate in the CRSA. Developed every five years, 
the SROS aims to tailor health care delivery to local needs by setting strategic 
goals for health care delivery and defining priorities based on the objectives 
of the PSRSs. Strategic planning requires the ARS to assess population health 
needs based on regional data regarding health care utilization, mortality and 
morbidity. Data are analysed by region and compared across regions to identify 
demand and over- or undercapacity.
The SROS also forms the legal basis for multiyear contracts for targets and 
resources contracts (contract pluriannuels d’objectifs et de moyens) between 
hospitals and the ARSs in terms of the responsibilities of each hospital and the 
volume of services to be provided. These contracts are typically negotiated for 
a period of five years and require hospitals to obtain authorization from the 
ARS for the services they provide (including expensive health technologies). 
They also require annual evaluation of existing capacity and service volumes. 
Hospitals may be financially penalized (up to 5% of total revenue) for failure to 
adhere to target contracts and the ARSs may suspend the authorization for the 
service. However, to date no hospital has been penalized. A new model contract 
was negotiated by the Ministry in charge of Health and the hospital federations 
for the SROSs for 2013–2018.
Health and social care services for the frail elderly and disabled
Since the creation of the ARSs, planning is done through an organizational 
pyramid.
1.  At the top of the pyramid, a regional scheme for organization of the health 
and social care sector (Schéma Régional de l’Organisation Sociale et 
Médico-Sociale) is established by the director of the ARS, on the advice 
of a dedicated ARS commission, the coordination committee dedicated 
to the health and social care sector (Commission de coordination dédiée 
au secteur médico-social), composed of representatives of the state, of the 
general councils and of the social security schemes involved in financing 
the sector, and of the heads of the general councils. This regional scheme 
should meet the objective of the PRS.
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2.  In the middle is the interdepartmental programme of support for 
individuals with disabilities or loss of autonomy (programme 
interdépartemental d’accompagnement des handicaps et de la perte 
d’autonomie), which translates the regional scheme for health and social 
care sector organizations into authorization for capacity-building. It is 
established by the ARS directors and the heads of the general councils.
3.  At the bottom of the pyramid, the heads of the general councils design 
departmental schemes for the disabled (schémas départementaux relatifs 
aux personnes handicapés ou en perte d’autonomie) to plan health and 
social care services in conjunction with the ARS commissions, the 
representatives of health and social care services and service users living 
in the departments.
Once this planning process is completed, a call for proposals is made by an 
ARS selection committee to choose capacity-building projects that meet the 
identified local priorities.
2.5.2 Human resources planning
The National Observatory of Health Professionals (Observatoire National de la 
Démographie des Professions de Santé) was created in 2003 to provide figures 
and guidance to the Ministry in charge of Health. Its annual reports provide 
information on weaknesses in information required for the steering of human 
resources in the French health care system by the Ministry in charge of Health. 
It also identifies gaps in strategic planning at the national and regional levels.
At the national level, the numbers of doctors, and to some extent their areas 
of specialization, are regulated by the numerus clausus, which is set by the 
government annually and controls access to the second year of study in medical 
schools. This numerus clausus is then applied at the regional level, taking into 
account current inequalities in the geographic distribution of doctors. There is 
also a numerus clausus limiting the entry of students in other health professions, 
such as nursing, midwifery, dentistry, speech pathology and physiotherapy (see 
section 4.2.1).
For doctors, after six years of study, all medical students undertake a 
national competitive examination (épreuves classantes nationales; ECN). 
Based on the results, students apply for open internship posts by area of 
specialization and location. In recent years, the lack of interest in certain 
specialties (anaesthesiology, intensive care, gynaecology and obstetrics, and 
paediatrics) has led the government to block a number of places for these 
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specialties in the national examination. A 2011 decree (décret n° 2011-954 du 
10 août 2011) prohibited students from sitting for the ECN if they failed to gain 
access to medical studies in France following the common first year (Première 
Année Commune aux Études de Santé) and pursued their medical studies in 
another EU country (see section 4.2.2). A Romanian medical school challenged 
the law, and in early 2013, the decree was overturned. Some unions of health 
professionals fear that allowing foreign-trained students access to the ECN will 
undermine regulatory effectiveness of the numerus clausus.
After graduation, there is no restriction on the areas where professionals are 
allowed to practise. Hospital work is dependent on posts offered by institutions 
but self-employed professionals can establish their practices wherever they want. 
As a result, there are regional disparities in the distribution of self-employed 
doctors and other health professionals.
Since the early 1990s, a range of tools and incentives have been developed 
that are designed to address the inequitable supply of physicians and to meet 
the objectives of the SROS. Access to medical specialties in each territory is 
now regulated by quotas set five years in advance, and a system of financial 
incentives to encourage doctors to work in underserved areas was established. 
The public service commitment contract (contrat d’engagement de service 
public) may be offered to medical students and residents who receive a 
monthly allowance during their studies in return for the commitment to work 
in an underserved area without practising extra-billing (i.e. under Sector 1 
agreements; see section 3.7.2). For nurses, a first attempt to implement a tighter 
form of planning was implemented following the 2007 national agreement of 
nurses with SHI. This includes financial and material incentives for nurses to 
settle in underserved areas and prohibition of settlement in overserved areas 
unless a retiring or leaving nurse is replaced (see section 4.2.1). For more details 
on incentives developed to address inequitable supply, see section 6.1.3.
2.5.3 Major medical equipment
Purchase of major medical equipment in both outpatient and inpatient 
settings in the private and public sectors is subject to authorization by the 
ARSs. In 2013, five types of equipment required such authorization: computed 
tomography (CT) scanners, MRI equipment used for clinical purposes, positron 
emission tomography (PET; tomographie par émission de positons) devices, 
decompression chambers and cyclotrons used for cancer therapy. Authorization 
is granted for five years, according to needs defined in the SROS.
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2.5.4 Cross-border mobility of patients and health workers
France has entered into trans-border agreements for the use of hospital facilities 
in the border regions of Belgium, Italy, Spain and Switzerland. France and 
Belgium, which have the most extensive cross-border patient movements, have 
implemented common protocols for emergency care as well as an agreement 
established by four hospitals in neighbouring cities that allows patients from 
both countries to receive care without preliminary authorization from either 
health system. Wider patient mobility throughout the EU, the EEA and the rest 
of the world is governed by European regulations and international agreements 
(see section 2.9.6).
In terms of mobility of health workers, France is a net receiving country, 
as emigration of French-trained professionals is low. French law distinguishes 
professionals with European diplomas, who are entitled to the same rights as 
French-trained professionals pursuant to European regulations, and those with 
diplomas from outside the EU, who are subject to stricter standards. Doctors 
with non-EU diplomas may be authorized to practise on a case-by-case basis, 
while paramedical professionals trained outside of the EU must resume their 
studies and obtain a French diploma (see section 4.2.2).
2.5.5 Health sector preparedness
Responsibility for the government’s response to exceptional health emergencies 
(situations sanitaires exceptionnelles) falls largely under the Minister of 
the Interior and the Ministry in charge of Health within the context of an 
interministerial crisis unit (cellule interministérielle de crise). Four national 
agencies have key roles: InVS, ANSM, ANSES and EPRUS (see section 2.3.4). 
EPRUS, in particular, has a transverse role, falling under the shared oversight 
of the General Directorate of Health and Health Emergencies Department 
(Département des Urgences Sanitaires), with a director selected from the 
prefectural corps attached to the Interior Ministry. EPRUS provides logistic 
expertise and support in terms of materials, training and personnel, including 
6000 voluntary reservists, mostly doctors and nurses.
At the regional level, health crisis preparation is undertaken pursuant to the 
organization plan for the health system response to public health emergencies 
(Organisation de la réponse du système de santé en situations sanitaires 
exceptionnelles), which defines appropriate care pathways for various 
emergency situations as well as coordination modalities among the actors, 
including assignment and management of response measures and the training 
Health systems in transition  France 39
of health professionals to respond to such emergencies. The ARSs must develop 
an organization plan, which is implemented under the control of the prefect in 
the event of a crisis.
2.6 Intersectorality
The National Public Health Committee (Comité national de santé publique) is 
the steering committee for broad intersectoral health plans. Created by the 2004 
Public Health Act, it was designed to improve coordination and information 
exchange among the ministries whose policies may have a health impact, 
particularly in the areas of health security and prevention. The Committee 
comprises directors or representatives from the ministries in charge of health, 
social security, social affairs, labour, education, security, defence, justice, 
finance, agriculture and environment, as well as UNCAM, the Directorate 
of Research, Studies, Evaluation and Statistics (Direction de la Recherche, 
des Etudes, de l’Evaluation et des Statistiques) and the interministerial 
missions regarding drugs and addictions, cities and road safety. While this 
is an intersectoral approach, to date the Committee has undertaken few 
operational activities.
Nonetheless, there are specific areas in which intersectoral cooperation 
is better defined and developed, as it is the case, for example, with health 
emergency preparedness (see section 2.5.5) and with policy against drug 
addiction, which is the oldest and more developed intersectoral action based on 
the Health in All policy approach. Ten ministries are part of the Interministerial 
Mission for the Fight against Drugs and Addictive Behaviours (Mission 
interministèrielle de lute contre les drogues et les conduites addictives). The 
interministerial mission was created in 1982 with the objectives of coordinating 
public policies on this matter but also providing funding and help in designing 
appropriate policies (MILDECA, 2015). It works with the help of the OFDT and 
the interministerial centre for anti-drug training (Le centre interministériel de 
formation anti-drogue), which focuses on the fight against cocaine.
Moreover, the Interministerial Committee to Combat Exclusion (Comité 
interministériel de lutte contre l’exclusion) currently takes actions that aim to 
reduce health inequalities within a multiyear plan against poverty and social 
inclusion, which was adopted in December 2012. Key initiatives include 
reducing financial barriers to access to care, for example by making more 
user-friendly access to programmes providing CMU-C (see section 3.5.1); 
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or by providing financial assistance to obtain CMU-C under a voucher plan 
for its purchase (aide à l’acquisition d’une complémentaire santé; ACS) (see 
section 3.5.4).
In order to promote healthier diets, the Ministry in charge of Health 
launched in 2005 the National Health Nutrition Programme (Programme 
national nutrition santé). This enlisted support from other ministries, most 
notably the Ministry of Agriculture, which in 2007 developed a food policy 
“to incite the agricultural and agrifood industries to launch varied, high-quality 
foods that meet consumer expectations and public health objectives”. The 
programme also focused on encouraging people to exercise more. Another 
objective concerned salt intake, including a contractual partnership between 
public health stakeholders and food industries to achieve a reduction in salt, 
sugar and fat intake.
2.7 Health information management
2.7.1 Information systems
Information on consumption of SHI-covered care by SHI beneficiaries
There are two coexisting information systems in France: one for hospital 
admissions used by hospitals to bill SHI based on the French DRG system 
and one for patient reimbursement claims for ambulatory and hospital care. 
For hospitals, the Agency for Information on Hospital Care groups data from 
the Programme of Medicalization of Information Systems (Programme de 
médicalisation des systèmes d’information; PMSI) at the national level. For 
reimbursement claims, there are several systems attached to different SHI 
schemes that are merged into a single database. Both types of information are 
used for reimbursement claims but not for medical purposes.
From 2003, they were both integrated in the SHI interscheme information 
database (Systeme National d’Information Inter-Régimes de l’Assurance 
Maladie; SNIIR-AM) to create a single comprehensive information system. 
To facilitate research using these data, permanent samples of SHI beneficiaries 
have been established. In order to improve the interoperability of the 
information systems and to monitor the creation of a single patient identifier 
for the electronic patient record (dossier médical personnel; DMP), a dedicated 
information systems agency, the Agency for Health Information Systems 
(Agence des Systèmes D’Information Partagés de Santé), was created in 2009.
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PMSI
The PMSI is based on the production of a standard discharge summary (résumé 
standardisé de sortie) for each acute hospital stay, which describes the nature of 
the treatment and examinations, the diagnosis underlying the hospital admission 
and associated diagnoses or complications. The discharge summary is then 
integrated into the homogeneous hospital stay groups (groupes homogènes 
de séjours; GHS), the French DRG system that was adapted from the DRG 
classification system for hospital stays used in the United States.
The PMSI was first introduced in 1983 and became exhaustive after the 
1996 reform. Initially limited to the acute care sector (médecine, chirurgie, 
obstétrique), it was later extended to HAD, for the rehabilitation sector (soins 
de suite et de réadaptation; SSR) and for the psychiatric sector (based on 
the summary of medical information for psychiatry (recueil d’informations 
médicalisées en psychiatrie). All of these systems retain data from their 
implementation date, and a patient’s course may be followed over the years 
and across systems.
National cost scales (echelle nationale des coûts à méthodologie commune) 
have been established. A national baseline for costs per stay (DRG based) in the 
acute care sector has been constructed from a voluntary sample of public and 
private hospitals, with a detailed accounting system producing an evaluation 
of the total cost of each stay. For each DRG, the median cost of all stays in the 
sample is taken as a reference point. Similarly, national cost scales exist for 
HAD and SSR. The SSR sector is also supposed to be paid on a DRG basis 
system in the near future.
Reimbursement claim systems
Reimbursement claim systems include patient data such as age, gender, place 
of residence, affiliation number, eligibility for 100% coverage and reasons for 
eligibility (such as CMU or long-term illness (affection de longue durée; ALD)) 
and data on type and quantity of care consumed.
In the SHI general scheme, the system for extraction, research and analysis 
for economic follow-up (extraction, recherches et analyses pour un suivi 
medico-économique) collects data on health care consumption. Data are 
maintained for the previous two years plus the current running year and older 
data are archived.
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Since October 2009, most of these systems have been merged into the SHI 
Interscheme Consumption Data Mart (Données de consommation inter-régime). 
This system includes information on ambulatory care usage for most of the 
population for the previous two years plus the current running year. The data 
for only a few small SHI schemes (such as the miners’ scheme) are not included.
The SHI interscheme system
The 1999 Social Security Finance Act (Loi No. 98–1194 du 23 décembre 
1998 de financement de la sécurité sociale pour 1999) established a national 
information system for SHI, the SNIIR-AM, primarily to provide information 
and feedback on professional practice for office-based physicians and public 
and private hospitals. The SNIIR-AM exhaustively regroups SHI claim and 
hospital stay information from most of the SHI schemes in the Interscheme 
Consumption Data Mart and PMSI for the previous two years plus the current 
running year. The unit of analysis is the prescribing physician and the patient, 
and thus information may be linked in order to study a patient’s care pathway 
or a physician’s practice profile.
As a research tool, SNIIR-AM has both strengths and weaknesses. Among 
its strengths are its exhaustivity and precise chronology, which allow for 
longitudinal analysis. However, there are data that SNIIR-AM cannot capture, 
including socioeconomic characteristics, diagnoses, risk factors, test results and 
compliance with treatment. Until recently, access to these data has been strictly 
limited. Following the Mediator scandal (see section 2.3.4), the push for greater 
transparency, including open data, has led to legislation to broaden access to the 
SNIIR-AM data for researchers and public institutions under certain technical 
and legal conditions (planned 2015 Health Reform Law; see section 6.2).
Samples of beneficiaries
Because the SNIIR-AM is based on reimbursement claims, it does not contain 
any information on beneficiaries who do not consume any care covered by SHI. 
To overcome this shortcoming, samples of beneficiaries have been established. 
A sample of beneficiaries (échantillon généraliste de beneficiaires) is a 1/97th 
sample of SHI beneficiaries and currently includes 600 000 people affiliated 
with the three largest SHI funds.
The DMP
In 2004, the DMP grouping of patients’ medical information and care 
consumption in ambulatory and hospital settings was initiated on a voluntary 
basis in order to improve quality of care and decrease redundancy in 
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consumption. Implementation has not been smooth because of both technical 
and patient privacy concerns. As a result, by June 2013, fewer than 400 000 
patients had DMPs (see section 4.1.4).
National information system on health professionals
The national Automated Directory of Health Professionals (Automatisation 
des listes; ADELI) provides information on gender, geographical distribution, 
specialty, type of practice (employed, self-employed, both), starting practice 
date, etc.) of all practising health professionals.
2.7.2 Health technology assessment
Governance and organization of health technology assessment (HTA; 
évaluation des technologies de la santé) are defined by the government and 
SHI. The major HTA body in France is the HAS, which has in-house expertise 
as well as the authority to commission assessments from external groups such 
as academic centres or professional societies.
All medical procedures and technologies (drugs, devices, equipment, 
reagents and tests) are assessed at the request of manufacturers or, in the case 
of procedures, professional societies. For technologies, regulatory approval 
is based on safety and may be supranational, for example undertaken by 
the European Medicines Agency (Agence européenne des médicaments) 
for medicines. The second assessment aims to inform coverage and pricing 
decisions and is specific to the French health care system.
Assessments are performed by ad hoc committees. Drugs are assessed by 
the Transparency Commission (Commission de la Transparence), while devices 
and procedures are assessed by the National Commission for the Evaluation of 
Medical Devices (Commission nationale d’évaluation des dispositifs médicaux 
et des technologies de santé; CNEDIMTS).
In order to be listed in one of the positive lists and covered by SHI, all new 
drugs, devices and procedures must undergo an assessment. This assessment 
is prior to market launch and is used directly to determine the coverage rate 
and less directly the price (statutory tariff). For new technologies, assessment 
is based on the documents provided by the manufacturer. The studies are 
critically appraised by two reviewers and discussed by the committee. There 
is a two-tier procedure.
Is the technology effective? Assessment of the level of medical benefit of 
the technology reflecting its clinical efficacy and its possible side-effects, the 
severity of the disease it is indicated to treat and the public health relevance 
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of the technology (intérêt de santé publique), which includes epidemiological 
aspects and quality of life. The degree of medical benefit or therapeutic value 
is represented by two assessments: SMR for drugs and one for devices and 
medical procedures (service attendu). These two are evaluated in absolute terms 
for all different types of use. The assessment informs decisions on coverage and 
the coverage rate, from 0 to 100% (see section 2.8.4).
Is the technology more effective than the available comparators? An 
assessment is made of the relative medical benefit of the technology in 
comparison with similar available treatments, termed the improvement in the 
relative medical benefit (amélioration du service medical rendu; ASMR) for 
medicines or the improvement in expected benefit (amelioration du service 
attendu; ASA) for medical devices and procedures. There is an explicit 
pricing decision based on the grade given by the drug or the device committee 
(Transparency Commission or CNEDIMTS) depending upon the improvement 
in medical effectiveness over the existing comparators (rated on a scale from 1 
for major improvement, usually assigned to life-saving technologies, to 5 for no 
improvement) (see section 2.8.4). Manufacturers have an incentive to provide 
sufficient data to assess drugs and devices because of the pricing objective.
Technologies are reassessed every five years based on the documents 
provided by the manufacturer and on systematic reviews of the literature.
Starting in October 2013, an economic evaluation has become a part of 
the assessment or reassessment of drugs and medical devices under certain 
circumstances. The HAS Commission for Economic Evaluation and Public 
Health (Commission d’Évaluation Économique et de Santé Publique; CEESP) 
undertakes an economic evaluation if:
• the product or technology is being initially assessed or confirmed as 
having an ASMR/ASA level 1, 2 or 3; and
• the product or technology may significantly affect SHI expenditure, given 
its impact on the organization of health services, professional practices or 
conditions of coverage of patients and, if appropriate, its price; or
• if the provisional or actual turnover for the product after two years on the 
market is €20 million or higher.
For other technologies, such as the equipment required for a procedure, 
reports are commissioned by the Ministry in charge of Health. The HTA 
report may recommend waiting until additional information is available or 
may commission surveys or observational studies. The manufacturer is usually 
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required to fund the studies, but the investigators must be independent from 
the manufacturer. Manufacturers may appeal the decisions of the drugs and 
devices committees and request a second hearing. HAS is empowered to 
undertake evaluation of medical practices and health programmes, which is 
also sometimes performed by hospitals.
2.8 Regulation
The French health care system was initially organized according to a 
Bismarckian model of provision and payment for health care. However, it has 
developed into a mixed Beveridge and Bismarck model, characterized by an 
almost single public payer, the increasing importance of tax-based revenue for 
financing health care and strong state intervention. SHI is financed by employer, 
employee and retiree contributions, increasingly substituted by earmarked 
income taxes. Providers of outpatient care are largely private, while hospital 
beds are predominantly found in public or private non-profit-making hospitals.
In the context of increasing health care expenditure, the increasing deficit 
of SHI and the overall social security system, the role of the state in steering 
the system through regulation has increased since the early 1990s. Regulation, 
therefore, involves negotiations among provider representatives (hospitals and 
health professionals), the state, represented by both the Ministry in charge of 
Health, the Ministry in charge of the Budget and Public Accounts, and SHI. The 
outcome of these negotiations is translated into administrative decrees and laws 
passed by the parliament. These include public health acts and acts related to 
social security funding and reforms.
The Directorate of Social Security proposes an annual Social Security 
Financing Act, which is debated and then approved by the parliament. This Act 
establishes the provisional health care budget, or rather the expected ONDAM 
(see section 3.3.3). Because in France providers are mostly paid by FFS and a 
per-case basis retrospectively, ensuring that SHI health expenditure will match 
the (approved) national ceiling for SHI expenditure is difficult (see section 3.3.3). 
Indeed, the Ministry in charge of Health approves statutory tariffs but does not 
control volume as there is still freedom of choice and no limitation of utilization 
of services. However, regulatory mechanisms such as semi-gatekeeping with 
financial incentives and non-refundable deductibles on physician visits, drugs 
and ambulance transportation (see section 3.4.1) can be seen as attempts to 
regulate volume by using price sensitivity.
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2.8.1 Regulation and governance of third-party payers
SHI
SHI schemes are under the supervision of the Directorate of Social Security. In 
order to ensure that SHI measures will meet the objectives of the government 
health policy, SHI schemes sign a triennial contract with the Ministry in charge 
of Health defining the objectives, the management and the governance of SHI. 
The objectives of this agreement are: to improve efficiency in the management 
of SHI, reduce inequities in access to health care services and develop risk 
management. Actions to meet these objectives set forth in the 2014–2017 
agreement on objectives and management include developing good quality 
patient care pathways.
UNCAM (see section 3.3.3) represents the SHI funds in negotiations with 
the state and health care providers. The director-general of UNCAM is also the 
director of CNAMTS. The director-general is appointed by the government, and 
the executive power of this position has been strongly reinforced at the expense 
of the UNCAM board, whose role is now limited to strategic matters. Collective 
agreements with doctors and other organizations of professionals in private 
practice are negotiated and signed by the director-general alone, illustrating 
the withdrawal of employee and employer unions from the management of 
SHI. SHI is, therefore, fully responsible for the economic consequences of the 
agreements that it negotiates and signs, for example with health professionals in 
private practice. SHI can also set the level of user charges, although this power 
is limited to a certain extent by the political acceptability of the proposals.
VHI
There are three types of VHI suppliers (see section 3.3.2), which operate 
under three different sets of regulation: the mutual insurance companies are 
regulated by the mutual insurance code, the commercial insurance companies 
are regulated by the commercial insurance code, and the provident institutions 
are regulated by the social security code. All three types of VHI suppliers 
fall under the supervision of the Prudential Control and Resolution Authority 
(Autorité de contrôle prudentiel et de résolution).
VHI suppliers participate in the governance of the health care system through 
the National Union of Complementary Health Insurance Organizations (Union 
Nationale des Organismes d’Assurance Maladie Complémentaire), which is 
consulted prior to the annual Social Security Finance Act and all health care 
reforms, in particular when they are related to health care system financing. 
It is also consulted prior to changes on SHI coverage rate and prior to the 
introduction of new products in the SHI benefit package and participates in the 
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negotiation of national agreements with health care professionals. As a member 
of the pricing committee, the Economic Committee for Health Products (Comité 
Économique des Produits de Santé; CEPS), the National Union participates in 
the negotiation of drugs and medical devices prices, along with representatives 
of several ministries and SHI.
2.8.2 Regulation and governance of providers
Professionals
Professionals practise under the regulations of the public health code, which 
includes all regulations related to patient and professional rights with respect 
to medical goods and health services, planning the provision of out-of-hospital 
services and ensuring coordination between hospital and ambulatory care. In 
France, roughly two-thirds of practising health professionals are independent 
self-employed providers. Despite recent regulations aiming to plan geographical 
distribution of doctors, they retain the freedom to establish their practices where 
they wish (see section 6.1.3).
The National Union of Health Professionals is the single organization that 
can legitimately negotiate with the payers at the national level on behalf of all 
types self-employed independent health professional. It is consulted annually by 
SHI and VHI representatives on matters related to the organization of the health 
care system and health professions, such as the relationship between office- 
based and hospital physicians, demography of medical professions, access to 
care, continuing medical training and regulation of health care expenditure. At 
the regional level, regional unions of health professionals negotiate with the 
ARSs (see section 2.4).
There is no formal recertification or relicensing process. However, in order 
to ensure lifelong quality of practice of health professionals, doctors, midwifes, 
dentists, pharmacists, biologists, nurses, physiotherapists and podiatrists must 
undergo DPC. Within the DPC process, accreditation exists for a limited 
number of high-risk medical specialties (i.e. specialties with a high medical 
risk for the patients). It is optional and concerns physicians or medical teams 
practising in hospitals. Medical specialties involved include obstetrics and 
gynaecology (including ultrasound imaging), surgery, interventional radiology, 
anaesthesiology and other interventional specialties such as cardiology. 
Accreditation permits physicians to claim a deduction on the premium they pay 
for their professional insurance. The accreditation process includes a registry of 
adverse events, use of practice guidelines and review criteria and participation 
in educational sessions in risk reduction.
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Hospitals
Both human and physical resources of hospitals are controlled by the government 
through different mechanisms. The Ministry in charge of Health, thorough the 
HAS, ensures that public and private hospitals and hospital physicians meet 
standards of competence through a certification process every four years.
Certification is a two-step process. First, a self-appraisal is conducted 
by hospitals based on HAS guidelines. It requires the compilation of a large 
amount of information, particularly with respect to quality indicators. Second, 
a team of experts assigned by HAS visits the hospital and undertakes the 
certification review.
Hospital quality assurance and risk management are monitored by the 
Ministry in charge of Health through Scope Santé (http://www.scopesante.
fr/). Hospital quality indicators are also compiled through the Coordination 
for the Measurement of Hospital Performance and Improvement in Quality 
of Care (Coordination pour la mesure de la performance et l´amélioration de 
la qualité hospitalière). Experimentation with financial incentives has been 
ongoing since 2012 under the programme of financial incentives to improve 
quality (Incitation Financière à l’Amélioration de la Qualité). Moreover, in the 
field of rare diseases, France has developed dedicated centres.
2.8.3 Registration and planning of human resources
At the national level, the number of doctors, and to some extent their areas 
of specialization, is regulated by the numerus clausus, which is set by the 
government annually and controls access to the second year of study in medical 
schools. This numerus clausus is then applied at the regional level, taking into 
account current inequalities in the geographic distribution of doctors. There is 
also a numerus clausus limiting the entry of students in other health professions, 
such as nursing, midwifery, dentistry, speech pathology and physiotherapy.
Registration by their professional association (see section 2.3.6) is mandatory 
for practising doctors, pharmacists, dentists, midwives, physiotherapists and 
nurses. It is usually granted upon request after the initial training and it is 
good for life. Moreover, registration in the national information system on 
health professionals (ADELI) in the ARSs is also mandatory for almost all 
health professionals.
Health systems in transition  France 49
2.8.4 Regulation and governance of pharmaceuticals
Before being put on sale, all drugs must obtain market authorization 
(autorisation de mise sur le marché; AMM) either at European or national 
level. This specifies the conditions for the prescription and supply of drugs for 
which a medical prescription is mandatory and identifies drugs that are subject 
to special prescription rules (see section 5.6.3).
In order to qualify for SHI coverage, a drug must be included in the so-called 
“positive list” of reimbursable drugs established by ministerial decree on the 
advice of the HAS Transparency Commission (see section 2.7.2) and the CEPS 
pricing committee.
In order to be included on the positive list, evidence must be supplied of 
the SMR for the drug (see section 2.7.2). The coverage and level of coverage is 
determined by decree based on the SMR and the seriousness of the condition 
(Table 2.1). However, drugs that lead to lower cost of treatment can be covered 
despite the fact that their SMR is insufficient.
Table 2.1 
Rate of coverage of drugs according to the seriousness of the pathology and 
evaluation of the SMR, 2014
SMR Rate of coverage (%) a
Serious illness Illness usually benign
Major or considerable 65 35
Moderate 30 30
Low but justifying reimbursement 15 15
Insufficient 0 0
Note: a Some ambulatory drugs are recognized as irreplaceable and particularly expensive by the Ministry in charge of Health, 
in which case they are covered at a 100% level. 
The vast majority of drugs are covered at a 65% rate. In 2011, among the 240 
new drugs examined, 191 were found to justify 65% coverage.
In addition to the SMR, the Transparency Commission evaluates the ASMR 
in comparison with available treatments or drugs already available for the same 
pathologies (see section 2.7.2).
The drug price, which serves as the basis for reimbursement, is then set 
through a bargaining process between the CEPS and the manufacturer, using 
an international benchmarking procedure for the most innovative products.
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CEPS is an interministerial committee defined by decree (article D162-2-1 
of the social security code). It is composed of representatives of the ministers 
in charge of health, of the economy and of research, plus representatives from 
SHI and complementary health insurance organizations. According to the social 
security code, the price must be set according to the ASMR, the price of other 
drugs with same therapeutic indications and the estimated volume of sales. 
Drugs offering a therapeutic advance can have a price higher than the reference, 
whereas drugs classified with no relative medical benefit (ASMR group 5) 
would get a statutory tariff, and so be subsequently covered only if its price is 
lower than that of its alternatives. Since 2003, a new procedure has allowed the 
manufacturer to propose a price that is consistent with prices already defined 
in four other European countries (the United Kingdom, Germany, Spain and 
Italy); the procedure was initially limited to ASMR groups 1 and 2 (major and 
important improvement) products but has now been extended to ASMR 3 and 
certain 4 (low and minor improvement) drugs as well; it is worth noting that the 
manufacturer may nevertheless opt for the standard bargaining process. Drug 
coverage and pricing processes are summarized in Fig. 2.2.
Depending on their level of toxicity or risk of inappropriate use, medicines 
are classified in the public health code based on different categories that will 
determine their prescription rules and facility of access. Drugs that fall into 
the category that does not require a prescription can currently only be sold in 
pharmacies. The distribution of drugs is closely regulated, both for wholesalers 
and for pharmacies. Wholesalers (grossistes-répartiteurs) have a public service 
mission and fall under the regulatory control of the ANSM. They are regulated 
in terms of the range of drugs supplied, level of stock, territory, delivery time 
and mark-ups. Since January 2012, the mark-up is 6.68% for manufacturer 
prices below €450 and 0% for prices above €450.
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Fig. 2.2 
Process for deciding SHI coverage and official tariffs for drugs 
Source: HAS, 2010.
Pharmacies have a monopoly on the dispensing of medicines. Generally, 
retail pharmacies must be owned by a qualified pharmacist or by a group of 
pharmacists associated within a company; these pharmacists or companies 
cannot be proprietors of more than one pharmacy. As an exception to this 
rule, mutual insurance associations and the SHI scheme for miners may also 
own retail pharmacies. The number of pharmacies is regulated by a numerus 
clausus that takes into account both the size of the population to be served and 
the distance to the nearest pharmacy. Pharmacists have financial incentives to 
deliver generic drugs (see section 3.7.1).
Direct-to-consumer advertising for drugs is subject to prior authorization 
and is restricted to specialties that meet three criteria: they can be delivered 
without physician prescriptions; they are not covered by SHI; and no restriction 
on advertisement has been included in the AMM of the product. Vaccines are 
the only exception to this rule. Since 2012, advertisements directed at health 
professionals are also subject to prior authorization and are prohibited for health 
products that are undergoing a risk–benefit re-evaluation.
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Internet sales of non-prescription drugs have been authorized since 2013, but 
uptake has been very limited because of the significant regulatory burden in 
establishing an online sales presence. Only pharmacists are eligible to engage 
in this activity, which must be directly linked to a physical pharmacy and 
authorized by the ARS.
All drug-related adverse events must be reported by physicians, dentists, 
midwives and pharmacists to the regional centre for pharmaceutical vigilance 
(Centre régional de pharmacovigilance), which is responsible for making the 
necessary inquiries and notifying the manufacturer. The ANSM oversees 
and coordinates the national system for pharmaceutical vigilance. Since 2011, 
patients and patient associations may directly declare adverse events. Validated 
reports of adverse events must be reported to the European Medicines Agency 
within 15 days. Moreover, ANSM inspectors have a key role in the fight against 
counterfeit pharmaceuticals, in collaboration with customs inspectors, the 
Ministry of Justice, the police and the gendarmerie. In the event of suspected 
fraud, drugs may be subject to recall or quarantine.
2.8.5 Regulation of medical devices and aids
The market for medical devices is more loosely regulated than the markets for 
drugs or major medical equipment, particularly in terms of quality and safety 
standards. Compliance with quality and safety standards is assessed by the 
provider for devices that present a very low risk for the patient (medical beds, 
stethoscopes, etc.). Other devices must be assessed by an independent body 
selected by the manufacturer (to obtain a European conformity (Conformité 
Européene) mark). Monitoring of the market is under the responsibility of 
the ANSM.
The CNEDIMTS advises the Ministry in charge of Health, which decides 
whether to include a device in the positive list based on its medical benefit 
rating. It also advises CEPS regarding pricing, which will depend on the ASA 
(see section 2.7.2). In this sector, the market price generally is not fixed; rather, 
the SHI statutory tariff is negotiated with the manufacturer and then is used as 
the basis for reimbursement. As a result, there is a high level of extra-billing for 
medical devices. Medical devices and prostheses are subject to various rates of 
coverage depending on the device. In certain cases (e.g. spectacles, dentures, 
hearing aids), the levels of coverage are particularly low.
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2.8.6 Regulation of capital investment
The ARSs are generally responsible for planning services and for the 
authorization of hospitals as well as for changes to the existing hospital 
infrastructure, including restructuring and mergers. The overall strategy for 
capacity and investment planning is mainly implemented through SROSs and 
the related target contracts (contrats d’objectifs et de moyens; see section 2.5.1). 
Target contracts form a regulatory framework that is explicitly designed to 
implement changes; this framework applies equally to all hospital facilities 
that fall within the health care sector. The only exception is the construction 
of (new) hospitals (private and public) and comprehensive emergency centres, 
which must be authorized by the Ministry in charge of Health. The ARS also 
delivers authorizations for the implementation of major medical technologies 
(see section 2.5.3).
There is a large body of legal rules controlling the building and operation of 
hospital facilities, covering infrastructure and equipment. All the relevant texts 
are referenced in a guide that is published by the Ministry in charge of Health.
Depending on the specific sector and public health priorities, capital 
investments in the health care sector are either covered by payments for 
service delivery or funded by specific national or regional programmes (see 
section 4.1.1). The ANAP (see section 2.3.3) oversees and audits hospital 
investments and reorganizations in the health and social care sectors; it also 
provides expertise to the central administration and to the ARSs.
2.9 Patient empowerment
The principles of health democracy (démocratie sanitaire) were instituted by the 
2002 Act on Patients’ Rights and Quality of Care (Loi No. 2002–303 du 4 mars 
2002 relative aux droits des malades et à la qualité du système de santé), which 
included improved representation of health system users; the right of patients to 
directly access their full medical records; and principles of professional liability 
and compensation for victims of medical malpractice. However, since then, 
public debate has focused on how to better account for the expectations of 
health care users.
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2.9.1 Patient information
In recent years, the government has taken the initiative in developing health 
information web sites for the general public. Since late 2013, two databases 
provide health care consumers with searchable data: one includes all drugs 
available in the French market (Base de données publique des médicaments; 
http://base-donnees-publique.medicaments.gouv.fr/) and the other, Scope Santé 
(http://www.scopesante.fr), is a web site set up by the HAS to provide data on 
quality and safety indicators for all public and private hospitals. The public also 
has access to the applicable official tariffs for physicians on the official SHI 
web site (http://www.ameli.fr/).
In terms of freedom of information, public access to documents, including 
medical records, is provided through the Commission on Access to 
Administrative Documents (Commission d’accès aux documents administratifs), 
an independent administrative authority that provides opinions on requests for 
information. However, even with a favourable opinion from the Commission, 
national and regional authorities comply with only approximately half of the 
requests for access to documents (CADA, 2012).
2.9.2 Patient choice
France is generally perceived as a country with extensive patient choice. Indeed, 
the public health code states that a patient’s right to choose a health professional 
and hospital is a fundamental principle of France’s health law. Implementation 
of a gatekeeping function has not significantly limited that right, as patients may 
designate the treating physician of their choice and, once a specialist referral is 
made, may visit any professional in that specialty even if it is not the specialist 
identified by the gatekeeper. In addition, patients can always visit another GP 
or a specialist without referral even though they are entitled to lower levels of 
reimbursement if they do so. Nonetheless, real choice, particularly with respect 
to specialists, may be undermined by extra-billing and geographical disparities.
2.9.3 Patient rights
Patient information on the process of care is mandated by law and must be 
provided in understandable terms. A number of tools exist to facilitate 
awareness of patient rights, including:
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• Charter of Rights and Freedom (La charte des droits et des libertés), 
which states the principles that apply to all hospitalized patients, including 
non-discrimination, respect of dignity and privacy, right to information, 
protection, informed consent and autonomy;
• information booklet provided to every person admitted to hospital;
• specific “admission contract” that must be given to individuals who are 
admitted to an institution for an extended period of time (over 2 months), 
signed by the patient or his representative; and
• provision of assistance from a “qualified person” to help to enforce 
patient rights.
Courts have repeatedly ruled that a signed document is neither necessary nor 
sufficient to meet the obligation of informed consent because physicians could 
simply ask a patient to sign the form without providing sufficient information. 
The recommended form of information and consent is by writing in the patient’s 
medical chart, which the patient may access, the exact information process that 
took place before the procedure. Nonetheless, many professional organizations 
continue to use information leaflets that patients must sign before undergoing 
an invasive procedure.
Patients are often unaware of their rights. A 2011 survey undertaken on 
behalf of the Ministry in charge of Health found that 70% of those questioned 
did not know their rights within the health context, including 44%, who 
believed that they were required to obtain their doctor’s authorization in order 
to access their health records (Ministry in charge of Health, 2011). To address 
this lack of awareness, the Minister in charge of Health, in conjunction with the 
Rights Advocate (Défenseur des droits), an independent constitutional authority 
charged with protecting rights and liberties and promoting equality, developed 
a comprehensive guide covering the major aspects of health care: access to care, 
the patient as actor in his or her health, quality of care, information regarding 
end-of-life issues and recourse and representation in the event of complaints 
against hospitals or health professionals (Ministry in charge of Health, 2014b).
The 2005 Act for Equal Rights, Access, Participation and Citizenship 
for Handicapped Persons (Loi pour l’égalité des droits et des chances, la 
participation et la citoyenneté des personnes handicapées) requires that all 
establishments open to the public, including hospitals and health professionals’ 
offices, be accessible to people with disabilities by no later than 1 January 2015. 
By 2014, only 30% of the establishments covered by this Law had met their 
obligations. A new voluntary measure, the programmed accessibility agenda 
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(Agendas d’accessibilité programmée), provides extended deadlines of one to 
six years to entities that agree to make all of the required changes within a 
defined time frame.
2.9.4 Complaint procedures
The 2002 Patients’ Rights and Quality of Care Act enumerated the general rules 
for patient complaint and compensation procedures, which differ depending 
on the setting in which care is delivered. It also established the possibility for 
patients to obtain compensation without demonstrating that there was an error 
either by a health professional or by an institution and simplified the procedure 
for patients pursuing claims in court (for more details see section 2.5.6 in 
Chevreul et al., 2010).
In public hospitals, the first step of a patient’s complaint (before a formal 
case is brought against the hospital) is addressed through a conciliatory 
procedure involving the hospital mediator (usually a senior physician) and the 
patient or the patient’s family.
Patients with complaints against self-employed doctors (office-based or 
working in private profit-making hospitals) may bring a case against doctors 
in the courts of justice and may bring a case to the physician’s professional 
association. The physicians’ associations are qualified to take disciplinary 
sanctions against their members.
2.9.5 Public participation
Patients and their representatives may participate in the CRSA in defining 
public health priorities at the regional level, including development of the 
PSRS (see section 2.3.7). Nonetheless, patient participation remains insufficient, 
although it is stronger at the hospital level.
Therefore, measures to improve patients’ participation are part of the 
planned 2015 Health Reform Law (see section 6.2) by putting representatives 
of patients on the board of each health agency and enlarging hospital patients’ 
commissions, which will be consulted on the hospital quality and safety policy 
and informed of adverse events.
2.9.6 Patients and cross-border health care
Unanticipated emergency care for French SHI beneficiaries travelling outside of 
France, including outside the EEA, may be reimbursed at the usual SHI tariffs 
upon presentation of the bills and justification of the urgency of the medical 
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need. Within the EEA and Switzerland, medically necessary care arising in 
the context of short stays (holidays, professional travel, language study, etc.) is 
facilitated by European health insurance card (carte européenne d’assurance 
maladie), which ensures that care is provided under the same conditions as for 
beneficiaries in that country.
For planned ambulatory care in a foreign country covered by regulation or 
agreement, the patient is not required to seek pre-authorization from the SHI 
fund and normally would pay for the services and then submit the bills for 
reimbursement based on the usual SHI tariffs. For scheduled hospitalizations 
and treatments involving major equipment (MRI, PET, etc.), the patient must 
seek authorization from the SHI fund, explaining the nature and reasons for 
seeking treatment outside of France. Hospitalizations are usually authorized 
unless it involves a treatment not covered by SHI.
In 2012, France reimbursed €583 million for cross-border health care, 
which constitutes a 43% increase over 2011 (Centre for European and 
International Liaisons for Social Security, 2012). Care provided for French SHI 
beneficiaries in Belgium, Spain and Portugal accounted for two-thirds of the 
cross-border reimbursements.
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3. Financing
Health care expenditure in France has grown more rapidly than the economy as a whole for many years (with the exception of the period 1997–2000), and faster than in neighbouring countries (with the 
exception of the United Kingdom); it rose from 10.4% of gross domestic product 
(GDP; produit intérieur brut) in 1995 to 11.6% in 2013. This is well above the 
EU average of 9.5%, and in Europe, second only to the Netherlands. From 1996, 
SHI annual expenditure has been capped by the national ceiling for health 
insurance expenditure (Objectif National des Dépenses d’Assurance Maladie; 
ONDAM). However, this ceiling was exceeded nearly every year until 2010; 
since then, the ceiling has been underspent as cost-containment measures have 
intensified. In 1996, a specific agency for managing social security debt was 
established, funded by a dedicated tax (amounting to 0.5% of income).
Just over three-quarters of total health care expenditure is publicly funded 
(77%; just above the EU average of 76%), principally through SHI. The 
proportion of costs covered by SHI varies across goods and services: from 
15% for drugs with low medical benefit (service medical rendu; SMR) to 80% 
for inpatient care. However, there are several conditions for which patients 
are exempted from paying a part of the costs, such as chronic conditions or 
pregnancy after the fifth month. Additional co-payments that are not allowed 
to be covered by voluntary health insurance (VHI; assurance complémentaire) 
have been created with the aim of reducing demand and thus SHI expenditure.
SHI resources mainly come from income-based contributions from 
employers and employees (including retirees). Since 1998, as a result of 
attempts to broaden the social security system’s financial base, employees’ 
payroll contributions have been almost fully replaced by a dedicated tax called 
the “general social contribution” (contribution sociale généralisée; CSG) based 
Health systems in transition  France60
on total income rather than on only earned income, as was previously the case. 
Additional revenue comes from specific taxes such as taxes on potentially 
harmful consumption (tobacco, alcohol) and taxes on pharmaceutical companies.
VHI provides complementary insurance, such as for co-payments and better 
coverage for medical goods and services that are poorly covered by SHI. It 
finances 13.8% of total health expenditure and covers more than 90% of the 
population. Over recent decades, VHI has gained a significant role in ensuring 
equity in access and financing health care. Since 2000, publicly financed 
complementary universal health coverage (couverture maladie universelle 
complémentaire; CMU-C) has been offered to those on lower incomes; it covers 
7% of the population.
Even after complementary insurance, out-of-pocket (OOP; reste à 
charge) payments from patients themselves account for 7.5% of total health 
expenditure. This raises issues of equity in access and financing, although this 
figure remains well below the EU average for OOP payments of 16.1% of total 
health expenditure.
Funding for long-term care (soins de longue durée) for the elderly and 
disabled is partly provided by a dedicated fund, the National Solidarity Fund 
for Autonomy (Caisse Nationale de Solidarité pour l’Autonomie; CNSA). This 
was created in 2004 following a heat-wave crisis in the summer of 2003 in 
which around 15 000 elderly people died. Its resources come from SHI and 
the “solidarity and autonomy contribution” (contribution solidarité pour 
l’autonomie) that is generated from the revenue equivalent to one unpaid 
working day ( journeé de solidarité). Local authorities increasingly also fund 
long-term care, as do individuals themselves.
Hospital acute care and hospitalization at home (hospitalisation à domicile; 
HAD), providing care equivalent to hospital care but in the patient’s own home, 
are paid by a diagnosis-related group (DRG; groupe homogène de malades) 
method under the medical activity-based payment system (tarification à 
l’activité; T2A). Self-employed professionals are paid on a FFS basis. Tariffs are 
negotiated between SHI and representatives of health professionals and approved 
by the Ministry in charge of Health, although extra-billing by doctors above that 
tariff is allowed in some cases. Pay-for-performance (P4P; rémunération à la 
performance) financial incentives to improve quality and efficiency of doctors’ 
practices were recently implemented through individual contracts with general 
practitioners (GPs; médecin généraliste ou omnipraticien).
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3.1 Health expenditure
In 2013, total expenditure on health (dépenses totales de santé) in France was 
estimated at €235 billion, or 10.9% of GDP 1 (Table 3.1), being higher than 
the average for EU countries (Figs 1.1–1.3). Health care expenditure in France 
grew more rapidly than national wealth for many years, with the exception 
of the period 1997–2000. Total expenditure on health as share of GDP has 
risen slightly faster than in neighbouring countries (with the exception of the 
United Kingdom), from 10.4% in 1995 to 11.6% in 2013 (Fig. 3.2).
Table 3.1 
Trends in health expenditure in France, 1995–2013, selected years
1995 2000 2005 2010 2013
Current expenditure on health, per capita (US$ PPP) 2 040 2 485 3 101 3 881 4 124
THE (US$ PPP) 2 099 2 546 3 229 4 029 4 361
Current expenditure on health (% of GDP) 9.8 10.0 10.2 10.8 10.9
THE (% of GDP) 10.4 9.8 10.6 11.2 11.6
Average annual real growth rate in THE (%)a na 3.1 1.9 1.3 na
Average annual growth rate in GDP 2.1 4.0 1.6 2.0 0.7
Public expenditure on health (% THE) 79.1 79.0 78.7 78.0 78.7
Private expenditure on health (% THE) 20.9 21.0 21.3 22.0 21.3
Government health spending, including social security  
(% of total government spending in US$ PPP)
13.1 14.0 14.5 14.5 14.6b 
Government health spending (% GDP) 7.8 8.0 8.0 8.4 8.5
OOP payments (% private expenditure on health) na na 34.6 35.2 31.6
OOP payments (% current expenditure on health) na na 7.4 7.7 6.7
VHI (% current expenditure on health) na na 13.2 13.5 13.9
VHI (% of private expenditure on health) na na 62.1 61.7 65.4
Source: OECD, 2014.
Notes: a Calculated as the mean of the annual growth rates in national currency units at PPP prices; b 2012 data; na: Not available; 
PPP: Purchasing power parity; THE: Total expenditure on health.
1 Data on health care expenditure reported in this section are from the OECD (OECD, 2014). Data for international 
comparisons is from the WHO Health for All database (WHO Regional Office for Europe, 2014). Caution must be 
taken in comparing health expenditures among countries as certain OECD countries (Belgium, Luxembourg and 
Switzerland) do not account for gross fixed capital formation.
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Fig. 3.1 
Health expenditure as a percentage of GDP in the WHO European Region, 2013 
Source: WHO Regional Office for Europe, 2015.
Notes: CARK: Central Asian Republics and Kazakhstan; CIS: Commonwealth of Independent States; Eur-A,B,C: Regions as in the WHO 
list of Member States, last available year; TFYR Macedonia: The former Yugoslav Republic of Macedonia.
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Fig. 3.2 
Trends in health expenditure as a percentage of GDP in France and selected countries, 
1995–2013 
Source: WHO Regional Office for Europe, 2015.
In 2013, France ranked 10th among WHO European Region countries for 
the level of per capita health care expenditure (Fig. 3.3), but in third place for 
health care expenditure as a proportion of GDP, after the Netherlands (12.9%) 
and ahead of Austria (11%), Switzerland (11.5%) and Germany (11.3%) (Fig. 3.1).
In terms of the share of public health care expenditure, France ranks 15th 
among WHO European Region countries, with a 77% share of total expenditure 
on health (Fig. 3.4).
Health expenditure (% GDP) 
6
7
8
9
10
11
12
EU
Italy
France
United Kingdom
Germany
Spain
2013201220112010200920082007200620052004200320022001200019991998199719961995
Health systems in transition  France64
Fig. 3.3 
Health expenditure in US$ purchasing power parity per capita in the WHO European 
Region, 2013 
Source: WHO Regional Office for Europe, 2015.
Notes: CARK: Central Asian Republics and Kazakhstan; CIS: Commonwealth of Independent States; Eur-A,B,C: Regions as in the WHO 
list of Member States, last available year; TFYR Macedonia: The former Yugoslav Republic of Macedonia.
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Fig. 3.4 
Public sector health expenditure as a percentage of total health expenditure in the 
WHO European Region, 2013 
Source: WHO Regional Office for Europe, 2015.
Notes: CARK: Central Asian Republics and Kazakhstan; CIS: Commonwealth of Independent States; Eur-A,B,C: Regions as in the WHO 
list of Member States, last available year; TFYR Macedonia: The former Yugoslav Republic of Macedonia.
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Personal health care consumption (i.e. consumption of medical goods and 
services) accounted for the largest share of public health expenditure (73.2%), 
followed by home and community health services (16.1%) (Table 3.2). Public 
expenditure on drugs has decreased by 1 percentage point since 2007, while 
spending on medical devices and facilities has remained stable (Table 3.3).
Table 3.2 
Public expenditure and current health expenditure on health by service programme, 
2012
Percentage of public 
expenditure on health
Percentage of current 
health expenditure a
Health administration and insurance 4.2 5.9
Education and training 0.9 0.8
Health research and development 1.9 1.5
Public health and prevention 2.3 2.4
Medical services 73.2 75.6
  Inpatient care 40.6 35.0
  Outpatient care 15.8 19.5
  Transport 2.0 1.7
  Drugs and medical devices 14.8 19.4
  Home or community health services and disability/
dependency allowances
16.1 12.8
Health system subsidies 1.4 1.0
Source: DREES, 2013a.
Note: a Current health expenditure accounts for both public and private expenditure; it differs from total health expenditure as it includes 
per diem allowances, certain public prevention activities, research and training and excludes gross fixed capital formation.
Table 3.3 
Public health expenditure on health by service input, 2007–2011
Service input Public health expenditure a (%)
2007 2008 2009 2010 2011
Medicines 14.2 13.6 13.4 13.3 13.1
Medical devices 2.0 2.1 2.1 2.2 2.2
Investment in medical facilities at primary, secondary, 
tertiary, intermediate, social care levels
3.1 3.1 2.9 2.9 3.0
Sources: Eco-Santé, 2014; OECD, 2014.
Note: a Public health expenditure on health in million euros, at 2005 GDP price level. 
The evolution of personal health care expenditure (i.e. expenditure dedicated 
to medical goods and services) is a result of growth in the volume of care 
provided and growth in the price of that care, which in turn is linked to general 
inflation and specific conditions governing the means of production. Overall, 
health care prices for medical goods and services have been relatively stable 
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from 2008 to 2012, ranging from 0.3% in 2008 to 0.4% in 2012 (Fig. 3.5). This 
is the result of contrasting trends in the relative price of different types of care 
in different sectors. There was a slight decrease in prices for hospital care and 
drugs over the last three years, while at the same time the price of outpatient 
care increased (DREES, 2012).
Fig. 3.5 
Growth rate of personal health care expenditure in price and volume, 2000–2012 
Source: DREES, 2013a.
In 2012, personal health care expenditure amounted to €183.6 billion, 
divided as follows by type of service:
• 46.3% on hospital inpatient care in public and private health care institutions;
• 28% on outpatient care, including care provided by doctors (10.8%), care 
by paraprofessionals (6.9%), dental care (5.7%), laboratory tests (2.3%) and 
medical transport (2.2%);
• 18.7% on drugs; and
• 7% on medical devices.
The large public sector, the significant debt burden and the budget deficit 
in France (see section 1.2 and Table 1.2) affect the country’s capacity to spend 
resources on health care. In 2012, the SHI deficit was -€5.9 billion (down 
from €8.6 billion in 2011), representing approximately 0.3% of GDP. Reforms 
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expanding the revenue base to include passive income (not related to labour; see 
section 3.3.2), which has been important in a context of rising unemployment; 
instituting ONDAM (see section 3.3.3), which has been in place since 1997 but 
was exceeded each year until 2010; and increasing reliance on private financing 
through VHI and higher levels of cost-sharing (see sections 3.4 and 3.5), raising 
questions about equity in access and financing.
3.2 Sources of revenue and financial flows
In 2012, SHI financed 75.4% of personal health care expenditure and 74.3% of 
total health expenditure (Table 3.4). Consequently, while France has a universal 
public health insurance system, the coverage it provides is not complete: 5% 
of total expenditure on health is financed by the state and around 21%, by 
private sources (Fig. 3.6). More than 90% of the French population has private 
complementary VHI that covers 12.9% of total expenditure on health, leaving 
7.3% to be paid by private households as OOP payments (Table 3.4). It should 
be noted, however, that while the amount of health care financed by the 
government, SHI and VHI is relatively well known, the amount spent by private 
households is less certain and probably underestimated (Lardellier et al., 2012).
Table 3.4 
Total expenditure on health by financing agent, 2000, 2005 and 2007–2013
Financing agent Percentage of total expenditure on health
2000 2005 2007 2008 2009 2010 2011 2012 2013
General government 
expenditure
5.0 4.9 5.0 5.0 5.2 5.0 4.9 4.9 5.0
SHI spending 74.9 75.3 74.8 74.5 74.5 74.6 74.3 74.3 74.7
OOP payments 7.4 6.8 7.1 7.4 7.3 7.2 7.3 7.3 6.7
VHI 11.9 12.3 12.3 12.4 12.4 12.6 12.8 12.9 12.9
Other private payments 0.8 0.7 0.7 0.7 0.7 0.7 0.7 0.6 0.6
Source: Eco-Santé, 2014.
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Fig. 3.6
Percentage of total expenditure on health by financing agent, 2013 
Source: Eco-Santé, 2014.
OOP payments are particularly important for optical care, dental care and 
drugs. They have remained relatively stable since 2000 as a result of an increase 
in public coverage and contrasting trends in VHI coverage. On one hand, VHI 
coverage increased with the implementation of free public complementary 
coverage for the less well off and with better coverage of medical devices (see 
section 3.5.1). On the other hand, it decreased with the de-listing of drugs with 
low SMR (see section 6.1.2) and the implementation of semi-gatekeeping and 
of deductibles (see section 3.3.1) (DREES, 2012).
The respective contributions of financing agents vary across sectors and 
over time. Since the early 1990s, around 92% of hospital expenditure has been 
financed by SHI, but the share of outpatient care financed by SHI is smaller 
and has decreased over time, from 77% in 1980 to 63% in 2010 (Fenina, Garrec 
& Koubi, 2011). This can be explained, on the one hand, by the fact that in 
outpatient care some professionals are allowed to charge patients above the 
official SHI tariffs (extra-billing, see section 3.7.2) and, on the other hand, by 
the fact that since the late 1970s, most reforms have significantly increased 
patient user charges on medical goods and overall outpatient care.
The financial flows in the French health care system are depicted in Fig. 3.7 
and described in detail in the following sections.
0.6%  Other
13%  VHI
7%  OOP
5%  General government
74%  SHI
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Fig. 3.7
Financial flows in the health care system (excluding long-term care and prevention) 
Source: data updated from Chevreul et al., (2010).
Note: CRDS: Social debt repayment contribution.
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3.3 Overview of the statutory financing system
3.3.1 Coverage
Breadth of coverage
French SHI provides nearly universal coverage, with 99.9% of the population 
covered in 2013 (see section 2.3.5). Individuals are generally covered on an 
employment basis, and any dependants of the insured person are also covered. 
Employees cannot opt-out.
For those not covered through one of the obligatory SHI schemes on an 
employment basis, the CMU Act offers SHI coverage to individuals who 
legitimately reside in France. CMU coverage is free for individuals with 
household revenues up to an established ceiling (€9534 in 2013–2014); other 
beneficiaries must pay an annual premium equal to 8% of revenues above the 
ceiling. Thus, coverage criteria have progressively moved from an employment 
basis to residency status. For transitory foreigners and undocumented migrants 
who have resided in France for at least three months, the AME provides free 
access to medical care for those with revenues below the CMU ceiling. Prisoners 
and their families are systematically covered by the SHI general scheme for the 
duration of the imprisonment.
Scope of coverage
Medical goods and services covered by SHI include:
• hospital care and treatment in public or private institutions providing health 
care, rehabilitation or physiotherapy;
• outpatient care provided by GPs, specialists, dentists and midwives;
• diagnostic services and care prescribed by doctors and carried out by 
laboratories and paramedical professionals (nurses, physiotherapists, speech 
therapists, etc.);
• pharmaceutical products, medical appliances and prostheses prescribed and 
included in the positive lists of products eligible for reimbursement; and
• prescribed health care-related transport.
In order to be eligible for coverage, diagnostic services, treatment, drugs and 
prostheses must be provided or prescribed by a doctor, a dentist or a midwife 
and dispensed by health care professionals or institutions recognized by SHI.
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Definition of the benefit package
SHI provides benefits in-kind and in-cash. The benefit package in-kind 
covered by SHI is defined differently for outpatient and inpatient care. Covered 
outpatient goods and services are included in positive lists (Table 3.5): the 
common classification of medical procedures for doctors (Classification 
commune des actes médicaux), the general nomenclature of medical 
procedures for other health care professionals (Nomenclature générale des 
actes professionnels), the list of reimbursable drugs (Liste des specialités 
pharmaceutiques remboursables) and the list of reimbursable medical devices 
and health materials (Liste de produits et prestations remboursables). There is 
no negative list.
Table 3.5 
Positive lists in the SHI benefit package
List Area of coverage
General nomenclature of medical procedures  
(Nomenclature générale des actes professionnels)
Health professional procedures other 
than those of doctors
Biological laboratory tests and procedures  
(Nomenclature des actes de biologie médicale)
Biological laboratories tests and 
procedures
Common classification of medical procedures  
(Classification Commune des Actes Médicaux)
Doctors’ technical procedures
List of reimbursable drugs (Liste des spécialités pharmaceutiques 
remboursables) 
Pharmaceuticals
Specific list of drugs for hospitals and other establishments  
(Liste des spécialités agréées aux collectivités)
Pharmaceuticals 
List of reimbursable medical devices and health materials  
(Liste de produits et prestations remboursables)
Medical devices and related services
For hospital inpatient care, there is a specific list for drugs (Liste des 
spécialités agréées aux collectivités), and the positive lists described above 
only apply for procedures reimbursed outside of the DRG system. In-hospital, 
expensive and innovative drugs and devices that are paid in addition to the 
DRG tariffs are included on special lists. For other categories of care, there is an 
implicit understanding of the range of services that can be delivered to patients 
because hospitals are paid on a DRG basis. Unless it is specified elsewhere 
(e.g. in a regulation or a specific guideline), hospital clinicians can decide what 
care to provide and what drugs to prescribe to patients (as long as drugs have 
AMM). Therefore, innovative procedures or products are often introduced first 
in hospitals (and not paid separately on top of the DRG system) and second 
inscribed on one of the lists mentioned above (lists included in Table 3.5 or 
special lists for innovative care are paid for on top of DRG tariffs).
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Initially, SHI focused on the coverage of curative care in case of 
illness or accident. In practice, however, preventive care is increasingly 
covered, particularly for services provided within doctors’ practices, such 
as mammography or cervical smear tests. Compulsory or recommended 
immunizations are also reimbursed, and care of pregnant women and newborn 
babies is free. A lump sum of €50 per year is available to smokers for smoking 
cessation products (€150 for pregnant women and young adults aged 20–25).
The range of services covered by SHI does not include cosmetic surgery 
or most thermal spa treatments (unless prescribed by a physician for one of a 
list of 12 specific conditions defined by SHI, such as rheumatic diseases, and 
subject to frequency and duration limits), nor does it include some services 
of uncertain effectiveness. The choices required in the allocation of scarce 
resources may result in non-reimbursement for certain procedures (e.g. bone 
densitometry performed in the private sector as a preventive measure) or limits 
on the frequency with which they can be reimbursed (e.g. mammography for 
screening purposes).
For most common health care or products, volumes of care are not specified. 
However, for expensive procedures or devices, volumes may be explicit. This 
is the case, for example, with respect to in vitro fertilization, for which four 
attempts are fully covered (the counter is reset in the case of a successful 
pregnancy) with an age limit of 42; or for drug eluting stents, with generally 
only one stent covered up to a maximum of three per patient in the case of acute 
occlusive artery dissection.
For certain kinds of care, such as physiotherapy and thermal spa treatments, 
prescription by a doctor is not a sufficient condition for reimbursement. 
Coverage for these kinds of treatment is subject to prior authorization by doctors 
advising the SHI Medical Service Office (médecins conseil du service médical), 
after examination of the patient’s case history and possibly a patient interview.
Cash benefits are also provided by SHI to compensate for sickness, maternity 
and paternity leaves, as well as in case of incapacity.
Actors involved in defining the benefit package
The positive lists are defined at the national level and apply throughout 
France in all regions. Drugs and medical devices are added to the list by the 
Ministry in charge of Health, while procedures are added by SHI (UNCAM) 
(see section 2.3.5) on the advice of designated committees of the HAS (see 
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section 2.3.4) based on HTA results (see sections 2.7.2, 2.8.4 and 2.8.5). Key 
actors involved in defining the benefit package, the rate of coverage and pricing 
decisions are described in Table 3.6.
Table 3.6 
Key actors regarding coverage, rate of coverage and pricing of services and goods 
covered by SHI
Stage Drugs Medical devices
Diagnostic and therapeutic 
procedures
Clinical studies Industry Industry Teaching hospitals and 
health professionals
Introduction to the market ANSM; notified bodies for 
CE marking
ANSM; notified bodies for 
CE marking
–
Assessment of clinical  
benefit
Transparency Commission 
(Commission de la 
Transparence) (HAS) 
CNEDIMTS (HAS) CNEDIMTS (HAS)
Assessment of efficiency CEESP (HAS) for  
ASMR 1,2, 3a
CEESP (HAS) for  
ASA 1,2, 3a
–
Coverage rate SHI SHI SHI
Pricing CEPS CEPS SHI
Coverage decision: 
registration on a positive list
Ministry in charge of Health Ministry in charge of Health SHI
Notes: a Most innovative products; CE: European Conformity (Conformité Européene) marking certifies that a product has met 
EU consumer safety, health or environmental requirements.
Depth of coverage
While the French health care basket is considered very generous in terms of 
goods and services covered, coverage is generally not 100%. A share of the 
tariff is the patient’s responsibility and varies with the category of goods and 
services (see section 3.4). Moreover, SHI does not cover extra-billing amounts 
over the statutory tariffs (see section 3.7.2).
The SHI rate of coverage by type of care is as follows:
Inpatient care. The coverage rate for hospital care is generally 80%, but 
increases to 100% in a number of cases:
• from the 31st day of a hospital stay;
• maternity care;
• newborns in the first 30 days;
• occupational injuries;
• individuals suffering from a specified ALD from a list of 30 or has an 
evolving and disabling form of another illness (affection hors liste) for 
treatment related to the chronic illness;
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• CMU-C and AME beneficiaries;
• disability pensioners;
• military pensioners;
• minors who are victims of sexual crimes for related treatment; and
•  infertility treatments.
For treatments or tests with a tariff over €120, a flat-rate fee (participation 
forfaitaire) of €18 is applied instead of the generally applicable co-insurance 
amount, subject to the same exceptions listed above. This fee does not apply to 
diagnostic imaging, emergency transport or transport between care facilities 
(including HAD) and applies only once per hospital stay. Whatever the level 
of coverage of care, most patients must pay a flat-rate catering fee ( forfait 
journalier) of €18 per day for hospital accommodation (€13.50 in mental health 
institutions), subject to the following exceptions: maternity care from the last 
four months of pregnancy until 12 days postpartum, newborns in the first 30 
days, beneficiaries of CMU-C and AME, occupational injuries, HAD, disabled 
children under the age of 20 living in institutions, military pensioners, and 
those covered under the Alsace-Moselle SHI scheme. This fee may be covered 
by VHI.
Outpatient care provided by self-employed health professionals. 
Coverage rates range from 70% of the statutory tariff for health care provided 
by doctors and dentists to 60% for medical auxiliaries and laboratory tests. 
The €18 flat-rate fee for treatments with tariffs above €120 also applies to 
outpatient services in lieu of the applicable co-insurance amount. The flat-rate 
fee also applies if the cumulative cost of treatments provided within a single 
visit exceeds €120, but in any case cannot be applied more than once per visit. 
The reimbursement of services provided by medical auxiliaries and laboratory 
tests is conditional on a doctor’s prescription. However, in order to support the 
financial incentives to follow a coordinated care pathway, coverage of doctors’ 
visits can vary. Under the “preferred doctor” scheme, patients are requested 
to register with the doctor of their choice, whom they should see to obtain a 
referral to a specialist. The preferred doctor is most often a GP, but it may be a 
specialist of any kind working in the private or public sector. The coverage of 
patients who directly access specialists or other GPs outside of the coordinated 
care pathway falls to 30%.
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Pharmaceuticals. Most drugs are covered at a rate of 65%, but this ranges 
from 100% for non-substitutable or expensive drugs to 15% for drugs judged to 
have a low SMR. Extra-billing for prescription drugs is not allowed and thus 
the market price is the same as the SHI statutory tariff.
Medical devices. Medical devices and prostheses are subject to various 
coverage rates depending on the medical device. The reimbursement rate is 
defined by reference to the statutory tariff, but manufacturers and distributors 
are free to set a price in excess of this tariff. In certain cases (e.g. spectacles, 
dentures, hearing aids), the reimbursement levels are particularly low.
Full coverage for defined categories of patients
As noted above, certain hospitalizations are covered for 100% of the 
statutory tariffs. Exemptions from co-insurance for all types of care apply in 
certain circumstances:
• exemptions linked to health status, including individuals covered by 
the ALD programme for treatment related to the condition;
• exemptions linked to the nature of the treatment provided, such as abortion 
and infertility treatments (AME beneficiaries are not covered for infertility); 
and
• exemptions linked to the person concerned, such as those involved in 
accidents at work, pregnant women after the fifth month of pregnancy, 
contraceptives for minors aged 15 or more, live organ donors, 
disabled children and pensioners.
Exemptions on economic grounds do not exist. However, the free public 
complementary VHI coverage for people with low incomes (CMU-C; see 
section 3.5.1) effectively provides full coverage on an economic basis.
Deductibles for regular goods and services
In order to raise additional revenue for SHI, f lat-rate deductibles 2 were 
introduced in 2005: €1 (participation forfaitaire) is charged for every physician 
visit, laboratory test and diagnostic imaging up to an annual limit of €50. The 
list of goods and services to which deductibles ( franchise médicale) apply was 
expanded in 2008 to include drugs (€0.5 per package), ancillary care (€0.5 per 
service up to a daily limit of €2) and medical transportation (€2 per transport 
up to a daily limit of €4). A second annual ceiling of €50 is set for these types 
2 Technically, the term “deductible” usually refers to a fixed amount that is required to be paid by a patient before 
a third-party payer will begin to reimburse for services. However, in France, the term is used to describe the 
amount that is deducted from the tariff covered by SHI. For example, if €20 is paid by the patient to the health care 
professional and the patient sends his/her claim for reimbursement to SHI, first the amount covered is calculated: 
for example, 70% of the total cost (70% of €20 is €14). Then the “deductible” is taken from this amount (€1, for 
example). Finally, €13 in total is reimbursed to the patient.
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of care. These deductibles do not apply to individuals under 18 years of age, 
beneficiaries of CMU-C and AME, and pregnant women from the sixth month. 
“Responsible” VHI contracts do not cover these deductibles (see section 3.5.3).
3.3.2 Collection
General government budget
The state finances 4.9% of total expenditure on health (Fig. 3.6), and only 
1.2% of expenditure related to personal health care consumption. The state 
finances activities in the areas of prevention (28% of state expenditure), medical 
research (30%), training of medical professionals (15%) and administrative 
costs of the health care system (7%). Other budget allocations are directed to the 
AME programme (see section 3.3.1), military hospitals, services for disabled 
veterans and emergency care (5%). Additionally, 14% of the state expenditure 
is directed to the CMU Fund for beneficiaries of CMU-C under the SHI funds 
(see section 3.5.4).
Finally, the state also participates in SHI funding by subsidizing the 
exemption of employers’ SHI contributions in order to encourage employment 
of low-wage workers in domiciliary support services or in defined areas.
Sources of SHI funding
Between its inception in 1946 and 1998, SHI was almost exclusively funded 
by contributions from employees and employers as a proportion of wages and 
salaries, initially with a ceiling on contributions and later without a ceiling. 
The contribution rates for SHI have steadily increased to cover health care 
expenditure, which has grown faster than the level of overall contributions for 
social security. Between 1992 and 1997, contribution rates remained stable at 
6.8% of gross earnings for employees and 12.8% for employers. In 2013, the 
employer contribution rate was 13.1%.
Since 1998, employees’ payroll contributions have been progressively 
replaced by an earmarked tax on all sources of income and have fallen from 
6.8% to 0.75% of gross earnings in 2013. As a result of attempts to broaden 
the social security system’s financial base, employee’s contributions have been 
mainly substituted by the earmarked CSG introduced in 1991. The CSG rate 
varies depending on the source of income. Initially it was a two-tier rate but 
slowly evolved to a range, with higher rates for revenue from capital or from 
games of chance and a lower rate for revenue from those with low incomes. It 
is 7.5% on earned income (of which 5.29 percentage points goes to SHI), 8.2% 
on capital (5.95 percentage points for SHI), up to 12% on gambling winnings, 
6.6% on pensions (4.35 percentage points for SHI) and 6.2% on benefits 
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(e.g. unemployment and sick leave allowances) (3.95 percentage points for SHI). 
The rate decreases to 3.8% of earned income for individuals with low incomes 
who were otherwise exempt from income taxation, which represent nearly 
half of French households. Moreover, because the revenue base of SHI has 
been broadened and partly disconnected from earnings, it is less vulnerable to 
wage and employment fluctuations. A share of CSG contributions is generally 
deductible from income tax. In 2012, 70% of the revenues from the CSG went 
to the SHI schemes, accounting for 35% of their financing.
The pharmaceutical industry is also required to contribute through a 1.6% 
tax on their turnover, a tax on advertising, a tax on drug retailing and an 
additional tax if their turnover exceeds a limit set in the Social Security Finance 
Act. In 2012, these taxes raised €1.04 billion for SHI. Additional revenue for 
SHI is levied on the profits of companies with turnover of more than €760 000. 
This 0.13% tax is estimated to have levied €55 million in 2013. Other taxes are 
levied on polluting activities of companies. In 2012, employers’ contributions, 
employee’s contributions and CSG revenue accounted for 82.3% of total SHI 
revenue. The remainder was provided mainly through state subsidies and 
additional earmarked taxes (e.g. on tobacco and alcohol consumption).
Main body responsible for collecting SHI funds
The Union for the Recovery of Social Security Contributions and Family 
Allowances (Union de Recouvrement des cotisations de Sécurité Sociale et 
d’Allocations Familiales) is in charge of collecting contributions and CSG at 
the local level. The money levied flows into a single national pool managed 
by the Central Social Security Agency (Agence centrale des organismes de 
sécurité sociale) and is distributed among the different national branches (SHI, 
retirement fund, family allowance, etc.) on the basis of contribution rates 
defined by law.
Main body responsible for solving the social security debt
Since 1996, the contribution for solving social security debt, the social debt 
repayment contribution (contribution pour le remboursement de la dette 
sociale) was implemented to address the increasing deficit of the social security 
system. The contribution is 0.5% of revenue regardless of the source (earned 
income, benefits, capital, sale of assets, etc.). At the same time, a special fund 
was created to manage the social security debt, the Agency for Funding Social 
Security Debt (Caisse d’amortissement de la dette sociale). To ensure that the 
social security debt is not continuously transferred to the next generation, the 
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parliament requires any new debt transferred to the Agency to be accompanied 
by an increase in the Agency’s income, ensuring that the time frame required 
to eliminate the debt is not extended.
Financing CMU-C and ACS
Revenues for the CMU Fund, which finances CMU-C for low-income 
individuals as well as subsidies to purchase VHI for those with revenues up to 
135% of the CMU-C ceiling (ACS) (see sections 3.5.1 and 3.5.4), mostly come 
from an earmarked premium tax on VHI contracts (€2 billion in 2012). The 
2013 Social Security Finance Act added a fraction of the revenues from tobacco 
taxes (3.15%) to the CMU Fund.
3.3.3 Pooling of funds
SHI retrospectively reimburses care and, consequently, there is no formal 
resource allocation mechanism, although the creation of ONDAM (described 
below) acts as a soft tool to control and allocate health care expenditure. 
Because SHI schemes vary in their resources and population characteristics, 
health insurance schemes are subject to a financial adjustment mechanism that 
takes into account their demographic profiles.
ONDAM
Since 1996, the parliament has set a maximum national ceiling for SHI 
expenditure (ONDAM) for the following year, including spending limits for 
specific health care sectors (ONDAM subtargets), as part of the annual Social 
Security Finance Act.
In order to set the ONDAM for the coming year (n + 1), the government 
proposes an annual maximum growth rate for SHI expenditure. This rate is 
applied to the current year’s (n) actual expenditure. However, often the current 
year’s expenditure is a provisional estimate that is calculated in September, since 
voting on the ONDAM takes place before the end of the year. When genuine 
expenditure is known for year n, the change in expenditure in year n amounts 
to a ratification of overspending and to the integration of this overspending into 
the baseline used for defining the ceiling for the following year (n + 1).
Once the overall ceiling has been set, it is divided into five target groups:
• care provided in private practice;
• hospital care paid on a DRG basis (including outpatient visits in the public 
sector);
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• health and social care for elderly and disabled people financed by SHI 
through the CNSA;
• expenditure related to the regional intervention funds ( fonds d’intervention 
régional); and
• other types of care, for example health care provided to French citizens 
abroad, social and health care not financed through the CNSA and health 
care networks.
Since the ONDAM target was introduced, priority has generally been given 
to the health and social care sector over the health care sector (see Table 3.7).
From 1997 to 2003, there was significant spending in excess of the ONDAM. 
To address this problem, a parliamentary Alert Committee was created in 2004. 
If the system exceeds its projected budget by more than 1%, the Alert Committee 
may ask the Directorate of Social Security (the watchdog for all social security 
branches) to present a financial rescue plan. From 2003 to 2005, there was 
a lower degree of overspending achieved through better control of spending 
for ambulatory care and drugs. However, in 2006 overspending reached 1%, 
and in 2007 the alert procedure was used for the first time, resulting in the 
implementation of a range of cost-cutting measures in the fall of 2007. As a 
result, overspending was more moderate in 2008 and further reduced in 2009, 
despite the costs associated with two influenza epidemics: seasonal influenza 
in early 2009 and the H1N1 influenza A at the end of 2009. Since 2010, the 
ONDAM targets have been underspent (see Table 3.7).
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Care provided in private practice
This target encompasses health professionals’ fees in private practice, including 
outpatient consultations in private hospitals, as well as prescription of drugs 
and medical devices, transport and per diem allowances for sickness and 
occupational accidents. SHI is responsible for ensuring compliance with the 
growth rates set by the government for these costs, which are included in the 
budget target agreed between the state and SHI.
During their annual negotiations with health professionals, SHI defines 
expenditure targets for each profession and measures to enable them to be met. 
To ensure that the professionals’ national agreements on statutory tariffs are 
consistent with the ONDAM target, the agreements are not implemented for 
a six-month period and the newly negotiated tariffs only become effective if 
the target is not exceeded. Otherwise, the previously negotiated tariffs remain 
in force.
The cost of medical goods prescribed in private practice is not directly 
regulated through the ONDAM. However, the annual Social Security Finance 
Act establishes a threshold rate of increase of the overall pharmaceutical 
companies’ turnover on reimbursable drugs: the K rate (taux K). Exceeding 
this rate results in financial penalties for pharmaceutical companies. However, 
there have been frequent criticisms of the discrepancy between the K rate and 
the ONDAM growth rate, the K rate being far below the ONDAM (0.4% for 
2014 when the ONDAM was 2.4%).
Health care provided by hospitals paid on a DRG basis
This target encompasses spending by public and private hospitals paid on a 
DRG basis (T2A; see section 3.7.1) and other hospital spending. Since 2010, 
overspending the ONDAM hospital care target has been strictly prohibited. 
While the volume (case-mix) of hospital activity has far exceeded projections in 
recent years, the target has been underspent because of cancellation of reserve 
appropriations and lower than expected spending on other items within this 
target. Since 2013, a “prudential coefficient” has reduced the DRG tariffs for 
both public and private sector by 0.35%. This reserve may be partly or fully 
returned depending on the level of expenditure relative to the ONDAM target.
Although the ARSs have both a strategic planning and an oversight role 
with respect to hospitals (see section 2.5.3), their impact on hospital budget 
allocations is more limited. Of the €42 billion allocated by the ARSs in 2010, 
they had decision-making power with respect to only €2.9 billion (Cour des 
comptes, 2012c).
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Health and social care for frail elderly and disabled financed by SHI
Budgets corresponding to the targets for health and social care for the elderly 
and disabled are transferred to the CNSA (see section 3.6). The budget for 
the elderly is used to finance health care costs and a share of social care 
cost in nursing homes (établissements d’hébergement pour personnes âgées 
dépendantes) as well as the community nursing services (Services de Soins 
Infirmiers à Domicile; SSIAD). The budget for the disabled is used to finance 
nursing homes and SSIAD. Budgets are allocated to ARSs depending on 
service capacities in their geographical areas. The ARSs allocate budgets to 
services following the same principle (see section 2.5.1).
Regional funding of specific programmes
The ARSs are financed by a state appropriation (77%) and contributions from 
the SHI schemes (18%) and the CNSA (4%). The regional intervention funds 
were created under the 2012 Social Securing Financing Act and combine these 
appropriations and credits to facilitate the capacity of ARSs to undertake 
transversal actions in the following areas: 24-hour services; experimentation 
and adaptation of care delivery, including multidisciplinary teams; working 
conditions in health care institutions; modernization and pooling of facilities, 
including information systems; and health promotion, educational activities and 
prevention, with a particular focus on loss of autonomy.
3.3.4 Purchasing and purchaser–provider relations
As already stated, SHI covers care provided by both public and private health 
care providers. Patients who consult these providers are reimbursed for a share 
of the cost of care (see section 3.3.1).
The relationship of independent health professionals with SHI is defined at 
the national level in agreements called “conventions” signed between UNCAM 
(SHI) (see section 2.3.5) and representatives of the professions. Conventions 
exist for doctors, nurses, physiotherapists, dentists, midwives, pharmacists, 
speech therapists, chiropodists, orthoptists, heads of biological laboratories, 
providers of transport and certain medical devices suppliers (e.g. opticians and 
orthodontists). In 2012, the first interprofessional agreement (accord cadre 
interprofessionel) was signed. It was designed to facilitate experimentation 
in coordinated care, with a particular focus on post-hospitalization patient 
care, care for patients with chronic or multiple diseases, and home care for 
dependent individuals.
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All professionals are subject to the terms of the agreement unless they 
expressly opt out. In exchange, SHI pays a part of the professionals’ social 
security contributions. These agreements govern health professionals’ relations 
with patients who have public coverage and with SHI. The method of payment 
and the amount health professionals receive, therefore, should conform to the 
terms of these agreements or to the minimum contractual regulations that the 
government sets out in the absence of an accepted agreement. Agreements 
for each profession cover a period of four or five years or extend until a new 
agreement is signed. However, there are regular amendments (at least annual 
for doctors) that take into account changes following the yearly Social Security 
Finance Act and other new measures. The Ministry in charge of Health plays 
a significant role in the negotiation. Negotiations between SHI (UNCAM) 
and doctors tend to be very difficult because of the power of the medical 
professionals’ associations, with SHI rarely managing to implement the full 
range of measures it seeks.
In recent years, conventions have included several types of measure to 
promote quality and efficiency in the health system. P4P based on public 
health objectives was included in the 2011 collective bargaining agreement 
with physicians (see sections 2.8.3 and 3.7.2). Interestingly, the 2007 nurses’ 
agreement was used as a means of introducing controls on the geographical 
distribution of health professionals for the first time (other than pharmacists, 
for whom distribution has long been regulated). However, it was not followed 
by similar measures for other health professionals, in particular doctors (see 
section 6.1.3).
Purchasing relations with hospitals differ. The Ministry in charge of Health 
is responsible for public and private hospitals and sets the DRG tariffs. SHI 
reimburses hospitals on a case-payment basis in public hospitals, private 
non-profit-making hospitals and profit-making hospitals with a SHI agreement 
(cliniques conventionnées). For the very few private profit-making hospitals 
with no SHI agreement (cliniques non conventionnées), patients pay for their 
care directly and are reimbursed based on specific statutory tariffs called tariffs 
without consultation (tarif d’autorité), which are very low and have not been 
increased since the 1960s.
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3.4 OOP payments
Of the 26.9% share of total health care expenditure not paid/reimbursed by 
SHI, VHI financed a 13.9% share and patients a 7.5% share in 2011 (WHO, 
2013). SHI coverage varies across sectors and thus OOP expenditure on health 
varies inversely with the level of SHI coverage: 39.6% of OOP expenditure is 
accounted for by medical goods, 8.2% by hospital care and 35.7% by payments 
to self-employed health professionals (DREES, 2012). Overall, the level of 
charges left to the patient is 23.3%, which is often covered by VHI.
In the health and social care sector, OOP payments for residential long-term 
care services have steadily increased and in 2012 averaged €2892 per month 
(ATIH, 2014), raising concerns about equity in access to these services.
3.4.1 Cost-sharing (user charges)
Patients are directly responsible for:
• the cost of health care not included on one of the positive lists covered by 
SHI (such as care provided by psychotherapists or psychoanalysts);
• deductibles for consultations, prescription drugs, nursing care and medical 
transportation up to an annual limit;
• co-payments (such as the hospital catering fee);
• co-insurance (difference between the statutory tariff and the amount 
reimbursed by SHI);
• additional co-insurance of 40% for care outside of the coordinated care 
pathway; and
• extra-billing charges by certain professionals.
Exemptions, deductible caps and programmes to facilitate access to VHI 
help to offset these user charges (Table 3.8; see also section 3.3.1). Nonetheless, 
extra-billing is frequent, and half of the population pays at least one extra-
billing charge per year. These charges vary widely in number and amount 
across sectors. In 2010, extra-billing by doctors practising in Sector 2 accounted 
for €2.5 billion, mostly attributable to specialists (€2.1 billion), compared with 
€18.4 billion reimbursed for doctors’ fees excluding extra-billing (CNAMTS, 
2011). In the inpatient sector, OOP payments are significant for patients 
not covered by VHI, ranging from a few hundred to a few thousand euros 
(HCAAM, 2013c). However, the medical device sector accounts for the largest 
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share of extra-billing charges. While VHI covers approximately 50% of these 
charges, coverage varies greatly depending on the VHI contract and the medical 
device in question.
Table 3.8 
User charges for health services a
Health service Type of user charge in place Cap on deductibles
GP and specialist visit b Co-insurance (30%) + €1 deductible €50/year
Outpatient prescription drugs Co-insurance (15–100%) + €0.5 per box €50/year
Inpatient stay Co-insurance (20%) + €18 catering fee –
Dental careb Co-insurance (30%); €1 deductible 
applies only to stomatologists,  
not dental surgeons
€50/year
Medical devices Co-insurance (various rates;  
e.g. 40% of official tariff for eyeglasses)
–
Notes: a Exemptions and/or reduced rates for all services for chronically ill (ALD), CMU-C and AME beneficiaries, specific treatments, 
specific populations (e.g. pregnant women, disabled); other protection mechanisms for all services from CMU-C and ACS; b Extra-billing 
may apply.
3.4.2 Direct payments
Since its origins, SHI has been based on the principle that a person consulting 
a doctor in the ambulatory sector directly pays for the service and is thereafter 
reimbursed by SHI and, usually, by VHI. Since the 1970s, exceptions have been 
carved out for the most expensive care as well as for low-income households 
(beneficiaries of CMU-C, ACS and AME), and currently 35% of ambulatory 
care is subject to third-party payment (i.e. the health professional receives 
payment from SHI, and VHI, rather than from the patient). Development of 
electronic billing since the early 2000s has helped to reduce the delays for 
reimbursement. Nonetheless, the existence of direct payments is seen as 
a barrier to equity in financial access to health care, and the government is 
seeking to universalize third-party payment, as in other countries with SHI 
systems, including Germany, Austria and the Netherlands (IGAS, 2013b). The 
planned Health Reform Law will include the generalization of third-party 
payment among its provisions (see section 6.2).
3.4.3 Informal payments
While certain doctors are legally permitted to bill in excess of official tariffs 
(see section 3.7.2), informal payments are uncommon in France. Doctors 
engaging in abusive practices, including insisting on cash payment, are 
subject to disciplinary sanctions. Nonetheless, a 2014 survey by a collective 
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of nongovernmental organizations acting for patient rights found that 5% of 
French patients had been confronted with a request by a health professional for 
an “under the table” payment, with patients over age 65, retired or chronically 
ill more frequently facing such requests (Collectif Inter-associatif sur la Santé, 
2014).
3.5 VHI
3.5.1 Market role and size
VHI is not used to jump public sector queues or to obtain access to elite 
providers, unlike in some other countries. The primary role of VHI in France 
is complementary coverage for patient co-insurance amounts and other user 
charges. VHI contracts provide better coverage for medical goods and services 
that are poorly covered by SHI, notably dental and optical care, for which 
extra-billing is the norm. Since the early 2000s, with the wide development of 
a market that was almost saturated, VHI providers extended complementary 
coverage and competed in offering coverage for goods and services that are not 
covered by SHI, such as omega-3 fatty acids and surgery for myopia. VHI may 
also be of a supplementary type, providing access to private amenities (such as 
a private room) that are not included in the benefit basket.
The population covered by VHI contracts increased from 50% in 1970 to 
more than 90% by 2010. The free CMU-C is offered on a voluntary basis 
by public SHI schemes to individuals with revenues below a defined ceiling 
(€7 934 for a single person as of July 2012). In 2012, CMU-C covered 7% of 
the population.
Among the factors contributing to the growth in the population covered 
by VHI contracts is the diminishing share of SHI coverage for outpatient care, 
which has increased households’ OOP expenses. The share of total health 
expenditure financed by VHI has not risen as dramatically, increasing from 
11% in 1990 to 13% in 2012 (Fig. 3.5). This is because the number of people 
with 100% SHI coverage for chronic conditions has increased with ageing of 
the population, resulting in a higher than expected share of SHI coverage of 
outpatient costs (HCAAM, 2013c).
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3.5.2 Market structure
VHI coverage may be purchased by individuals or by firms for their employees. 
Group contracts usually offer broader coverage than individual contracts, and 
85% are sponsored by employers who pay, on average, 56% of the premium 
(Perronnin, Pierre & Rochereau, 2012). Premiums for group contracts generally 
are not risk rated by age, but approximately 30% of contracts premiums are 
indexed to wages; 43% of privately insured individuals are covered by a 
company group contract (Garnero & Le Palud, 2013).
Access to VHI remains largely linked to social status. Wealthier people are 
more likely to be covered by VHI and to buy contracts with higher premiums, 
which most often reflect broader coverage (Safon, 2013). Among the population 
with no complementary coverage, 46% reported that they did not access VHI 
because of financial barriers (Perronnin, Pierre & Rochereau, 2011).
VHI access also varies by age group. The highest rates of people without 
VHI are observed among those aged between 20 and 29 years and those over 
80 years. For the former, this may result from lower health care needs, while 
reasons for the latter may be related to lower income and lower access to group 
contracts through loss of group coverage at retirement and higher premiums 
because of age-rating.
The French VHI market is characterized by a large number of insurers: 682 
in 2011 (DREES, 2012). This number has decreased by more than half since 
2001, as many firms merged or left the market as a result of heavy competition 
in a nearly saturated market and stricter underwriting rules.
VHI firms belong to one of three families, which differ according to their 
logic and principles: mutual, commercial and provident.
Mutual insurance companies.  These operate on a non-profit-making basis 
and their aim is to achieve solidarity and mutual aid among their members by 
avoiding, to the extent permitted by competition, differentiation in premiums 
for a given level of coverage. Mutual insurance represent 82% of VHI firms 
and account for 55% of total VHI turnover. They use limited risk rating, and 
some have income-adjusted premiums. They mainly offer individual contracts, 
and the majority of their group contracts are voluntary.
Commercial insurers. By contrast, commercial insurers may use a large 
set of characteristics, including health status, to rate premiums. These represent 
13% of VHI contracts, with 29% of total VHI turnover.
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Provident institutions. The smallest share of the VHI market (5%) and 
total turnover (16%) is held by provident institutions. They have a non-profit-
making aim and have specialized in mandatory group contacts, which account 
for 84% of their health insurance turnover.
3.5.3 Market conduct
There is no restriction on what insurers are permitted to cover; however, there 
are strong incentives for them to support public sector objectives and the 
solidarity principle.
In 2004, tax-based incentives were introduced for “responsible contracts” 
(contrats responsables) designed to encourage responsible health care 
consumption. They cover up to 100% of care provided through a coordinated 
care pathway with a designated gatekeeper (GPs and specialist visits with 
referral), at least 95% of the cost of the most important drugs (covered by SHI 
at the 65% level) and at least 95% of the cost of laboratory tests covered by 
SHI. Responsible contracts also must cover at least two types of important 
preventive care from a list defined by HAS (see section 2.3.4). To decrease 
moral hazard, these contracts are prohibited from covering certain deductibles 
(see section 3.4.1) and the additional co-insurance and co-payment on doctors’ 
fees when patients opt out of the pathway. Premiums from contracts meeting 
these criteria are subject to reduced taxes (7% as opposed to 14% in 2014). By 
2006, almost all VHI contracts were “responsible contracts” (Garnero & Le 
Palud, 2013).
VHI contracts differ on the level of coverage of charges above the official 
tariffs (extra-billing), the cost of drugs of low SMR, medical devices, private 
amenities and the cost of any covered services not included in the SHI benefit 
package. An increasing number of VHI firms offer tailor-made contracts, 
allowing individuals to choose the rate of coverage for each type of care.
VHI premiums generally are not income-related, unlike SHI contributions. 
As a result, wealthier individuals spend a lower proportion of their income on 
health care than do poorer people. Moreover, while the SHI premium is not 
related to age or risk, VHI premiums are variable (Jusot, Perraudin & Wittwer, 
2012). Premiums have dramatically increased: in 1998, the average annual 
premium of an individual contract was €340 per capita, compared with €530 
in 2006 (Allonier, Guillaume & Rochereau, 2013).
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Efforts to contain premium costs have focused on increased transparency 
to facilitate comparisons of the scope and depth of coverage. The 2012 Social 
Security Finance Act required VHI firms to report the amount and composition 
of their administrative costs as a percentage of premiums as of 2014.
3.5.4 Public policy
To address the economic barriers faced by poorer people in accessing 
complementary coverage, particularly those just over the CMU income ceiling, 
the ACS voucher scheme was created in 2004. Financial assistance in the form 
of a “health check” (cheque santé) is offered to people whose incomes fall 
below a defined ceiling (135% of the CMU-C ceiling as of January 2012) for 
the purchase of VHI. The amount offered depends on the age of the individuals 
in the household, ranging from €100 per year for individuals under age 16 to 
€550 for those over age 60, and may not exceed the contract amount. However, 
fewer than half of those eligible participate in this scheme (CMU, 2012). Recent 
reforms include selection of a limited range of contracts to facilitate choice and 
to ensure the quality of the offers.
To increase the population covered by group contracts, employers providing 
such contracts to their employees receive fiscal rebates, while employees 
may deduct the premium cost from taxable income. Under the National 
Interprofessional Agreement (l’accord national interprofessionnel) signed by 
representatives of employers and employees in 2013, all employers regardless 
of size will be required to offer group VHI contracts to their employees by 2016.
3.6 Other financing
Most additional sources of financing relate to health and social care sector 
services for elderly and disabled persons, including individuals with long-term 
mental illnesses.
Financing long-term care for the elderly
Following the heat-wave crisis in the summer of 2003, the CNSA was created 
to improve provision and funding of long-term care services, such as SSIAD 
and nursing homes.
There are currently three sources of funding for long-term health and social 
care for the frail elderly in France:
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At the national level. The CNSA pools SHI funds allocated to health 
and social services for elderly persons: the national ONDAM for elderly (see 
section 3.3.3); the “solidarity and autonomy contribution”, which is generated 
from the revenue of an unpaid working day for the French working population; 
and the additional solidarity and autonomy contribution (contribution 
additionnelle de solidarité pour l’autonomie; CASA), which is 0.3% tax applies 
to retirement and disability pension income. It funds a share of the personal 
autonomy allowance (Allocation Personnalisée d’Autonomie; APA) that is used 
to finance domiciliary staff, home care devices or residential care for frail 
elderly people.
At the local level. Local authorities (departments) finance a large share 
of long-term care allowances for the frail elderly. The APA is managed by 
general councils and is means-tested and adjusted in relation to the individual’s 
dependence level, living conditions and needs, as assessed by a joint health and 
social care team. It is also funded by CNSA funds (see section 3.6). In 2012, 
departments contributed €4 billion to APA, supplemented with €1.7 billion from 
the CNSA (Sécurité sociale, 2013b). Many other local actors undertake social 
actions to support the frail elderly.
Households. The OOP payment for care in residential care services made 
by households is currently €1500 per month on average. The constant increase 
of this figure is a major concern for the government as it challenges equity in 
access to long-term care. The government has, therefore, searched for solutions 
in financing long-term care for over a decade, but new sources of resources 
have been difficult, and reforms have never been issued (see section 6.1.4).
Financing care for the disabled
There are currently five sources of funding for health and social care for the 
disabled (all causes of disability) (see also section 2.4).
At the national level. There are three funding pathways:
• the CNSA receives resources from SHI (ONDAM for the disabled; see 
section 3.3.3) from the solidarity day, which finances domiciliary staff or 
devices in organizations caring for disabled people as well as a share of 
the two allowances for the disabled: the disability compensation allowance 
(prestation de Compensation du Handicap; PCH), and a small share of the 
special education allowance for children (allocation d’éducation de l’enfant 
handicapé; AEEH);
• the Family Allowance Fund (Caisse d’allocations familiales), which is a 
branch of the social security system, finances most of the AEEH; and
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• direct state financing for certain services, for example sheltered workshops 
(établissements et services d’aide par le travail) and adapted enterprises.
At the local level. The general councils (departments) also finance social 
and health services for the disabled and contribute to the PCH.
Households. The OOP co-payment for care financed by SHI in residential 
homes for disabled adults was €18 per day in 2010 (there is no OOP payment 
for children). OOP payment for this type of care financed by general councils 
varies across departments (however, it is estimated to be approximately the 
same). Funders of each category of services are outlined in section 5.8.2 and 
Tables 5.1 and 5.2.
Financing mental health care
Mental health care is provided by private practice health professionals, private 
psychiatric hospitals or the public mental health care areas (soins de santé 
mentale secteurs) (see section 5.11). Care provided for mental illness by GPs and 
psychiatrists in private practice is covered by SHI at the usual rate. However, 
people presenting an ALD-23 (long-term psychiatric condition) are fully 
covered (see section 3.2). Care provided by psychotherapists or psychoanalysts 
is fully financed by patients.
Care provided in public mental health care areas and in private psychiatric 
hospitals for adults and children is financed by SHI. As in the general hospital 
sector, patient co-payment (ticket modérateur) is 20% of a daily tariff that 
varies across hospitals. The hospital flat-rate fee for accommodation is lower 
than in the general hospital sector, at €13.5 per day in 2010 (see Table 3.8). Both 
the patient co-payment and the hospital flat-rate fee for accommodation can be 
fully covered by VHI.
People with mental disabilities also receive care and services from the health 
and social care sector for the disabled (Tables 5.3 and 5.4 in section 5.11 list the 
institutions that provide services for mentally ill patients); the financing sources 
for these services are described above.
The expenditure on mental health services was estimated to be €16.6 billion 
in 2007, divided into €13.4 billion for health care services (8.3% of total health 
care expenditure on services and goods) and €3.2 billion for the health and 
social health care sector for the disabled (Chevreul et al., 2013).
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3.7 Payment mechanisms
Payment mechanisms in the French health care system have long been based 
on FFS for health professionals working on a private basis and on prospective 
budgeting methods for health services. However, since the mid-2000s there has 
been a move towards the implementation of activity-based payment methods 
for health services, starting with the implementation of DRG tariffs in hospitals 
and the introduction of P4P for doctors, without impairing the FFS principle 
(Table 3.9).
Table 3.9 
Provider payment mechanisms
Provider/payers Local health authority Central SHI institution Private/VHI
GPs – FFS, T2A, P4P FFS
Public hospitals – T2A T2A
Private hospitals – T2A, FFS T2A, FFS
Dentists – FFS FFS
Pharmacies – Mark-ups on regulated prices 
+ dispensing fees + P4P
Mark-ups on regulated prices 
+ dispensing fees + P4P
Social care Capitation, T2A – –
3.7.1 Paying for health services
Payment for outpatient services
Generally, patients in the ambulatory care sector are expected to pay health care 
providers themselves and then claim reimbursement of a share of their expenses 
from their health insurance fund. However, there are situations in which the 
patient is exempt from making the initial direct payment. This system of direct 
payment by the health insurance fund to the provider is known as “third-party 
payment” (tiers payant) and is becoming increasingly common in ambulatory 
care. It currently applies to CMU beneficiaries and victims of occupational 
accidents, but under the planned 2015 Health Reform Law, it is expected to be 
extended to a larger part of the population. It may also be used in laboratories, 
pharmacies (for generic drugs only), hospital consultations and outpatient 
clinics, and by some doctors for expensive examinations and treatments.
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Payment of hospitals
All hospitals, except for long-term care and psychiatry, are funded using T2A, 
based on GHSs. Using data from the PMSI, each patient stay is classified in one 
of the approximately 2200 DRGs, and an associated GHS. Each GHS is subject 
to a lump-sum tariff that is set annually. GHS tariffs are calculated differently 
for public and private hospitals and do not include the same services (see below).
Within the T2A, there are two primary categories of hospital reimbursement: 
medical activity-based payment and non “activity”-based payment.
The medical activity-based category covers three areas:
• GHS tariffs per hospital stay, which have no cost weights other than regional 
weights to account for regional level variations in production costs;
• additional fees for outpatient consultations, emergency ward visits and all 
hospital activities other than inpatient care; and
• additional payments for expensive technologies and interventions include 
a defined list of expensive drugs and medical devices and intensive care 
activities; to avoid discouraging the use of expensive and innovative medical 
technologies, these are first allocated an additional payment and then over 
time integrated into the GHS tariffs.
Block grants and non “activity”-based financing cover three main areas:
• block grants provide annual lump sum funding, such as for emergency care, 
organ retrieval and transplants;
• public utility missions, also referred to as missions for general interest and 
contracting (missions d’intérêt général et d’aide à la contractualisation), 
serve to fund coordination of care, plus epidemiological surveillance and 
expertise; two separate lump sums are defined by the regional health 
agencies on a contractual basis: one for education, research-related activities 
and innovation in teaching hospitals (missions d’enseignement, de recherche, 
de référence et d’innovation); and the other for activities to meet national or 
regional priorities or specific public missions; and
• innovative medical technologies and procedures, especially those awaiting 
registration on a positive list, are financed through two research programmes: 
the hospital clinical research programme (programme hospitalier de 
recherche clinique), the main source of public funding for clinical research 
projects assessing the effectiveness of the new treatment strategy; and the 
programme supporting funds for economic evaluation (Programme de 
recherche medico-économique), assessing the efficiency of the innovation.
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In private profit-making hospitals, doctors’ procedures and services are not 
included in GHS tariffs and are paid separately, while they are included in the 
GHS tariffs for the public hospitals. Specific GHS tariffs are calculated for the 
private sector, together with an individual “transition coefficient” that aims to 
avoid large changes in hospital budgets from year to year and takes into account 
each hospital’s own historical costs/prices. Regional weights, similar to those 
of the public sector, are also used in the private sector, as well as a technical 
coefficient that applies to hospitals offering high-technology services.
Finally, special f inancing rules apply to hospitals in low-density, 
geographically remote areas that would otherwise be subject to consolidation 
because of low volume of use.
Payment for mental health care
Psychiatric areas provide integrated inpatient and outpatient public mental 
health care, generally coordinated by a hospital specialized in mental health 
and paid on an annual prospective global budget basis, as are private psychiatric 
hospitals (see section 5.11). An information system, “summary of medical 
information for psychiatry” (recueil d’informations médicalisées en psychiatrie), 
has been implemented, but the payment mechanism (valorisation de l’activité 
en psychiatrie) is still being developed.
Outpatient care provided by self-employed GPs or psychiatrists is paid for on 
a FFS basis. Consultations for psychotherapy provided by other self-employed 
professionals are also paid on a FFS basis, but tariffs are freely set by providers 
because there is no coverage by SHI.
Payment for pharmaceutical care
Outpatient pharmaceutical care is paid according to the official tariffs defined by 
CEPS (see section 2.8.4). Prices and payments for drugs are made on a package 
basis, and distribution of partial packages is prohibited even if it exceeds the 
number of units prescribed. However, under the 2014 Social Security Finance 
Act, a three-year voluntary project will test delivery of antibiotics on a unitary 
basis in retail pharmacies.
Drugs with marketing authorization that are not contained in the list of 
reimbursable drugs or for special drugs for inpatient care (see section 2.8.4) 
may be sold over the counter, with patients paying the full price, which is not 
regulated. Previously, VHI did not cover drugs not covered by SHI.
Inpatient pharmaceutical care is included in the GHS tariffs paid by SHI to 
the hospitals, with the exception of innovative expensive drugs, which are paid 
for on top of the GHS tariffs if listed on the special agreed products list.
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3.7.2 Paying health workers
Methods for paying health care professionals vary according to whether the 
professionals are self-employed in private practice or employed by institutions. 
However, some professionals such as doctors have mixed activities, and so their 
total remuneration may be a composite sum.
Health professionals working in the private sector
Self-employed professionals (GPs, specialists, dentists, nurses, physiotherapists, 
midwives, ambulance personnel, speech therapists, orthoptists and laboratory 
technicians) provide the vast majority of outpatient services and a large 
proportion of services in private hospitals and are paid directly on a FFS 
basis. Their gross income, therefore, reflects the number, type and price of the 
services they provide, minus their professional costs. Recently, new payment 
methods for particular tasks have been introduced. For example, a capitation 
system is used to pay for doctors’ management of patients with ALDs (€40 per 
patient per year), and currently there is experimentation regarding payment of 
health professionals involved in multidisciplinary provider networks.
Most health professionals are required to apply the statutory tariffs set out 
in the national agreements (conventions) (see section 3.3.4). However, there 
are exceptions, particularly for doctors with the permanent right to exceed 
the official tariffs (extra-billing). These are mainly doctors who have opted to 
work in Sector 2, as opposed to Sector 1 where the doctors are prohibited from 
extra-billing. In 2010, a quarter of doctors practised in Sector 2, although the 
proportion varies greatly among specialties (CNAMTS, 2011). Sector 2 doctors 
relinquish some of the social and fiscal advantages normally accorded by 
doctors under the agreements. Patients consulting a Sector 2 doctor are covered 
for the statutory tariff regardless of the level of extra-billing. Because extra-
billing raises equity of access issues, access to Sector 2 is tightly controlled by 
SHI, and currently only doctors with certain full-time public hospital positions 
may request to access this sector. Because extra-billing can be very significant 
for certain specialties and in certain areas, impairing patients’ access to care, 
measures have been implemented to contain extra-billing (see section 6.1.2).
In 2009, SHI began to offer individual contracts on a voluntary basis to GPs 
that provided incentives for practice improvement. In 2011, this P4P scheme 
based on public health objectives (rémunération sur objectifs de santé publique; 
ROSP) was incorporated into the physicians’ collective bargaining agreement 
with an expanded list of objectives and extended to additional specialties. GPs 
participating in ROSP receive additional remuneration on top of their normal 
FFS income, which takes into account the size of the population treated by the 
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doctor and 29 quality indicators with intermediate and final targets. Overall, 
the amount earned may exceed €7000 per year for a doctor achieving over 85% 
of the targets and treating more than 1200 patients. There is no penalty for 
the GPs who do not achieve the targets. In 2012, more than 89 000 physicians 
participated in the programme, receiving an average annual remuneration of 
€4215.
Physicians employed in public hospitals
Doctors working in public hospitals are state employees who benefit from 
conditions of employment similar to civil servants. The method and amount of 
payment vary according to category:
• university hospital doctors are categorized as state employees because of 
their teaching responsibilities; their pay is composed of a university salary 
for their teaching responsibilities and hospital fees that correspond to their 
treatment responsibilities; levels of pay correspond to grades on a national 
seniority scale;
• full- or part-time hospital doctors with tenure or on contract are paid on a 
monthly basis according to their grade (seniority) and the time worked; they 
also receive various allowances for being on call; and
• external practitioners working in hospitals on an intermittent basis (attachés) 
are paid on a monthly basis in proportion to the number of sessions they 
undertake, with allowances for being on call.
University hospital doctors are authorized to devote a part of their 
working time to private practice within the hospital. Their fees are received 
by the hospital administration, which transfers them to the practitioner after 
withholding their own fees for use of facilities.
Pharmacists
Since January 2000, pharmacists have been paid based on a mixed system 
linking a fixed-sum component (€0.53 per item) and a digressive sliding-scale 
margin; however, remuneration of pharmacists is evolving towards a fee-based 
system (honoraire de dispensation). Starting in January 2015, pharmacists will 
be paid a fixed sum of €0.80 per drug package (increasing to €1 in 2016), in 
exchange for a reduction in the price-based margins. Since 2013, pharmacists 
are paid for consultations with asthmatic patients and those treated with 
anticoagulants (€40/patient).
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Pharmacists’ remuneration has also been used to support the development 
of the generic drug market. Since 1999, pharmacists have been authorized to 
substitute another drug from the same generic group for the one prescribed 
unless the doctor has noted “non-substitutable” on the prescription. The 
absolute mark-up paid for generics are the same as for brand-name drugs 
and higher manufacturer rebates for generics are allowed (maximum 50% 
of manufacturer’s list price versus 2.5% for brand name drugs). This policy 
has allowed for rapid expansion of the generic drug market, which in 2011 
represented 24% of the reimbursable drug market in value and 13% in volume 
(IGAS, 2012a). In addition, a P4P scheme for pharmacists was initiated in 2013 
with an initial focus on generics. Pharmacists are eligible for an annual bonus 
of up to €3000 depending on the share of generics delivered as well as the 
increase in this measure. 
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4. Physical and human resources
In France, there is a high level of facilities, equipment and other physical resources. However, there are strong disparities in their geographic distribution.
Hospitals are in four main categories: regional hospitals, general hospitals, 
local hospitals and psychiatric hospitals. Capital investment is either covered by 
reimbursements for services delivery or funded through specific programmes. 
Two nationwide investment plans have been launched since the early 2000s in 
order to attain quality and safety standards. The ARSs are responsible for the 
control of capital investment and purchasing major medical equipment.
Following the general trend in European countries, the number of full 
time acute beds per 1000 inhabitants has been steadily declining over the last 
20 years. In 2013, it was 3.45. Reduction in acute care capacity was accompanied 
by the transformation of acute beds into rehabilitation and long-term care units 
and the development of day surgery and HAD.
About 5.3% of the French population works in the health care sector. Nurses 
and nursing aides form the largest group of professionals, accounting for 
approximately half of the health care workforce. Registered health professionals 
also include physicians, dentists, midwives, pharmacists, professionals 
involved in rehabilitation (physiotherapists, speech therapists, vision therapists, 
psychomotor therapists, occupational therapists and chiropodists) and technical 
paramedical professions (hearing aid specialists, orthoptists and radiographers). 
Other professions usually identified as contributing to health care include 
clerical and technical staff working in hospitals, laboratory technicians, 
paediatric auxiliaries, dieticians, psychologists and ambulance drivers.
Workforce forecasting and planning of educational capacity is mostly 
made at the national level using a numerus clausus for medical professionals 
seeking to prevent shortages or oversupply. However, it does not control 
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for the geographical distribution of medical professionals, as self-employed 
professionals are free to choose where they practise. In order to solve the 
resulting great disparities in the distribution of medical professionals, there 
has been increasing transfer of tasks from medical to other professionals such 
as nurses and the development of incentives for attracting health professionals 
to underserved areas.
4.1 Physical resources
4.1.1 Capital stock and investments
Current capital stock
At the end of 2011, there were 2694 hospitals in France. Non-profit-making 
institutions accounted for 61% (35% public and 26% private sector) and 39% 
were private hospitals operated for profit (DREES, 2013c).
The 947 public hospitals account for nearly two-thirds of inpatient beds 
(258 156 out of 414 395). There are three main types of public hospitals:
• 33 regional hospitals (centres hospitaliers régionaux), with the highest 
level of specialization and the technical capacity to treat more complex 
cases; most are linked to universities and operate as teaching hospitals;
• 802 general hospitals (centres hospitaliers), which account for the 
majority of short-term inpatient stays; among the general hospitals are 
ex-local hospitals, small community-level structures that fulfil a health 
and social care function, offering acute medical care, follow-up care and 
rehabilitation, and long-term care; and
• 88 hospitals specializing in psychiatric care (centres hospitaliers 
spécialisés).
There are also 24 other public establishments, primarily imaging and 
radiotherapy centres.
Private hospitals fall into two categories: non-profit-making or profit-
making. Non-profit-making hospitals are owned by foundations, religious 
organizations or mutual insurance associations. In 2011, they accounted for 
26% of hospitals (700) and 14% of inpatient beds (11 778). Two-thirds of private 
non-profit-making hospitals perform public service duties such as emergency 
care, teaching and social programmes for deprived populations; they are known 
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as “participants in public hospital service” (participant au service public 
hospitalier). Nineteen of them specialize in cancer treatment, with a broad 
remit that includes prevention, screening, treatment, teaching and research.
The private profit-making sector plays an important role in the French health 
care system. The share of hospitals that are operated for profit is higher than in 
most developed countries: private profit-making hospitals accounted for 39% 
of all hospitals (1047) and 24% of all inpatient beds (98 522) in 2011. They also 
accounted for 22% of part-time hospitalization places and tend to specialize in 
areas with higher profit opportunities (see section 5.4).
The market for hospital care is becoming increasingly concentrated. The 
number of hospitals has been declining since 1990, mainly because of hospital 
closures and mergers within the private sector. Nonetheless, new modes of 
cooperation may result in an increase in the number of hospitals over the next 
few years.
The overall area of the property assets of public hospitals is estimated at 
60 million square metres, a scale comparable to the rest of the state’s property 
holdings. However, to date, record keeping has not been standardized among 
hospitals, and consequently the Ministry in charge of Health has lacked 
reliable data in this regard (Cour des comptes, 2013a). In 2014, a new tool 
called OPHELIE was launched to remedy this problem by standardizing the 
inventory control and facilitating management of hospital property assets. 
Focusing initially on hospitals with investment projects, those undergoing 
audits as well as hospitals volunteering to participate, it will be rolled out to all 
public hospitals by 2017.
Investment funding
Depending on the specific sector and public health priorities, capital investments 
in the health care sector are either covered by reimbursements for service 
delivery or funded by specific national or regional programmes. Between 1983 
and 2003, the public and private non-profit-making sectors suffered from a lack 
of investment because of the financial constraints imposed by the global budget 
payment system in place at that time. Since then, two nationwide investment 
programmes have been launched to support improvements to meet current 
quality and safety standards: Hospital Plan 2007 (Plan Hôpital 2007) and 
Hospital Plan 2012 (Plan Hôpital 2012).
Hospital Plan 2007 was launched in 2003 as part of an ambitious reform of 
the hospital sector; €6 billion was invested over five years for select projects 
proposed by public and private hospitals. The plan was to be entirely funded 
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by SHI, in part by direct funding of the investments (€1.5 billion) and in part 
by underwriting 20-year loans to the hospitals (€4.5 billion). The Hospital 
Plan 2007 also provided for public–private partnerships (partenariat public–
privé), and each of the regional hospital agencies (Agences régionale de 
l’hospitalisation, predecessors to the ARSs) was to propose at least one public–
private partnership investment project. The French Accounts Commission 
(Cour des comptes) criticized the realization of these partnerships as being 
insufficiently planned and executed (Cour des comptes, 2014a). Since 2012, 
national oversight of investments undertaken by the ARSs and valued at over 
€50 million is provided by the Interministerial Committee for Performance 
and Modernization of the Health Care Supply (Comité Interministériel de 
Performance et de la Modernisation de l’Offre de Soins).
The second investment plan, Hospital Plan 2012, was introduced in 2007 
in order to extend the previous investment cycle. This new plan involved an 
initial endowment of €7 billion, again financed by SHI through direct funding 
(€5 billion) and through access to public lending at preferential interest 
rates (€2 billion). This plan has three major priorities: hospital information 
technology systems, restructuring of hospital facilities at the regional level (e.g. 
collaborations and mergers between hospitals) and improvement of compliance 
with safety standards (e.g. seismic compliance and asbestos removal).
In 2013, the strategy to support investment in health was reinforced with the 
goals of ensuring that investments were aligned with patient pathways, that they 
conformed to the strictest standards, that they integrated digital programmes 
and that they ensure financial sustainability. Regional schemes for investment 
in health (schémas régionaux de l’investissement en santé) were put into place 
in 2013, with the objective of ensuring coherence of investments at the regional 
level. Part of the focus of the regional schemes involves examining investments 
undertaken within the previous 10 years and identifying existing capacity 
available to meet the needs identified by the ARSs. This effort will be aided 
by the data compiled by the OPHELIE tool, which will enable consideration of 
future investment projects in light of existing property assets.
In December 2013, the French Government signed an accord with the 
European Investment Bank, which will finance public and private hospital 
construction and renovation projects under the Hospital of the Future 
Programme, amounting to €1.5 billion over three years.
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4.1.2 Infrastructure
In 2011, France had an average of 6.3 full-time hospital beds and 1 part-time 
hospital bed 1 (referred to as places) per 1000 inhabitants, with more than half 
the beds and 42% of the places dedicated to acute care (Table 4.1). In addition, 
0.02 places per 1000 inhabitants were available for home hospitalization 
services, 97.6% of which were dedicated to acute care.
Table 4.1 
Mix of beds in acute hospitals, psychiatric hospitals and long-term care hospitals 
in France, per 1000 population, 1990–2011, selected years
1990 1995 2000 2005 2010 2011
Total number of hospital beds 9.8 8.9 8.2 7.4 6.6 6.4
Acute care beds 5.2 4.6 4.2 3.8 3.5 3.4
Psychiatric hospital beds 1.7 1.3 1.1 1.0 0.9 0.9
Long-term care beds 1.2 1.4 1.4 1.2 0.6 0.5
Rehabilitation hospital beds 1.7 1.5 1.5 1.5 1.6 1.6
Source: Eco-Santé, 2014.
Consistent with the general trend among European countries, the total 
number of hospital beds in France has declined since 1990. Between 2003 and 
2011, the number of full-time hospital beds fell from 468 000 to 414 000. The 
number of acute care beds has been steadily declining since the late 1980s 
(Fig. 4.1a). Average length of stay in acute hospitals also has diminished, being 
lower than in comparable European countries, with an average length of stay of 
five days in 2011 (Fig. 4.1b). Bed occupancy rates have remained fairly stable 
(Fig. 4.1c).
1 Part-time hospital beds encompass beds for outpatient procedures and ambulatory care, including day or night care, 
provided in the mental health sector.
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Fig. 4.1a 
Use of hospital beds in acute care hospitals in France and selected countries,  
1990–2013. (a) Acute care hospital beds per 100 000 population.a 
(b) Average length of stay. (c) Bed occupancy rate. 
 
Fig. 4.1b 
Use of hospital beds in acute care hospitals in France and selected countries,  
1990–2013. (a) Acute care hospital beds per 100 000 population.a 
(b) Average length of stay. (c) Bed occupancy rate. 
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Fig. 4.1c 
Use of hospital beds in acute care hospitals in France and selected countries,  
1990–2013. (a) Acute care hospital beds per 100 000 population.a 
(b) Average length of stay. (c) Bed occupancy rate. 
Source: WHO Regional Office for Europe, 2015.
Note: In Fig 4.1a the data for France not available for 1990–1996.
The reduction in hospital capacity was most significant with respect to 
long-term care beds, which decreased by 40% between 2003 and 2011 through 
the transformation of certain units into nursing homes. Full-time psychiatric 
hospitalization capacity also has diminished significantly since the mid-1980s as 
a result of the French de-institutionalization policy (see section 5.11), accounting 
for approximately 58 000 hospital beds in 2011. Between 2003 and 2011, the 
number of part-time places increased by 2000, reaching 14 243.
4.1.3 Medical equipment
Purchase of major medical equipment is subject to authorization by the relevant 
ARS (see section 2.8.6). Two-thirds of CT and MRI units are found in public 
hospitals, although the number of MRI units is rapidly growing in private 
hospitals because of advantageous SHI tariffs. PET scanners are less profitable 
and so are less likely to be found in private hospitals. In 2011, the number of 
major medical imaging technologies was lower relative to population size than 
Bed occupancy rate (%) 
65
70
75
80
85
90
EU
Italy
France
United Kingdom
Germany
Spain
20
13
20
12
20
11
20
10
20
09
20
08
20
07
20
06
20
05
20
04
20
03
20
02
20
01
20
00
19
99
19
98
19
97
19
96
19
95
19
94
19
93
19
92
19
91
19
90
Health systems in transition  France106
the OECD average (Table 4.2). The availability of MRI units, in particular, has 
been questioned, in terms of both waiting times and geographic dispersion 
(Cour des comptes, 2010).
Table 4.2 
Items of functioning diagnostic imaging technologies (MRI, CT, PET) in France 
and OECD average in 2011
France 
(per million population)
OECD average 
(per million population)
MRI units 7.51 10.5
CT scanners 12.53 22.3
PET units 1.1 1.6
Source: OECD, 2014.
4.1.4 Information technology
In France, the development of the Internet has been rather slow compared with 
other European countries but has improved in recent years. By June 2012, 81% 
of people aged 12 years or over had access to the Internet at home, reflecting 
a 3% increase over 12 months (CREDOC, 2012). In addition, the Internet 
was often used for health-related purposes: in the same study, 37% of French 
population reported having looked for health information for themselves or 
one of their relatives on the Internet (Bigot & Croutte, 2011). The government 
has taken the initiative in establishing health care information web sites for 
the general public, including a searchable drug database (Base de données 
publique des médicaments; http://base-donnees-publique.medicaments.gouv.
fr/) and Scope Santé (http://www.scopesante.fr/), which provides information 
on hospital quality indicators.
Since the late 1980s, the French health care sector has seen a slow but 
continuous development of its information technology infrastructure (see 
section 2.7.1). Recently, development of information technology systems has 
become a priority on the political agenda, mainly because it is seen as a way 
to improve the efficiency of the sector. Moreover, in its 2013 National Health 
Strategy, the government underscored the need to ensure compatibility and 
interoperability among the information technology systems in the ambulatory, 
hospital and medicosocial sectors (Ministry in charge of Health, 2013).
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Inpatient classification system
Data from the PMSI (see section 2.7.1), which was first developed in the 1980s 
and became exhaustive with respect to acute care in 1996, formed the backbone 
of the T2A (see section 3.7.2), which has been in use since 2004.
Electronic billing
An electronic billing system has been gradually developed and implemented 
in the ambulatory care sector since the mid-1990s. An individual health 
insurance electronic card (Sesam-Vitale carte) is provided to all individuals 
enrolled in SHI. On the provider side, the billing system relies on an electronic 
identification card for health care workers (Carte de Professionnel de Santé). 
By 2012, 98% of doctors had such a card (Asip Santé, 2012).
DMPs
DMPs were instituted by the 2004 Health Insurance Act (Loi No. 2004–810 du 
13 août 2004 relative à l’assurance maladie), with the aim of grouping medical 
information gathered in ambulatory and hospital settings. After a long and 
costly phase of development and testing, the DMP was finally rolled out on a 
national basis in 2011. The decision to create a DMP is made by the patient on 
a voluntary basis, and participation has been very low: as of November 2013, 
only 5291 ambulatory health professionals and 378 health care facilities had 
incorporated the use of DMPs and 397 714 had been created.
Since January 2009, a system of patient pharmaceutical files (dossiers 
pharmaceutiques) has been progressively rolled out nationally. The file is 
created and accessed with the patient’s consent and allows pharmacists to 
check patients’ prescriptions within the previous four months, with the goal of 
preventing unnecessary prescriptions and contraindicated drug combinations. 
By December 2012, 98.4% of all pharmacies in France had installed the 
necessary equipment.
Electronic appointment booking systems
Certain hospitals, both public and private, offer the option of making 
appointments for consultations online. However, such systems are far from 
being generalized in France.
Incentives to expand use of information technologies
Because of the low professional interest in adopting electronic records, incentives 
have been put into place. The P4P provisions under ROSP (see section 3.7.2) 
include incentives for physicians to increase the use of information technologies 
in ambulatory care, including the electronic transmission of reimbursement 
claims by SHI and software for following patients and managing prescriptions.
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4.2 Human resources
In December 2010, there were about 1.5 million health care professionals in 
France, accounting for approximately 5.3% of the working population. The health 
care workforce has been steadily increasing since the late 1980s (Table 4.3). 
Registered health professions in France include medical care professionals 
(physicians, nurses, dentists, midwives), pharmacists, professionals involved 
in rehabilitation (physiotherapists, speech therapists, vision therapists, 
psychomotor therapists, occupational therapists and chiropodists) and technical 
paramedical professions (hearing aid specialists, orthoptists and radiographers).
Table 4.3 
Health workers in France per 100 000 population, 1990–2011, selected years
1990 1995 2000 2005 2010 2011
Physicians 306 323 330 338 331 329
Primary care doctors 162 164 161 165 161 159
Specialist physicians 144 160 169 173 170 170
Nurses 538 591 651 742 822 844
Midwives 19 21 24 27 61 29
Dentists 67 69 69 67 65 64
Optometrists na na 30 34 47 50
Pharmacists na 93 99 111 118 113
Psychologists na na na na 58 66
Radiographers 12 13 14 14 14 14
Occupational therapists na na 7 9 11 12
Source: Eco-Santé, 2014.
Note: na: Not available.
4.2.1 Health workforce trends
The density of physicians and nurses in France is currently very close to the 
European average (Figs 4.2 and 4.3). This density is mainly the consequence 
of the relative youth of the health care workforce, resulting in a low retirement 
rate. However, with large waves of professionals now beginning to retire, the 
health care sector may be confronted in the next decade with a reduction in the 
number of professionals, which may create or exacerbate difficulties in access 
to some categories of professionals, particularly in underserved regions.
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Fig. 4.2 
Number of physicians per 100 000 population in France and selected countries, 
1990–2013 
Source: WHO Regional Office for Europe, 2015.
Note: Data for France not available for 1990–2010.
Fig. 4.3 
Number of nurses per 100 000 population in France and selected countries,  
1996–2013 
Source: WHO Regional Office for Europe, 2015.
Note: Data for France not available for 1990–2010.
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At the regional level, the density of health care professionals is characterized 
by wide disparities that are roughly similar across the different health care 
professions, although of differing magnitude. The Parisian and the southeastern 
regions (Île-de-France and Provence–Alpes–Côte-d’Azur) have the highest 
density of health care personnel, followed by the other southern regions, while 
the northern and eastern regions suffer from a lack of such professionals. These 
regional disparities are not related to population needs and consequently raise 
equity issues that are likely to be exacerbated by anticipated demographic 
trends (HCAAM, 2011) (see section 6.1.3). 
Physicians
In 2013, there were a total of 218 296 doctors in France, almost equally divided 
between GPs (47%) and specialists (53%). International comparisons suggest 
there is currently no perceived shortage of physicians in France: with a density 
of 319 physicians per 100 000 inhabitants, the number of doctors is close to the 
EU28 average, lower than neighbouring countries such as Germany and Italy 
and higher than other EU countries such as the United Kingdom (Fig. 4.4).
In the longer term, the picture is mixed. The retirement of large cohorts of 
physicians who began working before the advent of the numerus clausus in 
the early 1970s was expected to decrease significantly the number of active 
physicians (Attal-Toubert & Vanderschelden, 2009). However, this decrease 
may be offset by other trends. Since 2003, retired doctors have been permitted 
to continue working in private practice, with earnings up to a fixed ceiling, 
while still drawing their pensions. In 2009, the Social Security Finance Act 
removed the ceiling, and subsequently the number of retirement-age physicians 
who continued to practise medicine increased by 300% (CNOM, 2013). In 
addition, the number of active physicians with foreign diplomas (European and 
other foreign countries) has increased to 17835 (7.8% of registered physicians) 
(see section 4.2.2).
Despite the fact that the overall number of physicians in France is currently 
at an all-time high, geographic inequalities remain, and certain areas are 
underserved, particularly isolated rural communities and disadvantaged 
communities. The problem is particularly acute with respect to specialists, for 
which an eight-fold difference between lowest and highest density departments 
is seen. French doctors have long enjoyed the right to set up their practices 
where they wish, and attempts to restrict freedom of settlement have faced 
strong opposition from professional associations. Policies to address the 
problem of so-called “medical deserts” have primarily focused on voluntary 
incentives and have had limited effects, although the issue remains a political 
priority (see section 6.1.3).
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Fig. 4.4 
Number of physicians and nurses per 100 000 population in the  
WHO European Region, 2013 
Source: WHO Regional Office for Europe, 2015.
Notes: CARK: Central Asian Republics and Kazakhstan; CIS: Commonwealth of Independent States; Eur-A,B,C: Regions as in the WHO 
list of Member States, last available year; TFYR Macedonia: The former Yugoslav Republic of Macedonia.
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Nurses
Nurses and nursing aides form the two largest groups of health professionals 
in France. In 2013, there were 595 594 nurses in France. With 1000 nurses per 
100 000 inhabitants in 2013, the density of nurses in France is relatively low 
compared with neighbouring European countries such as Germany, but higher 
than the EU28 average (Fig. 4.4). However, this fact is difficult to interpret 
given the differences in the scope of tasks performed by nurses and nursing 
aides in different countries.
The number of nurses steadily increased between 1991 and 2013 at an average 
growth rate of 3.0% per year (Eco-Santé, 2014), following a progressive increase 
in the numerus clausus since 1993. However, this increase in the workforce has 
not been sufficient to meet the rapidly increasing demand. Moreover, there are 
large persisting geographical disparities in the density of self-employed nurses, 
which parallel those observed for physicians (Sicart, 2013b).
Incentives to control the geographical distribution of nurses’ settlement of 
a new practice have been set up under the 2007 agreement. Limits have been 
established in areas with high density, and financial and material incentives are 
offered to encourage new practices in underserved areas.
Nurses may specialize in various fields, including paediatrics, anaesthesia 
and surgery.
Between 2009 and 2011, an average of 513 000 nursing aides were 
employed in health care institutions, providing routine nursing care such as 
maintaining personal hygiene and assistance with essential bodily functions. 
Their involvement remains marginal in outpatient settings, where they mainly 
work in SSIAD (see section 5.8.1) under the auspices of specific services that 
employ them.
Midwives
Midwifery is a distinct medical profession, with field of practice restricted to 
non-pathological situations. There were 20 035 midwives practising in France 
in 2013. While recent years have seen an increase in the share of self-employed 
midwives, geographic disparities are less of an issue than among physicians 
and nurses, because the majority of midwives are hospital based. Midwives 
in the ambulatory sector play a key role in facilitating shorter stays in 
maternity hospitals.
Health systems in transition  France 113
Dentists and dental auxiliaries
There were 40 833 dentists in France in 2013. The number of dentists has been 
relatively stable over recent years compared with other medical professions: 
between 1991 and 2013, the number of dentists in France rose by 7.0%, 
corresponding to an annual increase of 0.3% (Eco-Santé, 2014). The resulting 
density of dentists is high compared with other European countries (Fig. 4.5); 
nevertheless, this profession is subject to the same geographical disparities as 
other health care professions.
Fig. 4.5 
Number of dentists per 100000 population in France and selected countries,  
1990–2013 
Source: WHO Regional Office for Europe, 2015.
Note: Data for France not available for 1990–2010.
Some procedures carried out by dentists – notably orthodontic processes 
and the fitting of prostheses – are also performed by stomatologists (specialist 
doctors). The area of expertise of the stomatologist is more extensive, however, 
also covering surgery of the mouth and teeth. In 2011, 85% of the 1246 
stomatologists in France were self-employed.
There is no recognized profession of dental hygienist in France; dental 
assistants perform administrative activities in the practices of dentists 
and stomatologists.
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Pharmacists
Compared with other European countries, France has a relatively dense network 
of pharmacies. In January 2013, there were 21 939 pharmacies, corresponding 
to a density of 35 pharmacies per 100 000 population, whereas the density in 
Germany and the United Kingdom was 26 and 18 per 100 000, respectively. 
However, because of its vast territory, France has a lower density per 1000 km2 
(33.83) than the EU average (60.49) and its closest neighbours. Nonetheless, 
strict regulation has ensured that there are no significant geographic disparities 
in the distribution of pharmacies, unlike in other health professions.
Ownership of pharmacies is restricted to pharmacists. The government has 
tried to reduce barriers to restructuring and mergers of pharmacies, and the 
number of pharmacies has been diminishing at a rate of approximately 0.3% 
per year since 2002 (INSEE, 2013b).
In 2012, there were 73 892 practising pharmacists, corresponding to a density 
that is considerably higher than the EU average (Fig. 4.6). More than two-thirds 
of pharmacists work in pharmacies, while one-tenth work in biological test 
laboratories. The number of pharmacists has been steadily increasing since 
1975, at a rate of roughly 4% per year before 1985, and 1.5–2.0% since then, with 
the lower growth rate being the result of the numerus clausus introduced in 
1980. As with other health care professions, the adoption of a numerus clausus 
to limit workforce growth has led to a progressive ageing of the pharmacist 
population. In 2013, the average age of pharmacists was 46.4 years.
Public health professionals
In France, public health professionals do not form a clearly recognizable 
professional group (Cassou, 2006). The consensus is that France is facing a 
shortage in public health specialists, but data are lacking and no centralized 
planning is conducted at the national level. Most public health specialists are 
physicians who have specialized in public health either at the end of their 
initial training (as a medical specialty) or later in their career by becoming 
civil servants or medical inspectors in public health (médecins inspecteurs 
de santé publique). Apart from these two training paths, French universities 
offer a number of postgraduate public health diplomas, mostly focusing on 
epidemiology and biostatistics.
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Fig. 4.6 
Number of pharmacists per 100 000 population in France and selected countries,  
1990–2013 
Source: WHO Regional Office for Europe, 2015.
Note: Data for France not available for 1990–2010.
France’s first public health academic school, the School of Higher Education 
in Public Health (Ecole des Hautes Études en Santé Publique), was created in 
2004. It is also responsible for training public health civil servants including 
hospital directors.
Managerial staff
Public sector hospital directors are civil servants recruited mostly among 
students of public administration, after an initial training of four years. 
Successful applicants undergo a compulsory two-year additional training at 
the School of Higher Education in Public Health before starting official duties.
In 2013, there were 3100 qualified hospital directors in France, one-fifth of 
whom work as directors of a hospital. Others have administrative responsibilities 
either within a hospital or within the Ministry in charge of Health or related 
agencies. Although not very large, this professional group is well organized and 
forms an influential group within the health care system.
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4.2.2 Professional mobility of health workers
France is a net receiving country for foreign-trained health professionals. 
Emigration of French-trained professionals is low, while 7.4% of doctors 
practising in France obtained their diplomas in another country (compared 
with 30% in the UK). Fewer than 2% of nurses and pharmacists have foreign 
diplomas. Nonetheless, the number of health professionals trained abroad and 
practising in France has increased in recent years, particularly in rural and 
underserved areas and in disciplines facing cyclical personnel shortages.
French law distinguishes professionals with European diplomas, who are 
entitled to the same rights as French-trained professionals, and those with 
diplomas from outside the EU, who are subject to stricter standards. Paramedical 
professionals with non-EU diplomas must resume their studies and obtain a 
French diploma. Doctors with non-EU diplomas may be authorized to practise 
on a case-by-case basis, following an examination or competition validating 
their professional mastery.
Between 2007 and 2010, the number of foreign-trained doctors increased 
by 20%. Most doctors with foreign diplomas are from the EU (45%); countries 
with the highest representation in France are Algeria, Romania and Belgium. 
Among nurses, diplomas from Spain and Belgium are most frequent.
A growing number of French students who do not make the first-year 
cut-off to pursue medical studies choose to go abroad for their studies, with 
the intention of returning to do an internship and practise in France. Belgium 
and Romania are the top two destinations. Concerned about the effect that this 
trend could have on its management of the physicians supply, France put into 
place new rules to limit the possibility of students returning for internships 
following medical studies abroad. Under a 2011 decree (décret n° 2011-954 du 
10 août 2011), students who twice failed to make the first-year cut-off were 
prohibited from pursuing internships in France and required to complete their 
specialization abroad. However, in early 2013, this decree was overturned.
4.2.3 Training of health workers
Any student who has the qualifications to register with a university may enrol 
for the first year of medical studies, which is common to students of medicine, 
midwifery, dentistry and pharmacy. Every year, ministerial decrees specify 
the number of places available (numerus clausus) for training in these four 
professions within each of the 38 education and research units. Education 
standards are set at the national level.
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Medical training of physicians is divided into three phases. The first 
phase takes place over two years, and a competitive examination at the end 
of the common first year limits access to the second year of medical studies. 
The second phase of medical training takes four years and includes both 
theoretical and practical training. Since 2004, all students after these six years 
participate in the ECN and subsequently choose a third-phase specialty training 
programme according to their ranking. Prior to 2004, general medicine was 
not subject to the competitive entrance examination for medical specialists 
and thus was viewed as a default option. The ECN has also been used as a 
tool to attempt to address regional disparities in allocating internship posts by 
specialty and locality.
Midwives undergo four years of training and the practitioner’s licence 
is granted by the National Midwives Association (Ordre des sages femmes). 
Dentists undergo five years of training and the practitioner’s licence is granted 
by the National Dentists Association (Ordre national des dentistes).
Training of pharmacists takes six to nine years, depending on the specialty. 
At the end of the fourth year, students must choose among three available 
specialization areas: pharmaceutical industry, retail pharmacy and hospital 
activities. Students choosing pharmaceutical industry or retail pharmacy then 
follow a two-year course of specialty training. Students wishing to specialize in 
hospital activities participate in a competitive examination in the fifth year of 
study to enter four-year hospital pharmacy or biomedical residency programmes. 
Both pharmacists and physicians may specialize in medical biology, and 75% 
of biologists are pharmacists. Pharmacists must be registered by the National 
Pharmacists Association (Ordre national des pharmaciens) in order to deliver 
controlled drugs.
Access to nursing schools is regulated by a competitive examination and 
is subject to a regional numerus clausus. The basic training takes three years 
with subsequent optional specializations in theatre nursing, paediatric nursing 
and anaesthesia. In addition to the initial training, nurses must have two years 
of clinical experience in a hospital setting in order to qualify for self-employed 
status. Registration by the National Nurses Association (Ordre national des 
infirmiers) is granted after graduation and is valid for life.
Other registered paramedical professionals generally undergo three years of 
training, often in educational institutions under the authority of the Ministry 
in charge of Health. Exceptions to this are: speech therapists (five years of 
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training), orthoptists (three years of training), hearing aid specialists and 
dieticians (two years of training) and nursing aides and paediatric auxiliaries 
(one year of training).
Most health professionals, including doctors, midwives, dentists, 
pharmacists, biologists, nurses, physiotherapists and podiatrists, must undergo 
DPC. For doctors, there is no formal recertification or relicensing process. 
Accreditation is optional and concerns physicians practising in hospitals and 
in high-risk specialties, such as surgery, interventional cardiology or radiology 
(see section 2.8.3).
4.2.4 Doctors’ career paths
Once their training is completed, doctors can either work as salaried staff or 
establish their own practices as self-employed doctors. Half of all active doctors 
are self-employed; self-employment is more frequent for GPs (62.5%) than for 
specialists (39.8%). More than half of all salaried GPs work in hospitals (53.2%); 
19.4% work in preventive services; other GPs are employed in health centres, in 
social services or in the pharmaceutical industry.
Among specialists, 39% are self-employed, working in private practice or 
private clinics. An additional 13% of specialists have mixed practices, seeing 
patients in their private offices and working shifts in hospitals. Salaried 
specialists mainly work in public and private hospitals (80.5%); others work 
in preventive services (9.2%) or for a wide range of other public and private 
entities, including the pharmaceutical industry and biological test laboratories 
(Sicart, 2013a).
In order to pursue a career within public hospitals, doctors participate 
in a competitive examination to become a hospital practitioner (praticien 
hospitalier). Alternatively, at the end of the internship cycle, interns may 
become assistant clinical chiefs (chef de clinique des universités-assistant des 
hôpitaux), which includes both medical and university teaching responsibilities. 
Thereafter, the career progression may include becoming an assistant professor 
(maître de conference) or professor (professeur des universités-praticien 
hospitalier). These civil service positions are highly competitive and are created 
by the university management committee upon the recommendation of the 
hospital’s medical commission (Commission médicale d’établissement) and 
with approval of the Ministry in charge of Health, which publishes a list of the 
open positions. Before applying for an open position, a candidate must have his 
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or her professional and scientific qualifications validated for his/her medical 
specialty by the National University Council for Health Care (Conseil national 
des universitiés).
4.2.5 Other health workers’ career paths
Most other health professionals may work either as self-employed practitioners 
or as salaried employees, although health aides may only be employed.
The majority of nurses are employed as salaried staff, mainly by hospitals 
(67.9%), while 16.4% are self-employed and provide ambulatory care. Other 
institutions employing nurses include long-term care institutions, regional and 
local authorities, schools, temporary recruitment agencies and private firms.
Around 71.6% of midwives work in hospitals with childbirth facilities, where 
a large proportion of antenatal care takes place; 22.0% of midwives opt for 
self-employment, while 6.3% work for regional and local authorities or for PMIs.
Almost all dentists (90.4%) are self-employed, while most of those in salaried 
posts worked in health centres or as advisers for SHI regimes.
The vast majority of pharmacists (73.8%) work in retail pharmacies, either 
as the qualified title-holder or as an assistant. Other pharmacists work in 
management of biological test laboratories (10.3%), in hospitals and other health 
care institutions (8%) or within the pharmaceutical industry (4.6%).
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5. Provision of services
Both public and private providers deliver health care to the French population. Primary care is mostly delivered in the ambulatory care sector by self-employed professionals, while secondary care can be 
delivered both in the ambulatory and the hospital setting. From the late 1990s, 
GPs have gained a major role in the coordination of care, with the implementation 
of a semi-gatekeeping system that provides incentives to people to visit their 
GP prior to consulting a specialist. Drugs are dispensed by self-employed 
pharmacists, while the price of drugs, as in most countries in the OECD, is set 
administratively for all drugs covered by SHI. France is the third largest market 
for pharmaceutical drugs in the world. Hospital care is delivered by public, 
private non-profit-making and private profit-making hospitals. Long-term care 
for the elderly and disabled is provided through both residential care and home 
care. Mental health care is delivered by both the health sector and the social and 
health care sector. As in many other European countries, mental health care 
policy in France during the second half of the 20th century was influenced by 
a general movement towards community-based organization of mental health 
care services – the so-called “deinstitutionalization” process.
5.1 Public health
Public health policy and practice in France have historically been difficult to 
describe because they involve numerous actors and sources of funding. Further, 
large discrepancies exist between legislative texts and actual practice, which 
relies on the initiative of local actors. Nevertheless, reforms starting in 2004 
have resulted in a more clearly structured organization of the field.
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At the national level, the current system involves a number of institutions 
that provide multidisciplinary expertise in the field of health safety, two of 
which have broad remits covering many aspects of health safety: InVS, which 
is involved in surveillance, and INPES, which is involved in managing health 
crises and informing the population. Other specialized agencies provide 
expertise regarding specific types of risk and may exert policy enforcement 
duties (see section 2.3.3).
At the local level, municipalities are legally responsible for monitoring and 
purifying the water supply, controlling air and noise pollution, waste disposal, 
protection against radiation, hygiene in residential areas, food hygiene and 
industrial hygiene. Municipalities lacking the resources to carry out these 
functions are supported by the ARSs and their territorial delegations.
5.1.1 Surveillance of environmental and communicable 
disease threats
At the national level, the current system for the management of health risks 
involves a number of institutions that provide multidisciplinary and intersectoral 
expertise in the field of health safety (see sections 2.3.3, 2.5.5 and 2.6). On 
the one hand, there are specialized agencies that provide expertise regarding 
specific types of risk and may exert policy enforcement duties; on the other 
hand, two agencies have a broad remit that covers many aspects of health safety.
The specialist agencies include ANSM, EPRUS, ANSES, IRSN and the 
French Biomedicine Agency.
The two agencies with a broad remit are InVS and INPES. InVS has a 
mandate to monitor threats to population health, including infectious and chronic 
diseases and environmental and occupational health, as well as emerging threats 
of unknown origin that require continuous monitoring of health outcomes. InVS 
gathers surveillance data from various sources, including national monitoring 
systems that rely on networks of professionals, as well as a network of regional 
epidemiology units (cellules interregionales d’épidémiologie). It reports 
all new epidemiological threats to the Ministry in charge of Health. INPES 
plays a major role in all issues related to communication and health, including 
strategies for dissemination of health alerts to population groups. In order to 
increase effectiveness, the planned 2015 Health Reform Law (see section 6.2) 
intends to merge these two institutions into a single agency.
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The General Directorate of Health of the Ministry in charge of Health 
supervises the activity of the health agencies on a regular basis, issues 
regulations based on the advice provided by the agencies and deals with all 
emergencies regarding health safety. Moreover, the General Directorate of 
Health leads the Health Agency Networking Committee (Comité d’animation 
du système d’agences), a forum that brings together the directors of the major 
agencies involved in prevention and health security policy in order to develop 
a cohesive approach and strong leadership with respect to these policies. The 
Health Agency Networking Committee also includes HAS, HCSP, the National 
Institute for Medical Research (Institut national de la santé et de la recherche 
médicale) and the ARSs.
5.1.2 Occupational health
Employers are responsible for ensuring compliance with hygiene and safety 
standards through a Committee for Hygiene, Safety and Working Conditions 
(Comité d’hygiène et de sécurité des conditions de travail) and occupational 
health services (Services de santé au travail; SSTs) in companies. The 
Committee for Hygiene, Safety and Working Conditions represents the 
company’s employees in all issues regarding work conditions and safety; it 
verifies that regulations are correctly applied and makes proposals to improve 
working conditions.
The SSTs are run by occupational physicians and have a general remit to 
ensure that employees’ health is not altered by their work by confirming their 
ability to do their jobs, monitoring their health and ensuring that the exposure 
to risks in the workplace is within regulatory standards. There must be at least 
one occupational physician per 3300 workers. Large firms finance and host 
their own occupational medical services, whereas smaller firms are affiliated 
with external non-profit-making SSTs. Nationally, there are 953 occupational 
physicians working directly for firms and 4594 physicians working for external 
services covering multiple firms. The number of occupational physicians has 
diminished in recent years, with a nearly 10% decline from 2010 to 2011, largely 
through retirement, despite an increase in the number of internships offered for 
this discipline (IGAS, 2013a).
At the national level, the ANSES is responsible for oversight of workplace 
safety. The 848 SSTs are subject to regional oversight.
Two successive national plans for occupational health have focused on 
security, prevention and protection of workers’ health. The first (2005–2009) 
resulted in structural reforms, including the fusion of two antecedent agencies 
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to create ANSES and reinforced oversight of the SSTs to ensure financial 
transparency and better regional coverage of SST services. The second (2010–
2014) has focused on developing occupational health research and prevention 
measures, while reinforcing support for employers’ prevention efforts and 
coordination among the various national and regional partners.
5.1.3 Preventive services
Historically, the French health care system has been more oriented towards 
curative than preventive medicine. Moreover, certain prevention activities 
are hampered by fragmentation of responsibilities among the various actors 
involved, as is the case for alcohol and drug abuse prevention. Nonetheless, 
other key prevention services, such as immunization and perinatal care, are 
well organized.
Immunization
Each year, the national immunization programme is determined by the General 
Directorate of Health of the Ministry in charge of Health on the basis of 
proposals made by the Technical Committee on Immunization of the HCSP 
(see section 2.3.7) (Ministry in charge of Health, 2014a).
There are only three obligatory immunizations for the general population: 
tetanus, diphtheria and poliomyelitis. Municipalities offer free immunization 
sessions and are responsible for controlling the immunization status of 
all children within their jurisdictions. Immunization is also controlled at 
entrance into day nurseries and schools. Recommended vaccinations include 
immunization against whooping cough, rubella, measles, mumps, chickenpox, 
Haemophilus influenzae type b, Streptococcus pneumoniae (pneumococcal 
vaccine), group C Neisseria meningitidis (meningococcal C vaccine) and 
hepatitis B. Immunization against human papillomaviruses is recommended 
for girls aged 11 to 14 years, and immunization against seasonal influenza 
is recommended for all people aged over 65 as well as individuals with 
certain health conditions. Finally, there are a number of additional mandatory 
and recommended immunizations for health care workers, depending on 
their specific exposure risks. Most of the immunizations are performed by 
self-employed GPs. Mandatory and recommended immunizations are covered 
by SHI.
Perinatal care
Antenatal and postnatal care for mothers and infants is fully covered by SHI 
and can be provided by self-employed doctors or institutions. In addition, 
departmental PMIs, managed by the local assemblies, offer free consultations 
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for children up to the age of six years, with particular attention on families in 
difficulty and run preventive health and social care interventions for children. 
Health services are funded by SHI pursuant to partnership agreements with 
the departmental PMIs. In 2012, the model agreement was expanded to include 
home visits by midwives in the case of pathological pregnancies and coverage 
of vaccinations provided by the PMIs to pregnant women and new mothers.
5.1.4 Health promotion and education programmes
INPES runs large-scale health education programmes and provides resources 
for committees at the regional and departmental levels that carry out field 
activities. The 2004 Public Health Act introduced objectives related to health 
education and created regional public health plans that incorporate health 
education activities.
5.1.5 National screening programmes
National screening programmes in France are centred upon cancer. The Ministry 
in charge of Health decides which programmes will be implemented and shares 
responsibility for implementation with the National Cancer Institute. The 
2004 Public Health Act created 90 local structures, mainly at the departmental 
level, to carry out mass screening programmes; 90% of these structures are 
private non-profit-making associations, and around 50% are funded by general 
councils, while the rest are funded directly by either the state or SHI. Tests and 
related physician visits are funded by SHI. InVS is responsible for evaluating 
these screening programmes.
Two mass national screening programmes have been deployed in France: one 
for breast cancer and the other for colorectal cancer. Breast cancer screening 
is targeted at all women aged between 50 and 74, who are invited by mail to 
undergo a clinical examination and mammography every two years. Colorectal 
cancer screening is aimed at all people aged between 50 and 74, who are invited 
by mail every two years to go to their GP for free screening material, a faecal 
occult blood test and explanations on the programme and on the process to use 
the test. If people do not go to their GP in the next three months, they receive 
a second letter of invitation. After two letters of invitation, the centre sends 
them the test material at home expecting that people will do it and mail it back 
for interpretation.
Organized screening programmes for cervical cancer have been piloted in 
a number of departments. The 2014–2019 Cancer Plan called for a national 
screening programme for cervical cancer for all women aged 25 to 65 years 
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(INCa, 2014). However, the HAS recommends opportunistic screening because 
of the difficulties in targeting the populations of women who have not adhered 
to the recommended screening regimen (HAS, 2013).
Public health programmes in France are often targeted either by population 
(PMI services for women and children) or by disease (mass screening 
programmes for breast cancer and colorectal cancer). Providing such services 
free reduces financial barriers to access but does not ensure participation. 
Breast cancer and colorectal cancer together account for 16% of cancer deaths 
in France (Table 1.4), underscoring the need for efforts to ensure early diagnosis 
and treatment. In 2012, participation in the mass breast cancer-screening 
programme was just over 50%, lower than the 70% participation rate considered 
the minimum acceptable level according to European guidelines. Nonetheless, 
30% of the breast cancer cases in France each year were detected through the 
screening programme (INCa, 2013). Participation in the mass colorectal cancer 
screening programme was even lower (30%), and a study of factors influencing 
patient participation recommended actions targeted at patients under 60 years, 
men and individuals living in deprived areas (Le Breton et al., 2012).
5.2 Patient pathways
This section describes a typical patient pathway for a patient needing 
a hip replacement�
In France, a 70 year-old woman requiring a hip replacement due to arthritis 
would typically first visit her GP, who would prescribe radiography of the hip 
in order to confirm the diagnosis. The radiograph would typically be performed 
in a private ambulatory radiology practice but could also be performed as an 
outpatient examination in a hospital. The GP would then send the patient to an 
orthopaedic surgeon working either in the public or in the private sector. Both 
visits would be covered by SHI with a co-insurance rate of 30%, most often 
covered by VHI.
Alternatively, the patient could visit an orthopaedic surgeon directly, thus 
bypassing the gatekeeping procedure. For a surgeon who follows the Sector 1 
agreement (see section 3.7.2), the co-insurance rate would then be increased 
from 30% to 70% (see section 3.3.1), and the surgeon would be allowed to 
charge up to €8 on top of the official tariff, both leading to a maximum overall 
increase of €18 in the patient’s OOP expenditures. That additional expense 
would not be covered by the patient’s VHI, since insurers have strong financial 
incentives not to cover these fees.
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The patient is free to take an appointment with any orthopaedic surgeon 
she wishes, even if the GP has referred her to a specific one. The patient may 
have to pay in excess of the SHI tariff if she goes to a surgeon working under 
the Sector 2 agreement (see section 3.7.2) or if she wishes to improve comfort 
during her stay (e.g. a private room). The additional fee may be completely 
or partially covered by VHI depending on the patient’s contract. The patient 
would only stay for a few days in the surgical department before being either 
transferred to a rehabilitation hospital or discharged home, where she would 
receive home visits by a physiotherapist. HAS recommends home discharge 
in uncomplicated cases and when the patient is not socially isolated at home. 
In the rehabilitation centre, improvements over standard amenities, such as a 
private room, would again typically be charged over the SHI tariff and may be 
covered by the patient’s VHI.
Finally, all information regarding the acute and follow-up stays would be 
transmitted to the GP, who would be responsible for further care.
5.3 Primary and secondary ambulatory care
Primary and secondary health care that does not require hospitalization is 
delivered by self-employed doctors, dentists and medical auxiliaries (including 
nurses and physiotherapists) working in their own practices, and, to a lesser 
extent, by salaried staff in hospitals and health centres. The range of services 
available in ambulatory care is large, covering the majority of medical and 
auxiliary services that can be provided in such settings, including biological 
and radiological examinations.
Outpatient medical care is largely provided by self-employed doctors 
(both generalists and specialists) in their own private practices. Office-based 
consultations form the basis of GPs’ work, but home visits are also significant, 
representing about 15% of their work. A doctor in private practice undertakes 
on average 3500 consultations and visits per year, although this may vary 
significantly, particularly among specialists. Consultations account for 55% 
of specialists’ work, with the rest consisting of diagnostic and treatment 
procedures (notably surgery in private profit-making hospitals). In 2013, French 
people had an average of 6.4 outpatient contacts, which is close to the EU28 
average (6.9 in 2013) (see Fig. 5.1).
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Fig. 5.1 
Outpatient contacts per person per year in the WHO European Region, 2013 
Source: WHO Regional Office for Europe, 2015.
Notes: CARK: Central Asian Republics and Kazakhstan; CIS: Commonwealth of Independent States; Eur-A,B,C: Regions as in the WHO 
list of Member States, last available year; TFYR Macedonia: The former Yugoslav Republic of Macedonia.
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A small part of outpatient care is provided by salaried professionals working 
in public sector hospitals or health centres. Outpatient care and examinations 
in hospitals represent about 15% of all outpatient consultations. Around 1700 
health centres, usually run by local authorities or mutual insurance associations, 
along with some organizations offering free treatment to disadvantaged groups, 
are also active in the delivery of outpatient care, albeit on a marginal basis. 
These centres are either specialized centres involved in nursing (40%), dental 
care (25%) or general practice (about 5%) activities, or integrated centres 
providing all kinds of ambulatory care (about 30%).
Patients are free to choose their health care providers, although the level 
of SHI coverage for physician visits depends upon whether the rules of the 
gatekeeping structure are followed (see section 2.9.2). Access to physician care, 
both in terms of proximity and finance, is an issue in some areas and with 
respect to certain specialties. Doctors are free to choose where they wish to 
practise, and geographical disparities in the distribution of doctors have long 
existed (see section 4.2). Moreover, certain doctors practise in Sector 2 and, 
therefore, may engage in extra-billing beyond the official SHI tariffs, which 
has implications with respect to financial access to care.
Nursing care is mainly provided by self-employed nurses. Nursing and home 
care of patients makes up two-thirds of their work, with another third devoted 
to technical activities such as performing injections or intravascular perfusions. 
Since 1981, SSIAD units have been developed in the health and social care 
sector for disabled and frail elderly people. They are mainly staffed by salaried 
nursing auxiliaries, with nurses participating in the delivery of care to a lesser 
extent. Substantial geographical inequities of access to nursing care exist (see 
section 4.2.1).
Almost all dentists are self-employed in ambulatory practices, as are the 
majority of physiotherapists, speech therapists and orthoptists. Regarding 
diagnostic procedures, these are mainly performed within private laboratories 
owned by specialized physicians or pharmacists or in imaging centres owned 
by specialized physicians. About 3600 privately owned laboratories carry out 
biological testing procedures. These procedures may also be carried out in 
hospitals. Finally, there are some 22 000 pharmacies, which provide advice 
and health information in addition to dispensing drugs, small medical devices 
and bandages. Under the 2009 HPST Act, the role of pharmacists within the 
primary care system was acknowledged and formalized. While geographic 
disparities exist for most health services, this is not the case for pharmacies, 
which are readily accessible by the entire population and often constitute the 
first contact with the health care system.
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Quality improvement initiatives in primary and secondary ambulatory 
care, already implemented, include DPC for most medical professions (see 
section 4.2.3); the development of practice guidelines, which currently number 
nearly 350, including more than 120 for ALDs; and the role of the SHI medical 
representatives (délégué de l’assurance maladie) in counterbalancing the 
influence of pharmaceutical representatives by providing doctors with their 
individual prescribing profiles so that they can compare their own practices 
with the average profile of local doctors.
Lack of coordination and continuity of care is a weakness of the French health 
care system, and various initiatives have sought to address this problem. These 
include the gatekeeping structure developed under the 2004 Health Insurance 
Act, which introduced the concept of the “preferred doctor” to coordinate care 
as the patient’s point of contact within the health system (see section 3.3.1); the 
DMP, designed to centralize patient information to facilitate care by multiple 
health professionals across different settings (see section 4.1.4); and provider 
networks to provide multidisciplinary care to patients with complex needs (see 
section 3.7.2). Most recently, attention has been focused on the development 
of care pathways for patients over age 75 years who are at risk of dependency 
(see section 6.1.4).
5.4 Specialized ambulatory care/inpatient care
Acute medical, surgical and obstetric care is provided by public as well as 
private hospitals, with different areas of specialization.
Acute medical care is mainly provided by public hospitals, which account 
for nearly two-thirds of acute medical care capacity (67% of medical beds and 
50% of day-care beds) and are responsible for 65% of full-time episodes and 
42% of day-care episodes. Private profit-making hospitals account for 25% of 
full-time beds and 40% of day-care beds, and they provide 27% of full-time 
episodes and 50% of day-care episodes; they specialize in a small number of 
technical procedures for which there are profit opportunities, such as invasive 
diagnostic procedures (e.g. endoscopy or coronary angiography). The balance 
of acute medical activity is performed by the private non-profit-making sector, 
which are the main providers in the area of cancer treatment (see section 4.1.1).
Delivery of surgical care is divided fairly even between public and private 
profit-making hospitals, although the latter performs 67% of the surgical 
episodes in day-care settings. Surgical care accordingly represents more than 
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half of the acute care activity of the private profit-making sector. These hospitals 
tend to specialize in procedures that can be performed routinely within a short 
stay with a predictable length. Public hospitals perform a much wider range of 
surgeries than profit-making hospitals, including the most complex procedures. 
Surgical procedures performed in the private non-profit-making sector are 
mostly related to cancer treatment, as for medical stays. Finally, two-thirds of 
obstetric procedures are performed within public hospitals, while the private 
sector accounts for the remaining third, mainly within profit-making hospitals 
(one-quarter of all obstetrical stays).
Since 2008, policies to encourage ambulatory surgery have been successfully 
implemented, resulting in growth in all three hospital sectors: +17% in the public 
sector, +22% in the non-profit-making sector and +11% in the private sector. 
The last accounts for the largest share, with 70% of ambulatory surgeries taking 
place in private hospitals in 2011. Nonetheless, at nearly 40%, the overall rate 
of ambulatory surgery in France remains lower than in neighbouring countries; 
for example, the share of ambulatory procedures was 52% in Germany and 74% 
in Denmark in 2009 (Toftgaard, 2011). The French Government has set a target 
with the ARSs for ambulatory surgeries to exceed 50% by 2016 (DGOS, 2012).
Reforms of the hospital sector have consistently supported greater 
managerial autonomy of public hospitals. The 2009 HPST Act has increased the 
autonomy of public hospitals and their organizational flexibility and clarified 
their internal decision rules. Executive responsibilities, which were previously 
held by the administrative board (conseil d’administration) of the hospital 
(comprising representatives of the state, local authorities, hospital staff, patients 
and qualified personalities), are now held by the hospital director; accordingly, 
the remit of the administrative board, which has been renamed the monitoring 
board (conseil de surveillance), has been reduced to defining hospital strategy 
and controlling its implementation. Decisions directly relevant to the quality 
and safety of patient care are jointly taken by the director and the president of 
the hospital’s board of physicians (commission médicale d’établissement).
While regional disparities in acute care capacity have significantly 
diminished in recent years, disparities regarding human resources in acute 
care remain. Moreover, continuity of care between the hospital and ambulatory 
sectors is a particular challenge. Lack of coordination between inpatient 
and outpatient care may result in unnecessary rehospitalization. To address 
this problem among frail elderly persons, the Ministry in charge of Health 
has launched regional pilot projects to develop and test tools for improving 
coordination of care in this population (see section 6.1.4).
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5.4.1 Day care and other alternatives to full-time inpatient care
Alternatives to full-time inpatient care have been promoted since the late 
1980s and encompass: part-time care provided in hospitals (either day or 
night, including psychiatric care); ambulatory surgery (see above); ambulatory 
treatments (séances) such as chemotherapy, dialysis, radiation therapy and 
blood transfusions; HAD; and palliative care.
Of the 26 million hospital stays in 2011, more than half were for less than 
a day, not including outpatient consultations (DREES, 2013c). Nearly 40% 
of part-time hospitalizations are for psychiatric care, for which alternatives 
to full-time inpatient care have been developed since the 1970s. Between 
2000 and 2011, the number of part-time places increased by more than 50%, 
from 16 000 to 36 000, and the density increased from seven to 10 places per 
10 000 inhabitants.
Ambulatory treatments, such as chemotherapy and dialysis, are included 
among the alternatives to full-time hospitalization, although they are not 
counted as part-time hospitalizations. The vast majority of radiation therapy 
treatments (96%) are performed in ambulatory care, mostly in private hospitals. 
The public sector delivers the largest share (51%) of chemotherapy treatments, 
although the 19 non-profit-making cancer centres (see section 4.1.1) provide 
significant shares of both chemotherapy (13%) and radiation therapy (21%).
HAD units send medical or paramedical staff to the patient’s home on a daily 
basis in order to provide continuous and coordinated care in situations where a 
hospital stay otherwise would have been necessary. This form of intermediate 
care is targeted at patients with serious, acute or chronic, progressive or unstable 
disease requiring technical medical care of a certain degree of complexity and/
or intensity.
In 2014, HAD units provided a small share (1%) of full-time hospitalizations 
and 0.5% of SHI expenditure. In 2014, there were 309 HAD units covering all 
departments, accounting for 4 million days of treatment for 156 000 stays. The 
government anticipates that this level of activity will double by 2018 (Cour des 
comptes, 2013b). In 2013, the global cost was €859 million, and an average 
HAD day costs SHI €196.8 (ATIH, 2014). Nearly one-fifth of HAD places 
are located in the Paris region (DREES, 2013c). Administratively, HAD units 
are generally either public hospital departments (42%) or private non-profit-
making associations (39%). Each unit is led by a coordinating physician, who 
is responsible for the overall coordination of medical care, while a coordinating 
nurse organizes nurse’s rounds for individual treatments. Actual care is provided 
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by salaried staff from the HAD structure or by self-employed professionals. In 
2014, HAD care was mainly provided in the areas of complex wound dressings 
(25.2% of days), palliative care (23.6%), heavy nursing care (11.3%), perinatal 
care (5.6%) (see section 5.10) and cancer treatment (6.0%), although it included 
all domains of hospital care, including rehabilitation and psychiatric care. In 
addition, HAD care has been extended beyond patient homes and since 2007 
may be provided in long-term care facilities and other residential facilities, 
including those for disabled individuals since 2012.
5.5 Emergency care
The scope of French health policy for emergency care encompasses the 
regulation of pre-hospital emergency care, the organization of hospital 
emergency departments, as well as the availability of appropriate hospital 
beds for patients admitted by emergency departments. Emergency care was 
reorganized following the 2003 heat-wave under the Emergency Care Plan 
2003–2008 (Plan urgences 2003–2008).
Pre-hospital emergency care is handled by medical emergency call 
centres (services d’aide médicale urgente) and the continuity of care system 
(permanence des soins). The medical emergency call centres are freely 
accessible nationwide from any phone by dialling 15. The centres share 
information with the emergency call centres of the police (17) and fire brigade 
(18), so that medical emergencies are appropriately addressed. Likewise, either 
the medical or the fire brigade call centres respond to the European emergency 
number 112.
Emergency calls that reach the medical call centre are treated by specialized 
receptionists who are supervised and supported by physicians. The actions 
taken depend on the level of emergency. If on-site first aid is needed, the 
medical emergency call centres can send a mobile intensive care unit (services 
mobiles d’urgence et de reanimation), a first-aid team from the fire brigade or 
an on-call primary care physician. Otherwise, the patient would be advised to 
go to the nearest emergency hospital by ambulance if necessary. Finally, the 
patient may be advised to call back after a few hours in order to confirm the 
symptoms or to schedule a GP consultation.
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The continuity of care system is designed to provide a timely and appropriate 
response to patient needs at night and on weekends or public holidays when 
ambulatory practices are closed. The system, which now falls under the remit 
of the ARSs, relies on GPs who are on-call on a voluntary basis and are 
paid allowances.
The 750 emergency care structures (structure des urgences) situated in 
655 hospitals (76% public, 6% non-profit-making and 18% private) are the 
cornerstone of the French emergency care system. Certain hospitals have 
several emergency structures, and overall 85% are general units and 15% 
paediatric units. They are subject to authorization by the ARSs.
Concerns regarding the system of emergency care centre upon the 
increasing workload for hospital emergency departments, particularly because 
of the ageing population and the growing number of visits by patients who 
could be treated more efficiently in other settings. The number of doctors 
volunteering to be on-call in the continuity of care system has diminished, 
thereby weakening coverage and shifting a growing share of the burden to 
hospital emergency services (Cour des comptes, 2013c). Because of these trends, 
there is an increasing emphasis on alternatives to traditional emergency care 
settings. For example, the number of urgent ambulatory care centres (maisons 
médicales de garde) providing after-hours care without an appointment has 
increased over the past 10 years, from 98 in 2003 to 369 in 2013, through 
expanded public financial incentives. Box 5.1 illustrates the typical pathway for 
someone needing to seek care, here a person experiencing typical symptoms 
of a heart attack.
5.6 Pharmaceutical care
France is the third largest European producer of pharmaceutical products and 
one of the principal exporters worldwide. The French population is among 
the largest consumers of pharmaceutical drugs. While the growth rate of 
the pharmaceutical market has slowed in recent years and showed a slight 
decrease in 2012, sales of certain classes of drug continue to grow. Recent 
reforms targeting consumption include de-listing drugs with insufficient or 
low SMR, incentives for prescription of generic drugs and efforts to reduce the 
inappropriate prescription and overuse of antibiotics.
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5.6.1 Organization, distribution and dispensing of 
pharmaceuticals to the public
In 2012, the pharmaceutical industry in France included 254 companies, 13 of 
which account for more than half of the market. French firms are well positioned 
with respect to vaccines and medicines but have a weaker market presence with 
respect to biotechnologies and generic drugs. Turnover reached €50 billion in 
2012, with 48% attributable to exports. Sales of drugs in France amounted to 
€27.2 billion, including €21.1 billion in retail pharmacies and €6.1 billion in 
hospitals. Reimbursable drugs accounted for 75.8% of turnover (Ferrante, 2014).
Box 5.1
Patient pathway after a heart attack
In France, someone experiencing chest pain and shortness of breath (i.e. typical symptoms  
of a heart attack) and wishing to seek care would take one of the following steps:
• call the emergency regulation center (SAMU, Centre 15)
• call the fire brigade (dialing 18)
• call his or her GP
• call a cardiologist
• go directly to a general emergency unit.
While the majority of patients would first call their GP, the most appropriate action would 
be to dial 15. Given the nature of the symptoms, the specifically trained receptionist would 
immediately transfer the call to a physician at the call centre. The physician would ask a few 
specific questions to explore further the symptoms. Given the likelihood of a heart attack, a 
mobile medical unit would be sent to take care of the patient; a first-aid team from the local 
fire brigade may also be sent to precede the medical unit.
The first-aid team would check the patient’s vital signs and start cardiopulmonary 
resuscitation if necessary. Once the mobile medical unit arrives, the health professionals 
will start monitoring the patient’s heart rate and perform electrocardiography to confirm 
the diagnosis of myocardial infarction. The unit’s physician would then call the emergency 
regulation centre to confirm the diagnosis and ask for instructions regarding to which hospital 
the patient should be taken. The call centre will check available places among the regional 
cardiology emergency centres, choose the most appropriate place for hospitalization, inform 
the centre of the imminent arrival of the patient and inform the mobile unit of the hospital 
chosen. In the meantime, the mobile unit’s nurse would give the patient necessary drugs 
according to the heart attack treatment protocol.
The mobile unit would then transport the patient to the designated centre. Based on current 
protocols, the expected time to reach the hospital and the availability of a catheterization and 
angioplasty ward, the patient may receive a curative pharmacological treatment (thrombolysis) 
during transport.
Upon arrival at the hospital, the mobile unit would take the patient directly to the designated 
unit and ensure continuity of care in the transfer. 
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In terms of distribution, 64% of the industry’s turnover for drugs is 
distributed by wholesalers; 16.9% is sold directly to retail pharmacies and 
19.1% to public and private hospitals by industry subsidiaries or contractors. 
Wholesalers form a very concentrated sector, with only seven firms supplying 
a distribution network of nearly 200 sites across the territory. Wholesalers have 
a public service mission and are highly regulated in terms of the range of drugs 
supplied, level of stock, delivery time within defined territories as well as their 
profit margins. They supply the 22 000 pharmacies with drug orders within a 
few hours, with deliveries three times per day on average.
The French pharmaceutical market has three distinct components: medicines 
subject to mandatory prescription (prescription médicale obligatoire) and 
prescription-optional drugs (prescription médicale facultative), both of which 
are dispensed primarily through retail pharmacies, and drugs reserved for 
hospitals (see section 5.6.3).
Before 2008, patients had no direct access to non-prescription medicines. 
Under a 2008 decree, patients may have direct access to a specified list of 
non-prescription drugs at the discretion of the pharmacist. Many pharmacists 
were opposed to this measure because they feared it was a step towards ending 
their monopoly, thereby allowing non-prescription drug sales by other retailers, 
such as supermarkets, which are currently prohibited.
Internet sales of non-prescription drugs have been authorized in France 
since 2013, but uptake has been very limited. Only pharmacists are eligible to 
engage in this activity, which must be directly linked to a physical pharmacy 
and authorized by the ARS. By mid-2014, only 129 pharmacies had established 
web sites, a quarter of which were not operational.
5.6.2 Accessibility, adequacy and quality
Most prescription drugs are covered by SHI, although to differing degrees 
depending on the assessed SMR. SHI reimbursement rates for most covered 
drugs ranges from 15% to 100% (see section 2.8.4). Over 97% of the French 
population is covered by a VHI contract, which generally covers the most 
important drugs up to 100%. Under the ALD programme, patients with certain 
diseases are covered 100% for treatments related to the disease, including 
drugs. Minors aged 15 and older are eligible for 100% coverage for certain 
contraceptives. Among the prescription drugs that are not covered by SHI are 
certain contraceptives, drugs for erectile dysfunction and some vaccines and 
eye drops.
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5.6.3 Levels of consumption
Pharmaceutical expenditure per capita reached €525 in 2012 (DREES, 2013a), 
with each person consuming on average 48 packages of drugs (ANSM, 2013). 
For the first time ever, pharmaceutical expenditure decreased in 2012 (by 0.9%), 
which was the result of both a decrease in drug price and a slowdown in the 
increase in the volume of drug uptake. However, drug consumption per capita 
remains 22% above neighbouring countries (Sénat, 2013).
General prescriptions must include certain standard information (patient’s 
name, name of the drug, dosage, treatment duration, number of renewals, etc.), 
as well as the notation NR if the drug is prescribed for an indication that is not 
reimbursable. Most prescriptions are for a month’s supply (three months for 
certain drugs packaged for longer-term therapy) and renewable for a maximum 
of 12 months. For patients with long-term conditions that qualify for coverage 
under the ALD programme, a bi-zone prescription form must be used to 
distinguish drugs that are reimbursed 100% under ALD from those that are 
subject to the usual reimbursement rules.
Prescription of certain drugs is subject to restrictions or conditions, 
depending on their classification:
• drugs classified as limited to hospitals (réserve hospitalière) may only be 
prescribed or administered in the course of a hospitalization;
• drugs requiring a hospital prescription (prescription hospitalière) may 
not be prescribed in the ambulatory sector although they may be filled in 
retail pharmacies;
• drugs requiring an initial hospital prescription (prescription initiale 
hospitalière) may be prescribed in the ambulatory sector only as a renewal 
after an initial hospital prescription within the period of validity specified 
in that prescription;
• drugs for which the initial prescription is limited to certain specialists 
(prescription réservée à des médecins spécialistes) may be 
renewed by any doctor within the period of validity specified in the 
original prescription;
• drugs requiring particular monitoring during treatment (surveillance 
particulière) may only be prescribed if a certain number of biological tests 
specified in the marketing authorization are undertaken;
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• exception drugs (médicaments d’exception) are not covered by SHI 
unless they are prescribed for the indications set out in the therapeutic 
information sheet ( fiche d’information thérapeutique), and if the 
indication is not included, the prescribing doctor must inform the patient 
that the drug will not be covered; and
• narcotics and related drugs must be prescribed using a secure prescription 
form and must be filled within three days of the date of prescription.
5.6.4 Reforms
Reforms have primarily focused on reducing system costs for drugs, including 
de-listing drugs assessed by the Transparency Commission as having low SMR 
(see section 6.1.2).
Patients and pharmacists have been given strong incentives to accept 
generic drug substitution. Since 1999, generic substitution has been promoted: 
pharmacists receive financial incentives and if patients refuse to accept the 
generic drug, they must pay the full price and claim reimbursement afterwards. 
The 2014 Social Security Finance Law included a provision promoting biosimilar 
drugs, but with certain restrictions, including the express authorization of the 
prescribing doctor.
From April 2014, experimentation started in 78 pharmacies on unit 
dispensing, which authorizes pharmacists to sell a given list of antibiotics and 
drugs by unit and not by box, with the aim of diminishing waste and, therefore, 
cost. Currently, almost all medications are sold in fixed quantities in boxes that 
are pre-packaged by the manufacturers.
Improper use of antibiotics has been a particular focus of policies as well as 
education campaigns targeted at patients. The P4P provisions of ROSP include 
targets related to prescription of antibiotics (see section 3.7.2).
5.7 Rehabilitation/intermediate care
Depending on a patient’s condition after acute treatment, rehabilitation care 
may be delivered in an inpatient or an outpatient setting.
Following a hospital stay for acute care, a patient would typically be 
transferred to an inpatient follow-up and SSR unit as soon as daily monitoring 
by acute care specialists is no longer necessary. The SSR unit might be a general 
rehabilitation unit or a specialized unit, depending on patient needs. The SSR 
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unit then would discharge the patient home when she/he is able to perform 
daily life activities. Subsequent rehabilitation care would be performed by a 
physiotherapist working in an ambulatory setting and coordinated by the GP.
More than half of SSR stays are for rehabilitation, although the type of 
care offered in terms of pathologies, population and setting varies by sector. 
Public units account for 40% of SSR capacity, most of which are integrated 
within general hospitals. Public SSR units are dominant with respect to mental 
illnesses and nervous system disorders. The private profit-making sector has the 
smallest share of total SSR capacity (just over 25%), with 40% of care devoted 
to orthopaedic, cardiology and post-trauma rehabilitation, often in dedicated 
clinics. One-third of SSR capacity is found in private non-profit-making units, 
which provide follow-up care for a broader spectrum of pathologies, with a 
particular focus on children and adolescents.
The burden and complexity of SSR stays has increased in recent years 
because of the ageing of the population and also the shorter length of stays 
in acute care hospitals, which diminished by 17% between 2001 and 2009. In 
the same period, there was only a 3% decrease in the lengths of stay in SSR 
units because of the increase in the number of very long stays (more than 
three months), mostly the result of difficulties in discharging patients to other, 
more appropriate care settings because of a lack of capacity. SSR units are also 
challenged by unsuitable admissions, estimated at 10–20%, including patients 
admitted from acute care before being sufficiently stabilized, as well as those 
who may not require inpatient rehabilitation services but are awaiting admission 
into long-term care facilities or the availability of SSIAD places (Cour des 
comptes, 2012b).
The organization of SSR was reformed in 2008 and since that time capacity 
has expanded rapidly, although geographic disparities remain. Moreover, 
regions with SSR capacity below the national average also have low density 
of physiotherapists in the ambulatory sector, thereby compounding the lack of 
access to rehabilitation care (DREES, 2011b).
The ARSs are responsible for planning and optimizing the organization of 
rehabilitation services. The most recent SROSs have focused on improving 
coordination between the health sector and the medicosocial sector, as well as 
developing alternatives to inpatient SSR, including rehabilitation services in the 
context of day hospitalization, HAD and mobile rehabilitation teams.
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5.8 Long-term care
In France, long-term care for the elderly and disabled belongs to a specific 
sector of the social system that combines elements of medical and social care, 
and which is referred to as the “health and social care sector” or “third sector”. 
The health and social care sector is split into two subsectors that encompass care 
for the elderly as well as for disabled people. Care may be provided at home or 
in residences. In addition, intermediate care services provide temporary care 
to dependent patients and respite services for their caregivers.
5.8.1 Long-term care for elderly
Home care is mainly provided by self-employed physicians and nurses and, to 
a lesser extent, by SSIAD. The SSIAD delivers nursing care at home for both 
disabled and elderly people mainly using employed auxiliary nurses and, to a 
lesser extent, nurses, who are mostly self-employed. In 2010, there were 2130 
SSIAD units, corresponding to a capacity of around 106 000 patients (places). 
The vast majority of SSIAD places are dedicated to the elderly and only a small 
share (5%) is reserved for disabled people. Nearly two-thirds of SSIAD units 
are private, mostly non-profit-making institutions; the remaining units are run 
by public institutions in the health and social care sector. The SSIAD is entirely 
financed by SHI funds that are managed by CNSA (see section 3.6).
Residential care for elderly people is provided by many types of institution 
offering different levels of service. These include:
Collective housing facilities ( foyers logements). These offer a range of 
nonmedical facilities (such as catering and laundry) and almost no medical care. 
In 2010, there were 2800 such establishments, offering 147 000 places.
Retirement homes (établissements d’hébergement pour personnes agées 
dépendantes).  These accommodate the elderly but also offer medical care. 
In 2010, there were 7530 establishments with a total of 588 000 beds.
Long-term care units. These accommodate people whose care requires 
constant medical monitoring. These units are provided in autonomous nursing 
homes or in hospital wards for very sick and dependent people. In 2011, around 
32 000 beds were available in these institutions. These units belong to the health 
care sector, not the health and social care sector for the elderly and disabled.
There are great disparities in the distribution of these institutions. Some 
departments are also far better equipped than others, where capacity does not 
match population need.
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Moreover, in the early 2000s, intermediary services were created to 
accommodate for short periods frail elderly people not living in residential 
services. Care is provided on a daily basis (accueil de jour) or on a temporary 
basis (accueil temporaire), with the main goals of offering respite care for 
families and day care for patients with Alzheimer’s disease and other dementias. 
Following strong political support from the government, their capacities have 
reached 7500 for a daily care basis and 3600 for temporary care (out of which 
1250 places are reserved for those with Alzheimer’s disease) in January 2009. 
However, this is insufficient for the growing size of the population with 
Alzheimer’s disease.
Funding of residential institutions for frail elderly people is currently shared 
by the CNSA (through SHI funds) (see section 3.6), which covers the cost of 
medical care; general councils, which covers the cost of personal care for loss 
of autonomy; and users, who mostly cover the cost of housing and feeding.
Current challenges for the frail elderly sector are to provide sufficient 
services to meet the forecasted needs of an ageing population without building 
excessive capacity and still ensuring equity of access. Therefore, recent reforms 
and future development have focused on three areas:
• increasing the capacity of institutions to meet growing demand and to 
develop new services;
• supporting the “maintaining at home” policy (la politique du maintien 
à domicile), which is based on “lighter” forms of care (such as family 
placements and assistance with care in the home) through promoting the 
development of home services, such as nursing home services and HAD 
services, and the creation of intermediate care services promoting better 
integration and autonomy between home and residential care services; and
• financing such services and care and diminishing the economic burden of 
disability for frail elderly patients and their families (see section 6.1.4).
Additionally, with the ageing of the population, a growing number of patients 
with dementia are expected. In order to face this challenge, an Alzheimer’s 
Disease Plan was issued in 2008 for a four-year period. It has three goals: 
improving the quality of life of patients and their relatives by developing 
appropriate treatment, care services and respite care for the relatives; improving 
knowledge of the disease by developing research; and informing the public 
about the disease. It has been renewed, although the name has changed and 
scope broadened to neurodegenerative diseases (http://www.gouvernement.fr/
action/le-plan-maladies-neuro-degeneratives-2014-2019).
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5.8.2 Long-term care for disabled
About 3.2 million people are registered as disabled in France, of whom 
1.8 million are affected by a severe disability that limits their functional 
autonomy. Disability is measured in terms of an incapacity level, which takes 
into account the degree of difficulty with daily living. Specific committees for 
children and for adults at the department level evaluate the degree of incapacity 
and determine the right to certain benefits. They also have the authority to refer 
the disabled person to a specialized institution.
Adults
Around 200 000 disabled adults are accommodated in 4800 dedicated facilities. 
Various institutions provide services for disabled adults with different levels 
of functional autonomy, 90% of which are private non-profit-making and 10% 
public. Broadly, speaking, residential centres are linked to sheltered workshops 
and support people with disabilities who are capable of working during the 
day. Occupational centres take care of disabled adults who are not capable of 
working, with various service levels depending on the severity of the disability 
and the need for care. There are four sources of funding for dedicated facilities 
for disabled adults (see section 3.3.4); the health care part is paid by the CNSA 
on SHI funds while the costs of residential care are charged to the patient and/
or to the general councils of the department. Institutions for the most heavily 
dependent people are financed entirely by the CNSA. Additionally, the state 
finances sheltered workshops (Table 5.1).
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Table 5.1 
Institutions of the health and social sector that provide services to disabled adults
Institution Purpose Financing agenta
Specialized reception centres (maisons 
d’accueil spécialisé)
Cater to disabled adults who permanently 
need health care services 
SHI 
Medical reception centres (foyers 
d’accueil médicalisé)
Cater for severely disabled people who 
cannot work 
SHI, general councils
Sheltered workshops (etablissements et 
services d’aide par le travail)
Offer activities and help to disabled adults 
who have a below-average capacity to work 
The state
Occupational rehabilitation centres (centres 
de rééducation professionnelle)
Offer professional training to disabled adult SHI
Pre-orientation centres (centres 
de pré-orientation)
Used when a diagnosis is needed for further 
orientation in the system 
SHI
Social support services for disabled adults 
(services d’accompagnement médico-
sociaux pour adultes handicapés)
Devoted to severely disabled people, 
offering them care and support for 
professional and social integration
SHI, general councils
Companies for disabled people 
(entreprises adaptées)
Specific companies that are set up for 
disabled people but are included in the free 
market economy
The state
Respite care health beds (lits halte 
soins santé)
Temporarily offering care and social 
support to the homeless
SHI
Temporary reception centres for disabled 
adults (etablissements d’accueil temporaire 
pour adultes handicapés)
Respond to specific needs and support 
families
SHI
Experimental centres for disabled adults 
(etablissements expérimentaux pour 
adultes handicapés)
Develop new forms of housing and care SHI
Mutual aid groups (groupes 
d’entraide mutuelle)
Devoted to people with mental health-
related disabilities and aim to bring new 
answers to their support needs
CNSA
Residential care homes (foyers 
d’hébergement)
Cater to disabled workers coming from the 
“helping through work services” or from 
companies for disabled people 
General councils
Assisted living centres (foyers de vie) Devoted to disabled people who are not 
able to work but who have some functional 
autonomy
General councils
Multipurpose reception centres (foyers 
d’accueil polyvalent)
Offer housing, care and activities to 
disabled people
General councils
Social life support services (services 
d’accompagnement à la vie sociale)
Facilitate access to community services General councils
Note: a The SHI funds presented in this table are managed by CNSA.
Children
Nearly 130 000 disabled children are cared for in 2500 facilities. A large 
number of institutions offer treatment, special education and vocational 
training to children affected by motor, cerebral or intellectual disabilities. These 
institutions are mainly funded by the CNSA from SHI funds (see Table 5.2).
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Table 5.2 
Institutions of the health and social sector that provide services to disabled children
Institution Purpose Financing agenta
Educational centres for children suffering 
from mental disabilities (instituts 
médico-éducatifse) 
Aim to contribute to blossoming and social 
and professional autonomy
SHI
Institutions for children with multiple 
disabilities (etablissements pour enfants et 
adolescents polyhandicapés)
Offer adapted care and education to allow 
disabled children to become self-sufficient
SHI
Institutions for children with physical 
disabilities (instituts d’éducation motrice)
Offer care, education and general or 
professional training
SHI
Sensory training centres (instituts 
d’éducation sensorielle)
Offer care and education to children with 
visual or auditory disabilities
SHI
Medico-psycho-educational centres 
(centres médico-psycho-pédagogiques)
Perform check-ups, diagnosis, screening 
for signs of potential disorders and provide 
care for children with mental health-related 
disabilities 
SHI
Therapeutic and educational centres 
(instituts thérapeutiques, educatifs 
et pédagogiques)
Offer therapeutic and educational support 
specifically adapted to each child or 
adolescent suffering from behavioural 
disorders 
SHI
Home care and education services 
(services d’éducation spéciale et de soins 
à domicile)
Services delivered in disabled children’s 
home environment
SHI
Early social activity centres (centres 
d’action médico-sociale précoce)
Offer early screening for motor, sensory 
and mental disabilities
SHI, general councils
Temporary reception centres for disabled 
children (etablissements d’accueil 
temporaire d’enfants handicapés)
Respond to specific needs and support 
families with disabled children
SHI
Experimental centres for disabled children 
(etablissements expérimentaux pour 
l’enfance handicapée)
Develop new forms of housing and care SHI
Note: a The SHI funds presented in this table are managed by CNSA.
Disabled people may be eligible for monetary allowances to finance 
domiciliary staff or aid devices. The PCH is an allowance that aims to finance 
the wages of people employed to provide assistance to disabled people or their 
families, or the necessary technical aids (see section 3.3.4). In 2012, 147 000 
people received PCHs.
The AEEH is a special allowance funded by the Family Allowance Fund 
that partly covers the costs of the child’s education. Finally, expenses related to 
the disability can be partly or completely covered by the local authority once 
they have been agreed upon.
In the early 2000s, challenges for the disabled sector were to provide 
sufficient capacity for residential care, to diminish OOP payments and to 
develop incapacity benefits that compensated the absence of income of disabled 
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people who could demonstrate an inability to work. These were partly addressed 
by the 2005 Act for Equal Rights, Access, Participation and Citizenship for 
Handicapped Persons.
Current challenges are to tackle the problem of financing transportation 
to care services and to improve further access to services for the disabled. 
Indeed, in 2005 in each department, a one-stop shop was created to inform 
disabled people on services and allowances available and to help them with 
administrative matters: departmental homes for disabled persons (maisons 
départementales pour les personnes handicapées). However, these are reported 
to be performing poorly and improvement is required (IGAS, 2010).
5.9 Services for informal carers
Rules governing the activity of informal carers must be understood within the 
overall legal framework for family support. Although support within families is 
usually performed on a voluntary basis, France, as in other European countries, 
has a set of regulations that define the basic level of transfers among members 
of a family, such as regulations governing inheritance.
In terms of informal care, the legal support obligation (obligation alimentaire) 
stipulates that basic support for daily living is expected between members of a 
couple and for all ascendants and descendants (but not between siblings). This 
law has a subsidiary function and is usually enforced by court when assistance 
is not provided voluntarily, upon request by the person in need.
In contrast with this traditional perspective, concern about the growing 
burden of informal care for frail elderly people (especially those with 
Alzheimer’s disease) has triggered the development of laws giving specific 
rights to the informal carers of dependent or disabled people. Eligibility for 
financial assistance in order to pay a salary to the carer depends on his/her 
relationship with the person in need. Financial assistance cannot be used to 
pay a carer who is the spouse (or common law husband or wife) of the elderly 
person receiving APA or when it is the spouse, parent or child of the disabled 
person receiving PCH.
Finally, dedicated institutions at the city or local level (departments) or 
non-profit-making associations provide help to informal carers, such as 
information and counselling, psychological support and training.
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An estimated 7% of the French population meets the definition of “principal 
caregiver” for a person needing care as the result of illness, handicap or age 
(Jaeger, 2012). The planned law to address dependency (see section 6.1.4) 
includes provisions to support caregivers.
5.10 Palliative care
Several types of inpatient and outpatient entities contribute to palliative care 
in France.
Within hospitals, palliative care may be delivered within dedicated units, 
in dedicated beds in a given department or by a mobile palliative care team. 
Palliative care units are specialized departments with at least five beds 
that provide continuous monitoring of the patient. They usually employ a 
multidisciplinary team with physicians, nurses and psychologists, as well as 
other paramedical staff. Some departments may develop their own palliative 
care capacity under the responsibility of a referral physician and referral nurse 
trained in palliative care. Mobile palliative care teams include at least one 
physician and one nurse, both with a palliative care degree, as well as one 
psychologist and one personal assistant. The team may intervene in any hospital 
department as well as in nearby hospitals in assisting and training personnel 
in palliative care issues.
Palliative care networks are local associations that bring together physicians, 
nurses, psychologists and other professionals to assist GPs with palliative 
care. They visit patients at home upon the GP’s request and help to coordinate 
patient care.
Volunteers trained to support patients and their families may be involved in 
palliative activities, in conjunction with the palliative care structure charged 
with the patient’s care. Such volunteers are present in most palliative care units 
as well as in certain other settings.
In addition to these dedicated organizations, HAD units (see section 5.4.1) 
contribute substantially to palliative care, with roughly one-quarter of days (for 
less than 20% of stays) in such units undergoing palliative care.
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Palliative care capacity has steadily grown since the late 1980s. In 2011, 
French hospitals included 6500 beds dedicated to palliative care; there were 420 
mobile palliative care teams in activity and 110 active palliative care networks. 
Nevertheless, palliative care capacity is still lower than the demand for these 
services and is very heterogeneous across regions.
5.11 Mental health care
In France, services for mentally ill people are provided by both the health sector 
and the social and health care sector for the disabled, with an emphasis on 
community-based organization of mental health care services.
Services provided by the health sector
Services provided by the health sector take the form of both public and private 
outpatient and inpatient care. Public mental health care is provided within 
geographical areas of theoretically equivalent population size, called mental 
health care areas. Care is organized separately for adults and children. For 
each of these populations, care within each area is coordinated by a hospital 
(a public hospital in more than 90% of the cases) and includes a wide range 
of preventive, diagnostic and therapeutic services, which are provided in both 
inpatient and outpatient settings. Psychiatric ambulatory care centres (centres 
médico-psychologiques) are present in almost every mental health care area, 
providing primary ambulatory mental health care, including home visits, and 
directing patients towards appropriate services. In 2010, there were 857 adult 
mental health care areas and 375 mental health care areas for children (Cour 
des comptes, 2011a). The size and resources of mental health care areas are 
quite heterogeneous.
Overall, mental health care areas account for 40% of psychiatric hospitals 
and 80% of psychiatric beds. With 11 000 hospital beds, the private profit-
making sector accounts for 70% of the remaining full-time hospitalization 
capacity and is, therefore, an important actor in the field of mental health care. 
Private profit-making hospitals are only marginally involved in outpatient 
treatment, but they account for 20% of cases involving inpatient care. They 
accept patients with psychiatric disorders on the same basis as public hospitals.
A large number of psychological disorders are also dealt with on an 
outpatient basis by GPs or private psychiatrists or psychologists, some of them 
practising psychotherapy and, occasionally, psychoanalysis. In 2012, there 
were 12 400 psychiatrists in activity, the majority of whom (57%) were salaried 
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doctors in hospitals and the rest in private and mixed practices. The density of 
psychiatrists was 22 per 100 000 inhabitants in 2012. However, geographical 
heterogeneity is high. Although no reliable figures are available, it is estimated 
that about 35 000 psychologists work in France, either as salaried employees 
or in private practice. Besides the psychotherapies mentioned above, they also 
offer psychological support and follow-up in the context of schools or as part 
of social welfare provisions.
As a result of the de-institutionalization policy that started in France more 
than four decades ago in the 1980s, the vast majority of care in the psychiatric 
sector is ambulatory, with 77% of patients over the course of a year treated 
exclusively on an outpatient basis (DREES, 2013c). In terms of hospital care, 
part-time stays accounted for 89% of hospitalizations in 2011.
Services provided by the health and social care sector for the disabled
People disabled by severe mental illnesses may also receive services from 
the health and social care sector for the disabled. Many organizations for 
the disabled offer a wide range of services to mentally ill patients, including 
housing, health care treatment, professional training, schooling for children, 
professional education and sheltered workshops. However, only a few are fully 
dedicated to the population with mental illness.
Tables 5.3 and 5.4 show institutions of the health and social sector that 
provide services to adults and children with mental health-related disabilities 
and the share of the affected population for whom they provide services.
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Table 5.3 
Institutions of the health and social sector that provide services to adults with mental 
health-related disabilities: overall capacity and share of the affected population served
Institution
Overall capacity (2010 or 
last year available)
Percentage of adults with 
mental health-related 
disabilities served (2010 
or last year available)
Specialized reception centres (maisons d’accueil spécialisé) 23 968a 12.4a
Medical reception centres (foyers d’accueil médicalisé) 20 448a 24.3a
Sheltered workshops  
(etablissements et services d’aide par le travail)
116 016a 21.5a
Occupational rehabilitation centres  
(centres de rééducation professionnelle)
9 765a 12.7a
Pre-orientation centres (centres de pre-orientation) 1 250a 32.3 (2009)b
Social support services for disabled adults  
(services d’accompagnement médico-sociaux pour 
adultes handicapés)
7 282a 40.1a
Companies for disabled people (entreprises adaptées) – 4.5 (2001)c
Respite care health beds (lits halte soins santé) 501 (beds; 2007)d 29.1 (1995)e
Temporary reception centres for disabled adults 
(etablissements d’accueil temporaire pour 
adultes handicapés)
517a 15.6a
Experimental centres for disabled adults  
(etablissements expérimentaux pour adultes handicapés)
4 399a 25.9a
Mutual aid groups (groupes d’entraide mutuelle) – 100.0a
Residential care homes (foyers d’hebergement) 39 494a 17.4a
Assisted living centres (foyers de vie) 46 798a 19.20a
Multipurpose reception centres (foyers d’accueil polyvalent) 4 658a 16.40a
Social life support services  
(services d’accompagnement à la vie sociale)
38 165a 23.70a
Sources: a  DREES, 2013c; b FINESS, 2014; c DREES, 2001; d FNARS, 2008; e Marpsat, 2002.
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Table 5.4 
Institutions of the health and social sector that provide services to children with 
mental health-related disabilities: overall capacity and share of affected 
population served
Institution
Overall capacity (2010 or 
last year available)
Percentage of children with 
mental health-related 
disabilities served (2010 
or last year available)
Educational centres for children suffering from mental 
disabilities (instituts médico-éducatifse)
69 592a 18.9a
Institutions for children with multiple disabilities 
(etablissements pour enfants et adolescents 
polyhandicapés)
5 637a 4.1a
Institutions for children with physical disabilities  
(instituts d’éducation motrice)
7 505a 2.7a
Sensory training centres (instituts d’éducation sensorielle) 8 409a 1.9a
Medico-psycho-educational centres  
(centres médico-psycho-pédagogiques)
2 779 080 (consultations)  
175 160 (active files)a
100.0 (2003)b
Therapeutic and educational centres (instituts 
thérapeutiques, educatifs et pédagogiques)
14 984a 93.7a
Home care and education services  
(services d’éducation spéciale et de soins à domicile)
43 556a 4.6a
Early social activity centres  
(centres d’action médico-sociale précoce)
1 238 710 (consultations)  
65 010 (active files)
20.0 (2008)c
Temporary reception centres for disabled children 
(etablissements d’accueil temporaire d’enfants handicapés)
284d 6.0d
Experimental centres for disabled children (etablissements 
expérimentaux pour l’enfance handicapée)
1 155a 26.50a
Sources: a DREES, 2013d; b Coldefy, 2005; c CNSA, 2008; d DREES, 2008.
Critics of the mental health care system cite the lack of coordination among 
the health and social care sector, self-employed medical professionals and 
specialists and the private profit-making sector; the significant geographical 
inequalities regarding available resources; and the excess capacity for full-time 
hospitalization. These problems stem in part from the nature of psychiatric 
research in France, which traditionally has been monodisciplinary. In 
recent years, policy-makers have begun to recognize the need to develop a 
multidisciplinary research approach, with a particular focus on social sciences 
and health services, to better coordinate the different mental health actors and 
to develop smoother patient care pathways (Couty, 2009).
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5.12 Dental care
Dental care in France is provided mainly by self-employed dentists, who 
represented 90% of the roughly 41 000 practitioners in activity in 2011. The 
remaining 10% were salaried staff within specialized dental care centres, often 
managed by mutual VHI entities, or in hospitals.
National strategies to improve dental care have focused on children and 
adolescents. The government set an objective in the 2004 Public Health Act 
to reduce the tooth decay index by 30% among children aged 6 to 12 within 
five years. While this objective was met, dental problems remain frequent, 
particularly among children from low-income families or without good access 
to care. Since 2007, a free oral care examination programme called M’T Dents, 
has been offered to children aged 6, 9, 12, 15 and 18, with follow-up care (other 
than prosthetics, orthodontics or dental appliances) fully covered by SHI. In 
addition, hour-long oral health prevention sessions are provided to all children 
in primary school. While the HAS recommends an annual dental check-up 
for children and adults, a nationwide survey found that 30% of children aged 
5 to 15 had not had a check-up within the preceding 12 months. Moreover, 
significant disparities were evident depending on the family’s socioeconomic 
status. Unfamiliarity with the free programme, as well as fear of dental visits, 
may explain the differences in recourse to care (Calvet et al., 2013).
In 2012, dental care represented 5.72% of personal health care consumption 
but only 2.39% of SHI expenditure because of extra-billing, which accounted 
for 53% of dental care fees, primarily for dental prosthetics and orthodontics. 
Unlike doctors, all dentists may engage in extra-billing, but not for all services. 
Extra-billing for conservative dentistry (tartar removal, fillings, root canals) 
is prohibited. While VHI covers the largest share of dental care expenditure, 
a substantial part is financed by OOP payments, giving rise to inequalities in 
access. A survey of patients’ failure to seek treatment found that 47% of the 
forgone treatments were for dental care (Célant, Guillaume & Rochereau, 2014).
Access to dental care also varies by region. There are 63 dentists per 100 000 
inhabitants on average, with wide variations in their geographic distribution: 
half work in areas with more than 200 000 inhabitants, while only 6% practice 
in rural zones.
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5.13 Complementary and alternative medicine
There is no general regulation and very few data regarding complementary 
and alternative medicines in France. Some of the drugs and practices that 
may fall under this category, such as homeopathy, acupuncture and, to a 
lesser extent, osteopathy, play a significant role in the French health care 
system. Recent debates have emphasized the need to monitor the development 
of diverse and mostly uncontrolled health-related practices in order to limit 
fraudulent activities.
France is the largest national market for homeopathic products. These 
products are regulated by the public health code, which provides a definition 
for homeopathic drugs and distinguishes between two types of homeopathic 
substance, which fall under different regulatory frameworks. First, products 
that are extremely diluted (so that they are considered innocuous), which are 
administered orally or by external application and which are commercialized 
without any pre-specified therapeutic purpose, need only to be declared to 
the ANSM before commercialization. They may be covered by SHI at 30% 
and, in that case, their price is regulated. These represent the vast majority of 
homeopathic products. Second, all other homeopathic products (notably those 
that are being sold with a specific therapeutic indication) must follow the AMM 
process for new drugs before entering the market and are not covered by SHI. 
Distribution of homeopathic products is subject to the same restrictions as 
conventional drugs.
Acupuncture has been recognized as a medical activity in the common 
classification of medical activities for more than 20 years and is covered by 
SHI with a tariff that is currently half the tariff for a standard GP visit. Finally, 
osteopathy sessions, while not recognized as a medical activity, are covered by 
a number of VHI contracts, often on an annual lump sum basis and only when 
referred by a physician.
5.14 Health care for specific populations
In addition to the health care delivery structures outlined above, specific 
structures provide care for certain populations.
Since 1994, the public health care sector is responsible for delivering 
care to prisoners. Each prison contracts with a public acute care referral 
hospital that runs an ambulatory care department within the prison walls. In 
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addition, the hospital provides inpatient care for prisoners as needed. The 
transfer of responsibilities for the delivery of health care from the penitentiary 
administration to the health care administration has improved the quality of 
care delivered to prisoners. However, current concerns are related to access to 
mental health care in prison.
Hospitals in the military health care system are run by the Ministry of 
Defence. Although their primary aim is to provide care to military personnel, 
the general population also has access to these hospitals on the same coverage 
terms as other hospitals.
Undocumented immigrants, refugees and asylum seekers usually receive 
emergency care in the mainstream health care system. In addition, they 
may be allowed temporary stay and working permits if they are facing a 
serious medical condition that cannot be treated effectively in their own 
country. Finally, a few private non-profit-making associations provide care to 
undocumented immigrants, refugees and asylum seekers, regardless of their 
administrative status.
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6. Principal health care reforms
The main objectives of the reforms to the health care system since 2010 were to increase the governance and transparency of the system, to contain SHI expenditure without damaging equity in financial access, to 
increase geographic equity in access to care and to meet the needs of vulnerable 
populations, particularly by ensuring access to care of the frail elderly people 
and by decreasing social health inequities.
One of the major changes since 2010 has been a move towards more 
transparency in the system, particularly with respect to conflicts of interest 
of experts that came to light in the Mediator scandal. The main objectives of 
the enacted reform legislation were to restore confidence in the administrative 
decision-making process for health products, particularly drugs; to provide 
greater transparency; to reduce the influence of the pharmaceutical industry on 
experts and treating physicians; and to strengthen drug safety and surveillance.
Cost-containment measures have focused particularly on drug expenditure, 
with a continuous trend of de-listing drugs with insufficient SMR. However, 
despite an announcement by the Minister in charge of Health that all drugs 
with an insufficient SMR would be de-listed or subject to a systematically 
motivated decision if coverage were to be maintained, the measure has not been 
put into practice. Tight control of drug prices also continued with the adoption 
of economic evaluation as a new tool. However, formal assessment of how this 
has affected prices is not yet available. In order to preserve equity, controlling 
the level of OOP payments has been a major issue in recent year, based on two 
main tools: expansion of more homogenous complementary coverage to a larger 
share of the population and control of the level of extra-billing by doctors. The 
development of the P4P scheme for doctors was also aimed at increasing the 
efficiency of the system.
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To improve geographical access to care, a move towards qualitative 
incentives for doctors has been progressively undertaken. Because negative as 
well as positive financial incentives developed by the government proved to be 
ineffective, initiatives focusing on improving the workplace quality of life of 
doctors have flourished at the local level. In addition, new methods of health 
care organization through task transfer and the use of information technologies 
such as tele-health have been encouraged.
The increasing demand for long-term care remains a major concern in 
the government’s plan. However, despite strong government support, public 
coverage of long-term care for the elderly in order to provide greater equity in 
access remains one of the main challenges of the system.
6.1 Analysis of recent reforms
France’s mixed system of organization (see section 2.1) attempts to balance 
competing values such as equity, patient choice and efficiency. The resulting 
structural challenges have provided the impetus for health care reforms.
The objectives of the health care system reforms since the late 1990s 
have been:
• to improve health system governance and transparency;
• to control the growth of SHI expenditure while ensuring financial equity 
in access to care;
• to address geographic disparities in access to care;
• to meet the needs of vulnerable populations, particularly the growing 
number of frail elderly people, and to decrease social health inequities.
Box 6.1 presents the major reforms since 2009. For previous reforms, please 
see Chapters 2 and 7 of Chevreul et al. (2010).
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Box 6.1
Major health care reforms and policy measures, 2009–2014
 2009
•  The HPST created the ARSs, which merged and replaced other regional state and 
SHI institutions, with the goals of improving local access and quality of care, encouraging 
preventive medicine and modernizing hospital organization.
•  SHI began to offer individual contracts for professional practice quality improvement 
(contrat d’amélioration des pratiques individuelles) to GPs on a voluntary basis.
  2010
•  The coverage rate for drugs with insufficient relative medical benefit was decreased  
from 35% to 15%. 
  2011
•  The coverage rate for drugs with moderate relative medical benefit was decreased  
from 35% to 30%.
•  Concerns regarding conflicts of interests following the Mediator (benfluorex) scandal led 
to stronger disclosure requirements under the Health Security Law enacted in December 
2011 (Loi No. 2011–2012 du 29 décembre 2011 relative au renforcement de la sécurité 
sanitaire du médicament et des produits de santé). The renamed and reformed ANSM was 
given expanded authority, including the ability to require drug manufacturers to undertake 
comparative trials to measure the increased benefit of a new drug over an existing one and 
the power to impose criminal sanctions.
•  Following the success of the voluntary individual contracts for professional practice quality 
improvement, a P4P was incorporated into the physicians’ 2011 collective bargaining 
agreement, with an expanded list of objectives and extended to additional specialties 
(ROSP). GPs participating in ROSP receive additional remuneration on top of their normal 
FFS income, which takes into account the size of the population treated by the doctor and 
29 quality indicators with intermediate and final targets.
  2012
•  An agreement with physicians’ unions to address excessive extra-billing was reached in 
October 2012. The provisions included incentives for Sector 2 doctors, who may sign a 
voluntary three-year “access to health care contract” that restrains extra-billing practices 
(effective 1 December 2013), and outlines procedures potentially leading to sanctions  
for doctors whose extra-billing practices are found to be abusive. 
•  The national convention with pharmacists signed in April 2012 included P4P incentives. 
The indicators upon which the remuneration is based include increasing the rate of generic 
substitution for a list of 30 drugs, with an overall goal of 85%.
•  The 2012 Social Security Finance Act expanded the scope for economic evaluations by 
HAS, effective from 2 October 2013. The CEESP evaluates drugs with improvement of 
medical benefit (ASMR) ratings of 1, 2 or 3 that are likely to have a significant impact on 
SHI expenditures (annual sales of €20 million or more). The goal of the evaluation is to 
measure the interest to society of a new drug compared with existing treatments based  
on its cost–effectiveness. The advice of the CEESP should then be used by the CEPS in 
its price negotiations with the manufacturer.
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6.1.1 Improving health system governance and transparency
The institutional complexity of the French health care system and the conflicts 
of power and legitimacy associated with it are major issues, particularly with 
respect to the relationship between the state and SHI. Reforms, therefore, tend to 
search for institutional equilibrium. Since the late 1980s, health care governance 
has been substantially reorganized, with a process of decentralization at the 
regional level, an increase in the role of parliament and an attempt to clarify 
the respective roles of the state and SHI.
In the French context, decentralization was mainly a form of deconcentration, 
where policies and frameworks are defined at the central level and implemented 
at the local level, adapted to local situations. The Ministry in charge of Health 
and the government remain the main decision-makers in health care in France. 
The last major step forward in decentralization was made through the 2009 
HPST Act, which created the ARSs (see section 2.4). However, while creation 
of the ARSs, which are autonomous bodies, can be seen as a step towards 
devolution, the Ministry in charge of Health retains the power to nominate each 
ARS director. Moreover, the planned 2015 health reform will likely increase 
state control of ARS governance (see section 6.2). Indeed, power at the national 
level remains significant even when compared with other countries such as 
England, which is considered to be highly centralized (Ettelt et al., 2010) (for 
more details, see section 7.1.2 in Chevreul et al., 2010).
  2013
•  Under a provision of the National Interprofessional Agreement enacted as part of the 
Employment Protection Law (loi sur la sécurisation de l’emploi), all employers must 
provide group VHI coverage for their employees (effective 1 January 2016).
•  The 2013 Social Security Finance Act created the CASA, a 0.3% tax on retirement and 
disability pensions, for the purpose of financing a planned Aging and Dependency Law 
(see section 6.2). Consideration of the proposed law was postponed until late 2015 and 
will not be implemented until 2016.
•  The revenue ceilings for access to CMU-C and financial assistance to purchase a private 
VHI contract (ACS) (section 3.5.1) were exceptionally increased by 7%, pursuant to the 
recommendation of an interministerial committee to combat exclusion. While the ceilings 
are adjusted annually for inflation, this additional increase was undertaken to improve 
financial access to care by expanding VHI coverage for the less well-off population.
  2014
•  The 2014 Social Security Finance Act included a programme of regional pilot projects 
aimed at improving care coordination for frail elderly people and finding alternatives to 
the existing fragmented care organization.
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One of the major changes since 2010 has been a move towards more 
transparency in the system, particularly with respect to conflicts of interest of 
experts. In 2011, weaknesses in the French regulatory system for health products 
were underscored in the wake of the scandal over Mediator (benfluorex), an 
anti-diabetes drug that remained on the French market until 2009 despite 
mounting evidence of serious side-effects that led other countries to ban it 
as early as 1997. In a report on the investigation into Mediator, the Inspector 
General of Social Affairs (Inspection générale des affaires sociales; IGAS) 
identified multiple weaknesses in the regulatory system for drugs, including 
what it termed a structural and cultural conflict of interest on the part of the 
French Health Products Safety Agency because of its institutional cooperation 
with the pharmaceutical industry, as well as the reluctance by the Ministry in 
charge of Health to de-list drugs found to have an insufficient SMR for fear of 
opposition by prescribing doctors and patients (IGAS, 2011). The scandal led 
to fast-track reform legislation.
The main objectives of the reform legislation were to:
• restore confidence in the administrative decision-making process for 
health products, particularly drugs;
• provide greater transparency and reduce the influence of the 
pharmaceutical industry on experts and treating physicians; and
• strengthen drug safety and surveillance.
Enacted in December 2011, the Health Security Act (Loi No. 2011–2012 du 
29 décembre 2011 relative au renforcement de la sécurité sanitaire du 
médicament et du produits du santé) established a new national agency, the 
ANSM, to evaluate the benefits/risks of all human health products and provide 
ongoing surveillance. ANSM, which replaced the French Health Products 
Safety Agency, has expanded authority, including the ability to require drug 
manufacturers to undertake comparative trials to measure the increased benefit 
of a new drug over an existing one and the power to impose criminal sanctions.
To address the issue of conflicts of interest raised by the Mediator affair, the 
Health Security Law requires experts providing input into the decision-making 
process (e.g. members of commissions reporting to the ministries in charge of 
health and social security) to disclose their direct and indirect interests for the 
five preceding years in a declaration available to the public and kept up to date 
by the expert.
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To shed further light on the ties between health professionals and the 
pharmaceutical industry, drug companies are required to disclose the 
agreements and other benefits provided to a wide range of individuals and 
organizations participating in the health system. In 2014, the government 
initiated a new web site that identifies health professionals’ ties to businesses 
that market health products or cosmetics (www.transparence.sante.gouv.fr). In 
addition, limits have been placed on visits by pharmaceutical representatives 
in hospitals, and advertisements aimed at health professionals are subject to 
prior approval by ANSM.
The Health Security Law also includes new pharmacovigilance requirements 
designed to strengthen the surveillance of drugs on the market. Manufacturers 
must register, declare and monitor adverse side-effects, which may also have 
implications for post-authorization studies of safety and efficacy. Actions taken 
in other countries with respect to drugs authorized in France must also be 
reported. Any suspension, withdrawal or notification regarding a drug must 
be made public immediately at the expense of the manufacturer. Certain 
health professionals (physicians, dental surgeons, midwives and pharmacists) 
are also required to report adverse side-effects. A whistle-blower provision 
protects from discriminatory employment actions all those who report adverse 
effects in good faith. Doctors prescribing a medication outside of its authorized 
indications must explain orally the reasons to the patient, as well as noting it 
within the medical file and on the prescription.
Given the context of the Mediator scandal and the need to restore 
public confidence in the system of drug regulation in France, passage of 
this Law was relatively consensual among the stakeholders, including the 
pharmaceutical industry.
6.1.2 Containing SHI expenditure while striving for equity in 
financial access
The organizational structure of the French health care system makes the goal 
of cost-containment difficult to achieve. Indeed, controlling expenditure 
is a complicated task when consumption by patients and provision of care 
by providers are unrestricted, where care is largely publicly funded and 
retrospectively reimbursed, and where local SHI funds reimburse care 
without information regarding its appropriateness and efficiency. Certain 
expenditure categories, particularly drugs, have been the target of numerous 
cost-containment measures.
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Cost containment measures fall into two broad categories: strict accounting 
cost-containment policies (maitrise comptable des dépenses de santé), which 
have been implemented since the late 1970s and focus on controlling provider 
tariffs and the volume of care provided and on decreasing SHI expenditure, 
and medically based cost-containment policies (maîtrise médicalisée des 
dépenses de santé), which were developed later in the 1990s and aimed to 
reduce the financial and equity losses linked to medical practice variations 
while improving medical practice. The strict accounting cost-containment 
policies were strongly opposed by physicians (see section 3.5 in Chevreul et 
al., 2010). However, both types of policy continue to be used in France. The 
following subsections highlight measures taken since 2010 (for additional 
details and earlier cost-containment reforms, see section 7.1.3 in Chevreul et 
al., 2010), as well as measures to mitigate the impact of shifting costs from SHI 
to private expenditure.
Strict accounting cost-containment measures
Decreasing the benefit package
Decreasing the benefit package is one means of decreasing the financial burden 
on SHI. Of all health care goods and services, drugs were the most affected 
by this type of measure. Between 1990 and 2009, prescription drug sales in 
France multiplied 2.5 times, with SHI covering approximately 75% of the total 
(Cour des comptes, 2011b). The steady increase in pharmaceutical expenditure 
has led to a series of measures aimed at limiting the usage of certain drugs 
and/or reducing the cost for SHI. Cost-containment measures have included 
increasing patient contributions (often covered by VHI), either by de-listing the 
drugs completely or reducing the rate of SHI coverage, reducing drug prices 
and encouraging generic substitution. Economic evaluation is the newest tool 
in the cost-containment policies.
De-listing drugs has proven to be politically sensitive, as revealed by 
the history of de-listing since the late 1990s. In certain cases, drugs with 
insufficient SMR were subject to lower prices or reimbursement rates or even 
left at a 65% rate rather than being de-listed. A provisional coverage rate of 
15% was instituted for certain drugs as an interim step towards de-listing in 
2008. In 2010, the coverage rate for drugs with weak relative SMR decreased 
from 35% to 15%, and in 2011, the rate for drugs with moderate SMR was 
reduced from 35% to 30%. An additional 26 drugs were de-listed in 2011, 
including 17 that had been covered at 15%. The Minister in charge of Health 
announced in January 2011 that all drugs with an insufficient SMR would be 
de-listed or subject to a systematically motivated decision if coverage was to 
Health systems in transition  France162
be maintained. However, to date there has been no decree authorizing this 
alternative coverage procedure, and the left-wing government elected in 2012 
has not put this measure forward since then.
While this cost-containment strategy may be effective in reducing costs in the 
short term, the long-term effect is less clear. The French Accounts Commission 
has noted that de-listing drugs in a particular therapeutic class can have effects 
on prescription of drugs in other covered classes that may reduce or eliminate 
the cost savings. For example, when the class of expectorants was de-listed, 
savings of €45 million were anticipated. However, prescriptions were shifted 
to cough suppressants and bronchodilators, resulting in additional expenditure 
of €40 million for these drugs (Cour des comptes, 2011b) and highlighting the 
strong culture in French medical practice of offering prescriptions for every 
symptom. This underscores the need to address medical practice through, for 
example, changes in initial training and DPC (see section 4.2.3).
Price control
Strict control of tariffs was applied, notably to the price of drugs but also to other 
type of service such hospital remuneration, medical devices and professional 
tariffs. As a result of tight control of doctors’ tariffs, extra-billing, which is 
not covered by SHI, was permitted starting in the 1980s for certain categories 
of doctor (see Sector 2 doctors; section 3.7.2). However, extra-billing in some 
specialties has significantly increased OOP payments, thereby impairing access 
in some areas where extra-billing is the rule (e.g. gynaecologists in Paris). For 
this reason, policies to reduce extra-billing were developed starting in 2013.
Drug price control
The CEPS (see section 2.7.2) is authorized to reduce previously negotiated 
drug prices under four circumstances: at the time of renewal of the agreement, 
particularly if there has been a significant increase in volume following 
extensions of indications; when the drug’s patent expires and the first generics 
enter the positive list (generally 85% of the price of the brand name drug); when 
the evolution of drug expenditure threatens ONDAM targets (see section 3.3.3); 
or when studies of the drug once it is on the market reveal differences in efficacy 
or side-effects compared with the clinical trial data that were considered at 
the time the pricing agreement was made. Drug price reductions, both in the 
ambulatory and hospital sectors, constitute a significant source of savings in 
the annual health budget, with a target of €960 million in 2014 (Sécurité sociale, 
2013c).
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Economic evaluation is the newest cost-containment tool. Until recently, 
coverage and pricing decisions were made following HTA evaluations that 
were principally based upon clinical efficacy, not on cost–effectiveness or 
value to broader society. However, since October 2013, economic evaluation 
has been required for drugs meeting two conditions: having been evaluated as 
innovative (ASMR level 1, 2 or 3) and likely to have a significant impact on 
SHI expenditure (annual sales of €20 million or more in the first two years). 
The CEESP undertakes its assessment simultaneously with the Transparency 
Commission’s evaluation of the SMR and ASMR of the drug (see section 2.8.4) 
to avoid undue delay before a drug may be marketed. Based on a file prepared 
by the manufacturer that includes the data and methodology underlying the 
modelling of the new drug’s anticipated cost–effectiveness, the CEESP issues 
an opinion on the drug relative to existing therapeutic strategies, including the 
benefits expected or observed for patient health and quality of life. Unlike other 
countries, there is no fixed threshold for cost–utility or cost–effectiveness. The 
advice of the CEESP should be used by the CEPS in its price negotiations with 
the manufacturer. The first CEESP opinions were issued in early 2014, and so 
it is too soon to evaluate the effectiveness and appropriateness of its use.
An additional element in the reduction of drug expenditure has been the 
governmental pressure to expand the generic drug market, starting with the 
authorization of generic substitution under the 1999 Social Security Finance 
Act. For a pharmacist to substitute a generic for the brand name drug, the drug 
must appear on a list of drugs for which substitution is authorized. This list 
does not include all off-patent medicines. For example, paracetamol is not in 
this list. Doliprane, the brand name for paracetamol manufactured in northern 
France by Sanofi-Aventis, was the fourth most reimbursed drug in France in 
2013, accounting for €315 million and leading to suspicion of protectionism. 
While the possibility of generic substitution of paracetamol has been invoked 
since 2002 and most recently in December 2013 by the ANSM, for the moment 
the government has chosen instead to reduce the price of the brand name drug 
(Cour des comptes, 2014b).
In terms of market share, generic drugs in France represent a much lower 
proportion of reimbursable drugs than in other European countries. The generic 
market’s volume share (drug packages sold) grew from 3.4% in 1999 to 23% 
in 2011. However, in terms of value, it only accounted for 10.9% of the market. 
According to IGAS, the list of substitutable drugs in France is much more 
restrictive than in countries such as the Netherlands and Germany, which have 
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similar health systems. For example, in Germany, the market share of generic 
drugs among all covered drugs was 72.4% of volume and 34.7% of value 
(IGAS, 2012a).
Pharmacists have been the key players in expanding the use of generic 
drugs, largely because of financial incentives to encourage generic substitution, 
including higher manufacturer rebates compared with brand name drugs. Since 
the 2007 Social Security Finance Act, annual objectives for generic substitution 
have been set and a new incentive for patients was instituted in departments 
with low levels of generic substitution. Patients refusing generic substitution 
must pay for the prescription and then claim reimbursement from SHI rather 
than benefiting from third-party payment as is usually the case. Nonetheless, the 
rate of generic substitution strongly decreased between 2008 and 2012, falling 
from 82% to 72% of substitutable drugs, in part through public reluctance to 
accept certain generic drugs because of concerns about their efficacy and safety 
and partly from an increase in prescriptions marked as “non-substitutable” 
by doctors. To counter this trend, the SHI expanded the patient incentive for 
generics nationally to all SHI beneficiaries. In addition, a new P4P scheme 
for pharmacists was established in 2014, and the indicators upon which the 
remuneration is based include increasing the rate of generic substitution for a 
list of drugs newly included in the repertoire, with an overall goal of 85%. The 
government is also considering instituting penalties for doctors who abuse the 
designation “non-substitutable” in prescribing drugs.
The 2014 Social Security Finance Act authorized the substitution of 
off-patent biosimilar drugs (biosimilaires) at the pharmacy level, but only at 
the initiation of treatment. As in other European countries, France hopes to 
reduce drug expenditure through expanded use of biosimilar drugs.
Finally, the 2014 Social Security Finance Act also authorized a three-year 
trial that allows pharmacists in selected regions to dispense certain antibiotics 
in the exact prescribed number of units rather than by the box, with a fixed 
number of tablets in order to reduce waste and the risk of microbial resistance. 
The programme will be evaluated in terms of its effect on expenditure and also 
on the proper use of antibiotics.
Controlling the level of extra-billing by doctors
Extra-billing is permitted for doctors practising in Sector 2, which includes 42% 
of specialists and 11% of GPs. In an effort to discourage excessive extra-billing, 
a “carrot and stick” approach was taken in a 2012 amendment to the collective 
bargaining agreement between SHI and physician unions. Since 2013, Sector 2 
doctors may be subject to sanctions for excessive extra-billing, defined as fees 
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in excess of 150% of official SHI tariffs. In addition, a voluntary three-year 
“Access to Health Care” contract (contrat d’accès aux soins) provides Sector 2 
doctors with incentives to freeze their fees and average rate of excess billing at 
2012 levels and to perform a share of their services at statutory tariff levels. The 
incentives include social and fiscal advantages and access for Sector 2 specialists 
to the €2 higher statutory tariffs of Sector 1 doctors. Patients consulting doctors 
who have signed the agreement also benefit from improved coverage of the 
services by SHI. However, from April 2015, patients of non-signatory doctors 
may be exposed to increased OOP costs under a decree that places a ceiling 
on the amount of extra-billing that may be covered by VHI contracts (125% of 
official SHI tariffs in 2015–2016 and 100% thereafter).
The average rate of extra-billing by doctors practising in Sector 2 decreased 
from 56.9% in 2011 to 56.3% in 2013, marking the end of nearly uninterrupted 
increases in extra-billing since the 1980s. One explanation is fear of sanctions 
for excessive extra-billing. The financial crisis may also been a contributing 
factor, as doctors responded to the reduced purchasing power of their patients.
Decreasing the impact on equity of shifting costs from SHI to 
private payers
Certain cost-containment measures, particularly reductions in coverage rates, 
have resulted in a shift towards private expenditure (VHI and OOP payments), 
which has the potential to affect equity in financing and raises concerns about 
equity in access. Measures have, therefore, been put into place to increase the 
level of VHI coverage as well as equity in VHI contracts.
For the less well-off, who were more significantly affected by decreases 
in SHI coverage, these measures include free public complementary VHI 
(CMU-C) and a voucher scheme (ACS) to facilitate purchase of private VHI 
contracts by individuals with low income who are not eligible for CMU-C 
(see section 3.3). In 2013, the revenue ceilings for access to CMU-C and ACS, 
which are adjusted annually for inflation, were increased by an additional 7% 
to afford broader access to these programmes. Nonetheless, many people who 
are eligible for these programmes fail to take advantage of them (CMU, 2013).
Only a share of the working population benefit from group contracts paid 
by employers (see section 3.5.2), which generally offer better coverage at lower 
cost. In order to increase equity in coverage, all employers will be required to 
offer group contracts for VHI to their employees by January 2016, pursuant to 
the January 2013 National Interprofessional Agreement between representatives 
of employers and employees and enacted under the Employment Protection 
Law (Loi No. 2013–504 du 14 juin 2013 relative à la sécurisation de l’emploi). 
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While this measure should result in greater equality in complementary coverage 
among employees, it has a number of shortcomings. Changes to the individual 
market for VHI, including a potentially less healthy population, may result in 
premium increases for those contracts.
In addition, the rules for “responsible contracts” (see section 3.5.3) are 
also being used as a tool to ensure greater equity in the extent of coverage by 
contract. The current reform, effective from April 2015, aims to reduce OOP 
payments by expanding the minimum coverage requirements to include 100% 
of the co-insurance amounts for official tariffs for all forms of care, except for 
thermal treatments, homeopathic drugs and drugs reimbursed at 15% or 30%. In 
addition, responsible contracts will be required to fully cover the daily hospital 
catering fee (see section 3.3.1), regardless of the length of hospitalization, and 
must provide at least minimum coverage of optical care. Moreover, this reform 
also involves group contracts. Employer-provided group VHI contracts will be 
required to cover dental prosthetics up to 125% of the official tariffs as well as 
a higher minimum level of optical care.
Medically based cost-containment
The concept of medically based cost-containment focuses on prescribers’ 
behaviour; it aims to decrease medical practice variations by improving 
physicians’ knowledge and rewarding good practice although financial 
incentives (see section 7.1.2 in Chevreul et al., 2010), which recently has 
included P4P mechanisms.
In recent years, lifelong learning through continuing medical education 
( formation médicale continue) has been subject to major changes (see 
Chevreul et al., 2010). From 2010, a new DPC (model 22) for health professions 
in the ambulatory sector was developed with a centralized managing body 
(Organisme gestionnaire du développement professionnel continu). It was 
designed to ensure quality and independence from the pharmaceutical industry 
and to evaluate and facilitate registration for training programmes. To date, 
implementation of the DPC has been problematic, with the continuing education 
obligation undefined in terms of content, number of hours and sanctions and the 
financing mechanism insufficient (IGAS, 2014a). However, a growing number 
of doctors are fulfilling this obligation.
On the financial mechanism side, a voluntary P4P scheme was introduced in 
2009, consisting initially of voluntary contracts between SHI and GPs to improve 
individual practice (Contrats d’amélioration des pratiques individuelles) (see 
section 3.6.2 in Chevreul et al., 2010); GPs agreed to meet specific goals 
including chronic disease management, preventive health care and targets for 
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prescription of certain drugs and generics. Following its success with GPs, this 
scheme was incorporated into the physicians’ collective bargaining agreement 
effective in 2012, with an expanded list of 29 quality indicators and extended 
to additional specialties with public health objectives (ROSP). By 2013, nearly 
60% of physicians participated in ROSP. However, the 2013 results for ROSP 
revealed modest improvements in most of the targeted objectives, except for 
prevention, where rates of breast cancer screening and influenza vaccination 
were particularly low compared with the objectives (Sécurité sociale, 2013a).
6.1.3 Improving geographical access
While the number of physicians in active practice in France is at an all-time high, 
geographic inequalities remain and certain areas are underserved, particularly 
isolated rural communities and disadvantaged suburbs. With an average density 
of 330 doctors per 100 000 inhabitants, France ranks 14th among OECD 
countries and above the OECD average of 310 doctors per 100 000 inhabitants 
(Maurey, 2013). Consequently, the problem of so-called “medical deserts” does 
not result from an insufficient number of doctors but rather to their distribution 
across the territory.
In the short term, the shortage of professionals in some regions has been 
alleviated by the recruitment of foreign professionals, mainly from Belgium, 
Algeria, Germany, Morocco and, since 2007, Romania (Le Breton-Lerouvillois, 
2007). Indeed, foreign-trained doctors accounted for 25% of doctors newly 
registered with the French Medical Council (Conseil national de l’Ordre des 
médecins) in 2013 (CNOM, 2014). However, these doctors do not necessarily 
practise in the areas or within the specialties where the greatest needs exist.
Financial incentives
Since the early 1990s, successive governments have tried with little success 
to address geographical disparities via a variety of voluntary initiatives with 
positive financial incentives to attract doctors to underserved areas. In 2007, 
SHI implemented control over nurses’ geographical settlement using negative 
financial incentives and hoped that it would be able to extend this control 
to other professions in the future, especially to doctors. However, negative 
financial incentives to control doctors’ settlement (see section 5.2 in Chevreul 
et al., 2010) were abandoned from 2010.
These measures have been unsuccessful for two main reasons. First, sanctions 
were strongly opposed by doctors’ representatives. Moreover, incentives for 
settlement in rural areas have mainly focused on positive financial incentives 
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that did not counterbalance the negative issues faced by doctors choosing to 
live in areas that may be less attractive in terms of schooling for children, job 
opportunities for spouses, and so on.
Alternatives to financial incentives: quality of life, new practice models 
and task transfer
Innovation in regard to addressing geographical disparities has come from local 
policy-makers, who face tremendous pressure to find solutions to this critical 
situation. Local initiatives focused on improving the workplace quality of life 
of doctors, rather than providing financial incentives, have flourished. Such 
initiatives include providing practice structures so that doctors are not faced with 
the high start up costs in establishing their practices; offering the opportunity 
to work in group practices connected with other health professionals and so 
eliminate the need to find replacement cover when they go on holiday, which 
is often a problem for solo practitioners; paying doctors fixed salaries in lieu of 
the traditional FFS arrangement; and covering their liability risk.
Other initiatives to address medical deserts focus on new methods of health 
care organization that redistribute the role of different health care professionals 
and improve their coordination or efficiency in order to decrease the need for 
some categories of professionals and thus ameliorate accessibility problems. 
Experimentation with task transfer between professionals was permitted 
from 2004 and some such transfers have already taken place (e.g. between 
ophthalmologists and vision therapists). In 2008, a recommendation regarding 
the professional skill mix between doctors and other health care professionals 
was issued by HAS and the National Observatory of Health Professions. The 
proposed changes included a transfer of certain tasks from physicians to other 
health care professionals, an improvement in the education and training of 
nurses and a regulatory and financial framework for developing cooperation. 
In 2009, the transfer of tasks and cooperation between categories of health 
professionals was further encouraged, with protocols of cooperation being 
provided under the supervision of the ARS. Health professionals may design 
their own protocol or join an existing protocol that defines the nature of the 
cooperation, the services involved and the place and scope of the professionals’ 
interventions. Task transfer has developed more slowly than expected for two 
main reasons. First, there is opposition to task transfer because physicians are 
paid on a FFS basis and so a reduction in the tasks for which they have a 
monopoly reduces their revenue potential. Second, this approach also raises 
a question of logistics: in the same zones in which an insufficient supply of 
physicians is found, there are also fewer nurses and other health professionals 
to perform the transferred tasks.
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The use of information technologies was also perceived as a tool to reduce 
the need for health professionals, and the implementation of tele-health has been 
encouraged since 2010. Tele-health solutions have been developed mainly by 
the ARSs with the strong support of the Ministry in charge of Health, which 
announced a national strategy for telemedicine, including a methodological 
guide and recommendations on developing telemedicine projects (Ministry in 
charge of Health, 2012). The ARSs have a specific budget to develop these 
projects (€15 million in 2013), and since 2012, eight pilot projects have been 
financed and monitored in order to better understand the factors facilitating 
or limiting the development of telemedicine, to test financing models and to 
produce practice guideline. By the end of 2011, there were 256 telemedicine 
projects in France. While there is great enthusiasm for the possibilities of 
telemedicine to address access problems in underserved areas, it is too early 
to say whether it can live up to this promise. SHI is studying the financing 
options, with a particular focus on fixed-price reimbursements. The HAS 
has developed a framework for undertaking health economic evaluations of 
telemedicine projects.
Following the change of government in 2012, medical deserts once again 
became a priority on the political agenda, and in December 2012, the Minister in 
charge of Health presented the “Pact on Health Territories” (Le Pacte Territoires-
Santé), which repackaged a number of previously announced measures rather 
than developing innovative measures. The 12 proposed measures focused on 
the training and practice establishment of young physicians, the development 
of alternative practice settings, and targeted goals and practice adaptations for 
isolated areas.
To date, several measures have been implemented:
• a designated person in each ARS to facilitate the establishment of 
practices by new doctors; and
• experimentation with new methods of remuneration for multidisciplinary 
teams of health professionals until 1 January 2015 as a precursor to a 
new agreement (subject to arbitration in the event no agreement can be 
reached).
Finally, the proposed Health Law (see section 6.2) includes measures to 
reduce geographic disparities, including interim medical personnel and a 
corps of substitute professionals and new modes of cooperation between 
health professionals.
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6.1.4 Coping with the growing demand for long-term care for 
the elderly
The 2003 heat-wave was a shock for French society, given that 15 000 elderly 
died during this very hot summer mainly because of a lack of timely reaction 
from the social and health care sectors. This national trauma, combined with the 
reality of an ageing population, has made care for vulnerable and frail elderly 
people a major concern for policy-makers in France.
The population aged over 75 years is expected to nearly double by 2050, 
representing 15.6% of the population compared with 8% in 2011 (Vasselle, 
2011). Because the probability of becoming dependent greatly increases with 
age, the number of frail elderly persons is expected to grow 40% by 2030 and 
60% by 2060, rising from 1.15 million in 2010 to 1.55 million in 2030 and 
2.3 million by 2060, corresponding to an estimated 3% of the population. While 
life expectancy in good health is also increasing (63.5 years for women and 61.9 
for men in 2010), the demand for health and social services for the population 
of elderly individuals is clearly growing as well.
To meet these needs, two types of measure have been proposed on the one 
hand developing more services and, on the other hand, improving coordination 
of health and social care services in light of this population’s complex care 
needs, particularly for those with chronic diseases. Financing remains the most 
intractable part of the policy equation.
Since the mid 2000s, two plans have been put in place with the aim of 
developing capacity in both residential care and the home care setting in 
order to support the policy objective of “ageing in place” (maintien à domicile). 
However, despite the genuine political will to develop services to respond to the 
needs of the frail elderly, the implementation of policy solutions did not move as 
quickly as was hoped. One reason for this is the difficulty in finding property 
developers for residential care, particularly for intermediary services between 
the residential and home care services (see section 5.8). A second reason is the 
heavy financial burden of residential care on general councils. A third reason 
is the difficulty in attracting skilled professionals to this sector because of the 
heavy burden of working with disabled frail elderly people, the relatively low 
salaries and the poor prospects for career development (see section 7.1.5 in 
Chevreul et al., 2010).
The current government has broadened the scope of the policy focus to 
include identification of risk factors in order to delay the loss of autonomy; to 
address the ways in which society must adapt to meet the needs of an ageing 
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population in terms of urban planning, lodging, transport and civil engagement; 
and to improve assistance to those who have become dependent – with the 
ongoing priority on ageing in place – along with measures to reduce the 
financial and care burdens on families (Aquino, 2013; Broussy, 2013; Pinville, 
2013). A proposed law on the adaptation of society to an ageing population 
encompassing measures to address these priorities was introduced in 2014 as 
part of a two-step approach (see section 6.2).
Beyond providing and improving long-term care services, there is a growing 
recognition of the need for better care coordination for elderly patients moving 
through the system, both to improve the quality of care and as a source of cost 
savings, particularly those arising from avoidable hospitalizations as well as, 
in the longer perspective, those incurred in residential care by allowing people 
to remain at home longer. In order to develop and test tools and strategies to 
improve care coordination, the Ministry in charge of Health launched nine 
regional pilot projects in 2013 and 2014 aimed at optimizing the care pathways 
across the health, the social and health and the social sectors for frail people 
over 75 years. Under regional pilot projects designed to improve care for frail 
elderly individuals, each participating ARS can set the priorities for their local 
area based on an analysis of population needs and existing services, while 
benefiting from a common set of tools:
• personalized health plan (plan personnel de santé), which is an 
action plan developed by the preferred doctor (see section 3.3.1) and 
incorporating the objectives and expectations of the patient, to be 
implemented by a multidisciplinary team that includes the preferred 
doctor and at least two other health professionals; the €100 consultation 
fee is covered by SHI and shared among the health professionals involved 
in the care process;
• information-sharing platform at the local level for health professionals and 
families; and
• secure messaging tool to allow patient information to be shared among 
treating health professionals.
The lessons learned from this pilot programme will serve to facilitate 
expansion into other regions as well as other target populations.
The second and more politically and financially difficult step will be to 
address financing for residential long-term care. Financing long-term care 
for frail elderly persons is a long-standing concern for policy-makers. In 
2010, French long-term care spending was estimated at €34 billion, or 1.73% 
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of GDP, of which 70% was publicly funded (Charpin & Tlili, 2011; Comité 
interministériel sur la dépendance, 2011). Nonetheless, public coverage does not 
provide adequate and equitable financial protection for the growing number of 
frail elderly individuals, who are expected to constitute 3% of the population 
by the year 2060. Since 2005, various financing reform proposals have been 
debated, ranging from a newly covered risk under the social security system 
to targeted subsidies for private long-term care insurance. However, to date no 
reform measure has been enacted.
While the social security system was the main funding source for long-term 
care after its creation, since the 1970s, local authorities’ responsibility for funding 
long-term care has grown following the creation of a universal allowance with a 
means-tested co-insurance (APA; see section 3.6). Overall, this can be regarded 
as a shift from national solidarity-based financial protection to local tax-based 
financial protection. Despite the attempt to compensate for disparities among 
local authorities through a national funding source allocated based on needs and 
wealth criteria, this shift has increased geographical inequity. Moreover, it is 
more regressive, particularly because a share of local taxes is not income based. 
This situation will worsen if no action is taken to reinforce national solidarity 
(Chevreul & Berg Brigham, 2014).
Two major questions are, therefore, at the heart of the debate: how to ensure 
the sustainability of APA funding given the rapidly increasing financial 
burden on local authorities and how to decrease the burden of user charges 
that exceed the average revenue of elderly persons because of the cost of lodging 
and catering fees in nursing homes (€2892 per month on average in 2012; 
ATIH, 2014). An estimated additional €400 million will be required annually 
for the next 20 years to finance the anticipated care needs of the elderly and 
dependent population.
While long-term care taxes are higher for the salaried population than for 
self-employed people and retirees, increasing equity in financing by equalizing 
the long-term care tax treatment of the entire population would be a logical 
first step. The previous right-wing government did not do so in order to cater 
to its electorate. The left-wing government elected in 2012 partly did so by 
implementing the additional contribution, CASA, on retiree pensions in order 
to finance its planned reform to address loss of autonomy (see section 6.2). 
However, increasing self-employed and retiree taxes up to the general population 
level will not be sufficient to finance the anticipated demand in the medium to 
the long run, and additional revenue sources will have to be found.
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To achieve this aim, a genuine political and societal choice is needed in order 
to strike the right balance between increasing the ability of elderly people to 
use their own assets to pay for care and increasing solidarity, which is link to 
increase contributions for the long-term care system. Details about the second 
phase of the reform to address loss of autonomy, in particular the financing 
mechanism, have not been announced (see section 6.2). Unlike the 2007–2011 
period, when the long-term care financing reform was announced by the 
president and entrusted to powerful ministers, this reform was announced by 
a delegate minister, who has little power in the government and is unknown to 
the general population. Given the significant level of political support necessary 
to achieve the financing reform, these developments do not offer much reason 
for optimism in the short term. 
6.2 Future developments
The National Strategy for Health and the 2015 Health Reform Law
Following the instalment of the newly elected left-wing government in 2012, the 
Ministry in charge of Health launched a National Strategy for Health (Stratégie 
nationale de santé) for guiding public policy for the coming year. This is the 
starting point for the planned 2015 Health Reform Law, which is expected to 
be enacted by the end of 2015.
The Strategy focuses on decreasing social and geographic health inequalities. 
While the French health care system currently focuses on acute care, the reform 
stresses, on the one hand, the importance of developing prevention and care 
for chronic diseases, and, on the other hand, the importance of improving 
efficiency and equity in financing by decreasing OOP payments.
This guidance was translated into the planned 2015 Health Reform Law, 
focusing on developing prevention measures aimed at young people, defining 
patient care pathways, improving geographical access to care in underserved 
areas and ensuring financial access to care.
However, many measures are not dedicated to addressing health inequalities, 
and the reform legislation may be viewed as a rather inhomogeneous group 
of measures addressing various health system issues. Some are dedicated to 
changes in the management of the system by improving coordination of the 
policies of the state, SHI and ARSs, which could be seen as a step backwards 
in the decentralization process. The reform also proposes a series of measures 
to increase patient rights and patient input, such as increasing user participation 
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in designing health policy and in the management of health agencies and other 
institutions. Overall, this reform, while addressing important issues in the 
system, mostly draws upon previously proposed measures and mechanisms 
with very little innovation.
Coping with the growing demand for long-term care for the elderly: 
reform to prevent and provide for loss of autonomy
The first part of a two-step plan to address loss of autonomy (projet de loi 
relatif à l’adaptation de la société au vieillissement) is expected to be enacted 
by the end of 2015 and to be operational by mid-2016. The first step focuses 
on measures designed to facilitate ageing in place, with the key measure 
consisting of increased ceilings and reduced individual financial participation 
under the APA (see section 3.6) to pay for assistance at home for an estimated 
700 000 dependent frail elderly individuals. Other provisions of the proposed 
law include financing of measures to prevent and delay the loss of autonomy; 
adaptation of housing options, from new technologies for automation in 
private homes to modernization of nonmedical collective housing facilities, 
renamed autonomy residences (résidences autonomie; see section 5.8.1); and 
respite assistance for caregivers. These measures will be financed by CASA 
(enacted in 2013 as described above), which is estimated to raise €645 million 
per year. However, most of the 2013 and 2014 revenues raised were not kept 
for the reform but channelled to cover deficits in an unrelated social security 
programme. Starting in 2015, the CASA revenues should be fully dedicated to 
financing the autonomy reform.
The second step of the reform will focus on institutional care, in particular 
reducing OOP payments for nursing home residents. Once more, the most 
significant challenge will be finding the revenues to finance expanded public 
coverage of institutional care. There is actually no political declaration on 
suggested mechanisms and one can wonder if this will remain a “ghost reform” 
after more than a decade of promised long-term care financing reforms that 
were repeatedly delayed and ultimately not acted upon.
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7. Assessment of the health system
The French health care system has long enjoyed the reputation of being one of the best in the world. It combines universal health coverage with a generous supply of health services. This reputation comes in large part 
from success in meeting its goals of full coverage, access without waiting lists, 
patient choice and satisfaction. The combination of a basic universal public 
health insurance system and voluntary complementary private insurance, which 
provides reimbursement for co-payments required by the public system as well 
as coverage for medical goods and services that are poorly covered by the public 
system, results in low OOP costs by international standards, and high medical 
care utilization. France’s average life expectancy of over 80 years is in part 
testament to the strong combination of good health care and good public health 
policies in France. Despite these positives, there are also some shortcomings, 
particularly when considering efficiency and socioeconomic inequalities 
in health outcomes and inequities in access to health care. Major problems 
include lack of coordination between the hospital sector, the ambulatory care 
sector and the health and social care sector, in particular in caring for patients 
with chronic diseases but also in developing preventive care and intersectoral 
policies. However, major efforts have been undertaken since 2009 to address 
these issues.
Health expenditure per capita is higher than the OECD average and France 
ranks usually among the top four countries depending on the indicator used and 
year. The high level of health expenditure has become increasingly important 
at a time when the public system is facing chronic deficits, and improving 
allocative and technical efficiency is a major concern in order to ensure the 
financial viability of the system. Measures developed since 2010 have been 
particularly effective in achieving SHI cost-containment and financing equity, 
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as shown by the fact that the national ceiling for SHI expenditure has been 
underspent since that time, while the percentage of OOP expenditure has 
remained stable over the same period.
7.1 Stated objectives of the health system
Under the 1946 Constitution, the French State guarantees health protection to 
all, a right that dates back to the 1789 Declaration of the Rights of Man and of 
the Citizen. The 2004 Health Insurance Act sets out the stated objectives of the 
French health system:
• universal coverage, independent of age or health status;
• equitable access to health care;
• equitable contribution to the costs of the health care system; every 
person is expected to contribute, to the extent of his/her capacity, to the 
appropriate use of the resources endowed by the nation to SHI; and
• continuity, coordination, and effectiveness of care.
France’s average life expectancy of over 80 years is in part a testament 
to the combination of broad access to health care and strong public health 
policies. Despite these positives, weaknesses remain. Major problems include 
lack of coordination between hospital and ambulatory services, geographic 
disparities in health care resources and financial barriers to some specialists 
because of extra-billing and certain services and devices having poor SHI 
coverage. In the broader economic context, high levels of health expenditure 
and chronic deficits have raised questions about the financial sustainability of 
the system, particularly in light of the growing demand for health services by 
an ageing population.
In terms of governance, increased responsibility for coordination and 
planning of the French health care system has devolved to the regional level 
over the last decades and in particular from 2010. However, the National 
Health Conference, an advisory body to the Ministry in charge of Health, has 
criticized the governance at the national level as fractured and bureaucratic, 
thereby impeding progress in organization and coordination at the regional 
level (National Health Conference, 2013). Such structural impediments may 
also hinder development of Health in All policies at the national level (Leppo 
et al., 2013). Political commitment to intersectoral approaches, while strong in 
certain areas such as emergency response, nutrition and the fight against illegal 
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drugs, has not otherwise appeared to be a priority. However, following the 2012 
National Strategy for Health goals, a new interministerial committee (Comité 
interministériel de la santé), comprising all ministers as well as the secretary 
of state for the budget, was created in June 2014 to ensure improvement in 
population health and reduction of health inequalities through improved 
coordination on all matters affecting health determinants (socioeconomic, 
geographic, environmental, educational, etc.; see section 6.2).
7.2 Financial protection and equity in financing
7.2.1 Financial protection
Overall, financial protection of the French population is good. France is among 
the OECD countries for which public financing of health care expenditure is the 
highest and OOP spending is the lowest. In 2011, the Netherlands, the Czech 
Republic, Japan, Denmark, Norway and Sweden were the only countries with 
a higher share of publicly funded health expenditure. This is achieved through 
a strong commitment by the French to their public SHI (93% of the French 
population declare that the SHI system should remain publicly funded) and 
the 1999 Universal Health Coverage Act, which provided universal health care 
coverage for all people living in France (see section 3.2). In 2013, 77.4% of 
personal health expenditure was publicly funded, with the remainder financed 
by a combination of VHI (13.8%) and OOP payments (8.8%). Reduction of 
financial barriers for groups at greatest financial risk was partly achieved 
through the 1999 Universal Health Coverage Act by the provision of CMU-C 
and through the implementation of the ACS, which provides means-tested 
vouchers for VHI, thus reducing exposure to OOP expenditure (see section 3.3).
However, the proportion of the population covered by complementary health 
insurance does not fully reflect the degree to which financial risk is covered. 
Indeed, there are large discrepancies within the covered population in terms 
of the cost of contracts and level of coverage (see section 7.2.2). While 94% 
of the population had complementary health insurance in 2012 (either VHI or 
CMU-C), among those covered by VHI, 70% say that hospitalization is well 
covered by their contracts, as opposed to vision correction (52%), extra-billing 
by specialists (48.5%) and dental prosthetics (46.4%) (Célant, Guillaume & 
Rochereau, 2014).
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In 2011, OOP expenditure in France as a share of household consumption was 
the lowest of OECD countries after the Netherlands, and well below the OECD 
average (OECD, 2013) (Fig. 7.1). OOP spending is mostly for gaps in depth of 
coverage, including poorly covered goods and services (optical, dental, devices); 
extra-billing, particularly by specialists; and flat-rate deductibles designed 
to moderate consumer behaviour (capped at €50/year) (see section 3.3.1). 
Reductions in the scope of coverage, as a result of de-reimbursement of certain 
drugs and decisions by some VHI firms to no longer cover certain drugs with 
low SHI reimbursement contribute to OOP expenditure. OOP spending on 
drugs increased 4.2 percentage points between 2005 and 2008, growing from 
13% to 17.2% of personal health expenditure and reaching 18.3% in 2012 
(DREES, 2013a). However, in 2013, OOP spending decreased for the second 
year as a result of reductions in drug expenditure, most notably a decrease in 
non-covered drugs for the first time, as well as a decrease in the cost of optical 
devices, and a slowdown in the rise of extra-billing fees (DREES, 2014).
Fig. 7.1 
International comparison of public financing and OOP spending  
(2012 current health expenditures) 
Source: DREES, 2014.
Note: a 2011 data.
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7.2.2 Equity in financing
Overall, the financing of the health system results in a redistribution of 
resources both horizontally from the well to the sick and vertically from 
people with higher incomes to those with lower incomes, through taxes on 
revenues (HCAAM, 2013b). SHI has facilitated a 19% reduction of inequalities 
in standards of living (four-fifths from the method of financing and one-fifth 
from services) (Duval & Lardellier, 2012).
The financing of SHI is considered progressive because of the tax relief 
provided to individuals with low salaries as well as the different CSG 
contribution rates depending on the type of revenue (HCAAM, 2013). However, 
private expenditure through VHI and OOP is regressive, and the transfer of 
expenditure not covered by SHI towards VHI, for which the functioning and 
financing principles are not solidarity based as they are for SHI, has exacerbated 
inequalities in the financial access to care (HCAAM, 2013b). Moreover, people 
with lower incomes spend a greater share of their disposable income on private 
health care expenditure than the wealthier (Duval & Lardellier, 2012). Under 
the Kakwani index, which measures vertical equity, OOP financing would be 
considered progressive if the annual share borne by the lowest revenue deciles is 
lower than their share of total revenues. In France, the poorest 20% account for 
7.1% of total revenues but for 14.7% of OOP spending, resulting in a Kakwani 
index of 0.25, demonstrating that OOP expenditure is vertically inequitable and 
regressive (Geoffard & de Lagasnerie, 2012).
Patients with the highest levels of OOP spending are on average older 
(60 years or more), with one or more chronic diseases covered by the ALD 
programme (see section 3.3.1) and are three times more likely to have been 
hospitalized than the general population (HCAAM, 2013c). While patients who 
benefit from the ALD programme are covered 100% for care related to their 
chronic condition, they still may face high OOP expenditure for other health 
care, as well as for hospitalization (the daily hospital catering fee is not covered 
by ALD, even for hospitalization related to the covered disease) and extra-
billing in excess of official tariffs that is not covered by SHI.
Individuals do not pay for private VHI contracts according to their incomes 
but rather based on an estimate of their needs determined by age in the case 
of mutual firms or often by health questionnaires for commercial insurers 
or potentially in optional group contracts offered by provident institutions 
(see section 3.5.2). Moreover, group VHI contracts generally provide better 
coverage than individual contracts. Indeed, employees covered by group 
VHI contracts have a double financial advantage over those with individual 
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contracts: employer contributions reduce the cost of the contract and employee 
contributions are subject to income tax exemptions, which are more beneficial 
to those with higher incomes and are thus regressive (HCAAM, 2013a). Starting 
in 2016, all private employers will be required to provide group VHI contracts 
to their employees and finance half of the expense (see section 6.1.2).
However, given the increasing importance of private financing in the 
French financing scheme, reforms have focused on ensuring financial access 
to complementary health insurance for those with the lowest revenues as well 
as on improving the content of VHI contracts for the population in general. In 
January 2013, the multiyear plan to fight poverty and support social inclusion 
comprised initiatives to expand access to free or subsidized complementary 
health insurance (CMU-C and ACS) and to ensure better coverage of certain 
items (such as vision care and hearing aids) under CMU-C (see section 6.1.2). 
The ceilings for CMU-C and ACS were increased in July 2013, expanding 
access to as many as 500 000 and 850 000 new beneficiaries, respectively 
(CMU, 2013). However, these figures assume a higher rate of participation in 
the programmes than is currently the case (80% for CMU-C and 40% for ACS). 
Indeed, the take up of ACS has fallen over the period 2010–2012 (CMU, 2013; 
IGAS, 2014b). In order to further reduce the financial burden of purchasing VHI 
contracts, ACS beneficiaries may also be eligible for supplementary financial 
assistance (aides supplémentaires à ACS) from the SHI funds. The number of 
beneficiaries of this type of assistance increased by 61% from 2011 to 2012.
In 2012, a €30 flat charge to access AME, the programme covering certain 
undocumented residents (see section 3.3.1), was eliminated. However, a very 
strong increase in expenditure for this programme in 2013 has led the Minister 
in charge of Health to reconsider financial incentives to hospitals providing 
care to AME beneficiaries and to evaluate the practices of regional SHI funds 
in granting or refusing AME coverage. The Paris region accounts for 70% of 
care financed through the AME. The policy challenge will be on how to remove 
financial barriers that prevent people from accessing care while also guarding 
against fraud.
Additional measures to ensure financial access for patients with low incomes 
are targeted at health care providers, who are prohibited from engaging in 
extra-billing for individuals covered by CMU-C and ACS. Beneficiaries of 
CMU-C and AME are also entitled to third-party payment and so do not need 
to advance the funds for their treatment and then seek reimbursement. Third-
party payment will be extended to ACS beneficiaries starting in 2015, and the 
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Minister in charge of Health plans to generalize third-party payment for the 
entire population by 2017 (Ministry in charge of Health, 2013) (see section 6.1.2). 
However, self-employed physicians strong oppose this measure.
Officially authorized extra-billing (billing in excess of official tariffs) 
for doctors practising in Sector 2 is another challenge to equity in financing, 
especially when it comes to financing care provided by self-employed specialist 
physicians. However, the government has developed measures to restrain 
excessive extra-billing (exceeding 150% of the SHI tariff), and the average 
rate of extra-billing by doctors practising in Sector 2 decreased from 56.9% in 
2011 to 56.3% in 2013, marking the end of nearly uninterrupted increases in 
extra-billing since the late 1970s (see section 6.1.2).
7.3 User experience and equity of access to health care
7.3.1 User experience
The French population has a relatively high level of satisfaction with the 
provision of health care, with 88% rating the overall quality of the health care 
system as good or very good, compared with 71% of the EU28 (European 
Commission, 2014).
Freedom of choice of health care provider is a traditional feature in France. 
Despite disincentives for patients to directly access secondary care without prior 
approval from their “preferred doctor” (see section 3.3.1), freedom of choice of 
doctors has not effectively been restricted, as patients are still able to choose 
the doctors they want to visit (whether referred or not) and they can very easily 
switch preferred doctors by completing a form with the doctor of their choice.
The number of physicians in France also gives patients greater options in 
their choice of provider. While not particularly high compared with some other 
European countries (about 330 physicians per 100 000 population in 2011), 
physician density is just over the OECD average (320) and higher than in several 
other developed countries, including the United Kingdom (280), the United 
States (250) and Canada (240). Despite the fact that this covers a relatively 
unequal picture within the countries, the relatively high numbers of physicians, 
in particular in urban areas, plus a high level of choice, have resulted in good 
access to health care in terms of availability of services.
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In terms of patient participation in health system governance, there have 
been mixed results for the initiatives already in place. Major improvements 
have been made since the 2002 Act on Patients’ Rights and Quality of Care 
(see section 2.9), which introduced the concept of health democracy. First, 
representation of health system users was implemented in hospitals by creating 
a commission of user relations and quality of care to ensure respect for patient 
rights and provide advice on patient admissions and treatment. After 2009, it 
was expanded to the health and social care sector and provided for participation 
by patients and their representatives in the CRSAs (see section 2.9.5) that are 
used to define health priorities at the regional level. However, this is still 
considered to be insufficient (Compagnon & Ghadi, 2014), and the National 
Strategy for Health has emphasized the need to involved and accommodate 
patients and their representatives within the organization, functioning and 
evolution of the health system, which has been included as part of the planned 
2015 Health Reform Law forecasted for the end of 2015 (see section 6.2).
Waiting times are not a significant issue in the French health care system. 
Indeed, patients in France are three times less likely to report forgoing care 
because of long waits than the EU27 average (Eurostat, 2012). However, waiting 
times for some diagnostic procedures, particularly MRI, have raised questions 
about the availability and geographic distribution of high-technology medical 
equipment and also for some specialists, such as ophthalmologists.
7.3.2 Equity of access to health care
High levels of accessibility and choice combined with low OOP expenditure 
have resulted in overall high system utilization. SHI benefits are the same 
across the population, although the level of coverage varies under certain 
circumstances (e.g. 100% coverage for chronic diseases under the ALD 
programme; see section 3.3.1). However, VHI has become an integral part of 
the financing system, and the benefits covered under VHI contracts may vary 
significantly, with group contracts generally providing better coverage than 
individual contracts (see section 3.5.2).
As a result, despite universal coverage and relatively low OOP payments, 
inequities are seen in health care utilization. For the same level of need, 
individuals with high incomes are more likely to have specialist visits than 
those with lower incomes. This disparity is particularly true for specialist visits. 
A study of income-related inequities in utilization in OECD countries found that 
France and Spain were the most inequitable in the needs-adjusted probability 
and frequency of specialist visits (Devaux & de Looper, 2012).
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In addition to the differences in utilization levels by income, population 
surveys report financial constraints as a barrier to seeking care. Nearly 26% 
of the population declared that they had forgone at least one health treatment 
for financial reasons (Célant, Guillaume & Rochereau, 2014). While France 
falls below the EU27 average for unmet health needs for financial reasons, it 
is just above average for those in the lowest income quartile (Eurostat, 2012). 
The largest income gaps for unmet need are evident with respect to care that 
is poorly reimbursed. For example, individuals in the lowest income quintiles 
are four times more likely to report an unmet need for optical care for financial 
reasons than people in the highest income quintile.
In addition to the financial burden of certain poorly reimbursed care and 
devices, there is also concern that the deductibles for doctors’ visits, ancillary 
care, transportation and drug prescriptions (not covered by VHI) increase 
access problems. However, because deductibles fall most heavily on a 
vulnerable population (sick people), an annual ceiling for deductibles has been 
set at €50 per person per year (see section 3.2).
Additional explanations for unmet care needs may be found on the demand 
and/or the supply side. On the demand side, one could hypothesize that lack 
of familiarity with the system, time costs or level of income inhibits treatment 
seeking. On the supply side, ensuring geographical access has been an ongoing 
concern of French policy-makers. While the average physician density of 
330 doctors per 100,000 inhabitants should provide adequate coverage, their 
distribution across the territory has left some areas underserved. French doctors’ 
freedom of settlement has made efforts to address this issue challenging. 
Financial incentives have been unsuccessful in addressing geographical 
disparities, and current reform efforts have focused on alternatives, including 
new practice models and task transfer (see section 6.1.3). Moreover, the absence 
of physicians who do not practise extra-billing in certain areas is likely to 
play a role. More alarming is the refusal of some physicians to treat patients 
benefiting from CMU-C, ACS or AME coverage; some doctors appear to be 
prejudiced against these patients for whom a third-party payment system applies 
(physicians are directly paid by insurance rather than the patient) and there is 
no possibility of charging over the official tariffs (extra-billing) (Défenseur des 
droits, 2014).
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7.4 Health outcomes, health service outcomes and 
quality of care
7.4.1 Population health
Overall, the health status of the French population is good, as reflected by life 
expectancy and healthy life-years (see Fig. 1.2). Infant and maternal mortality 
rates have decreased significantly since the late 1970s, as has the adolescent 
birth rate (see Table 1.7). However, mortality from all cancers and from diabetes 
has increased over the same period (see Table 1.4). There are marked health 
disparities between men and women and between regions. Moreover, social 
inequalities in health status persist (see Table 1.6). These differences reflect 
the combined effect of differences in health risk behaviours, level of exposure 
to environmental risks and work conditions.
Morbidity
Major improvements in morbidity linked to cardiovascular diseases have been 
seen in recent years (see Table 1.5). Nonetheless, the growing incidence of 
diabetes remains a major concern.
Several risk factors contribute to the burden of noncommunicable diseases 
in France. The number of adults who are overweight or obese has grown 
significantly since the 1990s. A 2009 survey found that 13.9% of men and 
15.1% of women were obese (DREES, 2011a). Excessive alcohol consumption 
underlies a large share of morbidity, including cancers, chronic liver disease, 
psychiatric problems and consequences from accidents. However, alcohol and 
tobacco consumption per inhabitant has decreased since 2000, the latter due 
in part to the emergence of electronic cigarettes. Nonetheless, France still has 
one of the highest alcohol consumption rates in the EU.
Infectious diseases are responsible for a large share of morbidity. While 
most often banal, especially in children, infectious diseases pose greater risks 
for those already in fragile health, including the elderly and those with chronic 
illnesses. Public health surveillance is concerned not only with the level of 
vaccination coverage but also monitors four infectious diseases: legionellosis, 
tuberculosis, AIDS and sexually transmitted infections. The growth in 
antibiotic-resistant strains of bacteria is also a major public health concern.
Mortality
Within Europe, France’s overall mortality rate is among the lowest. Since 
2004, cancer is overall the primary cause of mortality in France, followed by 
heart disease and violent deaths (accidents, suicide and other external causes) 
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(see Table 1.4). However, gender differences are apparent, with cancer being 
the leading cause for men and heart disease the leading cause for women. 
Excess mortality for both heart disease and cancer is found in men linked to 
alcohol and tobacco use as well as to environmental exposures in the workplace. 
Nonetheless, between 2000 and 2010, an increase in certain cancers in women 
is linked to increases over the same period in smoking behaviour (larynx, 
trachea, bronchial and lung) and alcohol consumption (pancreas, liver and 
bladder). Excess mortality among men remains high with respect to traffic 
accidents (3.9 times higher than in women) and suicides (3.1 times higher). The 
suicide rate in France is among the highest in Europe for both men and women.
A 2003 study of mortality amenable to health care found that France ranked 
favourably compared with other European countries on all classifications: 
excluding ischaemic cardiopathies, only Sweden and Norway had lower rates 
of avoidable mortality; when 50% of ischaemic cardiopathies were included, 
France had the lowest rate of avoidable mortality. For life expectancy adjusted 
for incapacity, France ranked first among the 14 countries studied (HCSP, 2013). 
The periodic report on the health state of the French population (L’état de santé 
de la population en France), which reports on the indicators identified in the 
2004 Public Health Act, did not include mortality amenable to health care 
among its indicators because of definitional problems (DREES, 2011a).
The five-year survival rates for breast cancer and colorectal cancer have 
improved since the 1990s. For breast cancer, five-year survival for patients 
diagnosed in 2001–2004 was 89%, compared with 81% for those diagnosed 
in 1989–1991. This trend is seen in most western countries, ref lecting 
improvements in therapeutic treatments since the early 2000s as well as early 
diagnosis from screening. Five-year survival for colorectal cancer increased 
from 53% to 58% for patients diagnoses in the same period. For cervical cancer, 
the five-year survival rate is 65%, reflecting a slight decrease over time that 
paradoxically may be linked to screening, which permits early detection of 
invasive lesions that have a poorer prognosis (Grosclaude et al., 2013).
One-third of deaths before age 65 were for causes considered avoidable 
through risk reduction (tobacco, alcohol, dangerous driving and suicide). 
Between 2000 and 2008, the greatest reductions in avoidable mortality were 
seen for traffic accidents, AIDS and alcohol-related deaths (DREES, 2011a). 
In 2013, mortality from traffic accidents reached its lowest level since 1948 
and was 10.5% lower than in 2012 (Ministry of the Interior, 2014). Policies 
imposing lower speed limits and lower thresholds for blood alcohol of drivers 
have unquestionably been key factors.
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7.4.2 Health service outcomes and quality of care
There have been many recent initiatives to improve health care quality and 
its measurement in France. Over the past decade, a French project team has 
collaborated to develop and validate a series of patient safety indicators. Since 
2008, the HAS has undertaken national campaigns to collect data on quality 
and security indicators for hospitals, which are now required not only to collect 
the data but also publish it (see Scope Santé, section 2.9.1). The National 
Programme for Patient Security 2013–2014 (Programme national pour la 
sécurité des patients) is a key element in the 2012 National Strategy for Health.
Preventive care
The development of prevention policies within a system built upon a curative 
focus has been fairly recent, starting in 2002 and increasing in emphasis after 
2010 when a framework for actions to support prevention, health promotion 
and therapeutic education was designed. It is currently the major aim of the 
National Strategy for Health and the planned 2015 Health Reform Law (see 
section 6.2). A wide range of actors is involved in prevention policy at the 
national level, which has complicated coordination and led to interministerial 
governance of this issue.
Immunization services are well organized in France (see section 5.1.3), and 
child vaccination rates are high: at age 2, 98% of children were vaccinated 
for diphtheria, tetanus, polio and pertussis (DTPCoq in French) in 2010 and 
90% for measles in 2011 (Fontenau, Guthmann & Lévy-Bruhl, 2013). Influenza 
vaccinations for individuals age 65 and older are covered 100% by SHI. During 
the 2010–2011 influenza season, the vaccination rate for persons of this age 
group suffering from chronic illnesses (most frequently cardiac disease and 
diabetes) was 71%, while it fell to 57.8% among those who were not chronically 
ill (Guthmann, Fonteneau & Lévy-Bruhl, 2012).
Care for patients with chronic conditions
The French health care system is oriented to curative care as opposed to 
managing long-term chronic diseases, which are complex and require the 
involvement and coordination of various professionals belonging to the hospital, 
ambulatory and health and social care sectors. Given that the number of people 
with chronic conditions has increased alongside longer life expectancy and 
medical progress, increasing attention has been paid to improving coordination 
of care and developing care models that are better equipped to meet the needs 
and improve the quality of life of the chronically ill population. Some of these 
initiatives come from the SHI, which has developed disease management 
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programmes: first, one focusing on patients with diabetes and, since late 2014, 
one focusing on patients with asthma. Moreover, indicators of good follow-up 
of chronic diseases have been introduced in ROSP (see section 3.7.2).
The HAS has also developed guidance for pathways for patients with 
the following chronic conditions: chronic obstructive pulmonary disease, 
Parkinson’s disease, chronic kidney disease, congestive heart failure, 
bronchopulmonary cancer and malignant pleural mesothelioma, Hodgkin’s 
lymphoma (adult), type 2 diabetes (adult) and atrial fibrillation. These guides 
aim to help physicians better deal with acute episodes and to retard the 
progression of the disease to the extent possible by improving care practice 
and coordination as well as by fostering patient involvement and participation 
in care, particularly through therapeutic patient education. Moreover, tools for 
patients and health professionals are provided.
However, one of the limitations of such programmes is that while doctors 
have a high level of awareness of practice guidelines published by HAS, the 
recommendations may not be assimilated because they are too long and 
sometimes confusing. For example, a 2013 report of the National Academy of 
Medicine (Académie nationale de médecine) identified a number of areas of 
overprovision of care, including excessive biological testing and high-technology 
imaging and overprescription of drugs (Mornex, 2013). For cancer screening, 
a large number of mammographies are undertaken over age 75, despite the 
recommended age cut-off, resulting in overdiagnosis of small lesions of limited 
medical interest that do not change the life expectancy of the patient and may 
expose her to needless anxiety, additional testing and even surgery.
Moreover, the management of acute episodes and disease-related 
complications is a key element in ensuring high quality care for patients with 
chronic conditions and avoiding unnecessary hospitalizations. For avoidable 
hospital admissions for adults with asthma and chronic obstructive pulmonary 
disease, France has much lower rates than the OECD26 averages (OECD, 2013). 
Nonetheless, regional variations in the rate of hospitalizations for exacerbations 
of chronic obstructive pulmonary disease, ranging from 0.1 to 2.0 per 1000 in 
2010, have led the Ministry in charge of Health and the largest SHI fund to 
request a study by the HAS regarding the appropriateness of hospitalizations 
during such acute episodes (HAS, 2012). Better data are needed for certain 
conditions. For example, avoidable hospital admission rates are not available 
for diabetes because it is not necessarily included as secondary diagnosis in the 
PMSI database, which also does not include the patient’s ALD status.
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Improvements have been observed in in-hospital mortality rates (deaths 
within 30 days of admission) following acute myocardial infarction and 
ischaemic stroke. Between 1995 and 2010, 30-day mortality for all patients 
with acute myocardial infarction fell from 12.9% to 3.9% (Hanssen et al., 2012), 
while for ischaemic stroke in adults aged 45 and over the 30-day mortality 
deaths fell from 10.6% to 8.5% between 2005 and 2010 (OECD, 2013).
Finally, the Eurobarometer survey showed a major increase in the proportion 
of adverse events reported (+61 percentage points) (European Commission, 
2014). This may reflect better awareness by patients of the recourse available 
to them. A 2009 national survey of serious adverse events (événements 
indésirables graves) in hospitals found a frequency of 6.2 per 1000 days of 
hospitalization (9.2 in surgery and 4.7 in medicine), with more than 40% 
classified as avoidable (Table 7.1) (DREES, 2011c). Since January 2010, the 
surgical checklist has become part of the hospital certification process.
Table 7.1 
Number of adverse patient safety events identified in 2007
Adverse events ENCC ENCC PMSI PMSI
Number of 
hospital stays
Number of 
hospital stays
Population  
at risk
Prevalence rate  
(%)
PSI 5: foreign body left during 
procedure
75 173 7 639 056 0.08
PSI 7: infections caused by IV lines 
or catheters
915 4 274 6 248 132 0.68
PSI 12: postoperative pulmonary 
embolism
3 003 18 968 2 829 610 6.70
PSI 13: postoperative sepsis 1 852 8 368 1 190 606 7.03
PSI 15: laceration or accidental puncture 1 149 6 887 7 725 975 0.89
PSI 18/19: obstetric trauma for 
vaginal delivery
415 2 933 640 967 4.58
Total 15 107 98 288 – –
Source: Nestrigue & Or, 2011.
Note: ENCC: National hospital cost scale for the acute care sector. 
7.4.3 Equity of outcomes
While France has achieved a good level of equality in access, particularly 
with respect to primary care, there is concern that the universal coverage 
policies introduced in the 1990s have not reduced other persisting areas of 
inequality. For example, the seven-year gap in life expectancy at age 35 between 
working class men and managers persists (Danet, 2012). Individuals in the 
lowest income quintile are three times more likely to report very poor health 
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than those in the highest income quintile (Célant, Guillaume & Rochereau, 
2014). In terms of mortality, regional (see Fig. 1.3) and gender (see Table 1.3) 
differences are apparent. Indeed, adult male mortality is more than double adult 
female mortality.
An integrated and comprehensive policy has been argued to be the 
appropriate response for addressing interdependent health determinants. 
However, previous attempts to establish a broad intersectoral approach to health 
policy have faltered (see section 2.6). The Ministry in charge of Health’s 2012 
National Strategy for Health emphasized the need to prioritize addressing the 
determinants of poor health (Ministry in charge of Health, 2013) and established 
a new interministerial health committee for addressing health inequalities.
7.5 Health system efficiency
If the French population is willing to keep the SHI system public, the share of the 
population that is ready to spend more of their income on health has decreased, 
falling from 70% in 2010 to 55% in 2013. Indeed, improving the efficiency 
of the health care system to ensure the financial viability of the system is 
important in order to avoid the growth of the deficit and its related burden on 
future generations, or alternatives such increasing statutory contributions or 
reducing the services provided, which would adversely affect both the economy 
and access to care (HCAAM, 2013c).
7.5.1 Allocative efficiency
In France, there is no formal mechanism of resource allocation for the overall 
health care system and across sectors of care as there is in the United Kingdom. 
The main resource allocation mechanism in place is the ONDAM, which sets 
the overall level of SHI expenditure and its distribution across six subsectors 
of care (ambulatory care, health care in hospitals paid on DRG basis, health 
care in other hospitals, health and social care for the elderly, health and social 
care for disabled people, and other types of care; see section 3.3.3). However, 
the ONDAM subsector targets are not necessarily based solely on population. 
Fig. 7.2 shows the ONDAM annual growth rate approved by the parliament 
and the size of the overrun or underspending for the period 1997–2012. The 
establishment of an Alert Committee in 2004 (see section 3.3.3) has insured 
greater credibility of this system and, since 2010, the overall ONDAM targets 
have been underspent, suggesting that the implemented SHI cost-containment 
measures have been successful.
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Fig. 7.2 
Annual growth rate in ONDAM and size of overrun or underspending of targets 
Source: DREES, 2013a (provisional results for 2011 and 2012).
Note: The size of the bubbles shows the relative size of the overrun (white bubbles) or underspending (black bubbles) compared with 
the established targets.
Coordination of planning and financing in different sectors of care and 
public health policies
There is a need for improved efficiency in resource allocation in France, in 
particular in the coordination of public health policies and the planning of health 
services and professionals. This is evidenced, for example, by OECD health 
indicators, which point to the poor results of the French system with regards 
to avoidable mortality in males (see Fig. 1.2). Improvements in coordination 
between the different sectors have gradually been attained through initiatives 
led by the state at the general policy level and also by the Ministry in charge 
of Health in the field of health and social services (see sections 2.4 and 2.8.2).
Budget forecasting by programmes integrated across ministries at the 
national level
There has been a move towards broader integration of health care and public 
health policies through two organic laws (a type of law that supplements 
constitutional provisions for purposes of implementation) that dramatically 
changed the paths of resource allocation for both the State Finance Act (in 2003) 
and the Social Security Finance Act (in 2005). These laws required budgets to 
follow policy objectives cutting across traditional administrative boundaries. 
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Solidarity and integration and response to health threats, for example, became 
state objectives with dedicated budgets across ministries and administrations. 
Cross-cutting missions are solidarity and integration, health, health safety and 
social benefits and pensions.
Within the social security budget, baseline figures and trends are used to 
define the specific objectives of the Social Security Finance Act, not only for 
SHI programmes but also for other programmes of the social security branches 
(such as workplace safety and environmental safety). These programmes 
for quality and efficiency (programmes qualité efficience) establish precise 
objectives (targets) and indicators. For SHI, the focus is on five key areas: equal 
access to care, prevention, improved quality of care, efficiency in the provision 
of care, and financial sustainability of the system (Sécurité sociale, 2014). These 
targets and indicators represent an endeavour to improve the fairness and 
efficiency of the system and financial sustainability while avoiding negative 
effects on health gains and health equity. A budget is set for each programme 
followed by a report on spending and achievement of targets based on the 
established indicators. The 2014 report on the SHI programmes for quality and 
efficiency emphasized the need to strengthen efficiency in order to control the 
expenses associated with a high level of access to care (Sécurité sociale, 2014).
The annual State Finance Act also establishes policy objectives across 
administrative boundaries. Annual performance reports (rapports annuels de 
performances) by programme area measure the actual versus expected results 
in meeting the objectives based on indicators and the associated costs (Mission 
Ministérielle Santé, 2013). For general government expenditure on health, there 
are programmes focusing on the two main areas financed by the state: one for 
prevention, health security and health resources and the other for the public 
mechanisms to ensure access to free care for the poorest residents (CMU-C 
and AME). For 2013, the government found mixed results in meeting its 
objectives, particularly with respect to the AME programme, which exceeded 
the projected budget.
The organic laws instituted a major shift from a spending model to 
an investment model. SHI had historically been labelled a “blind payer”, 
reimbursing providers without assessing the effectiveness of interventions. 
The laws impose an obligation to make prospective decisions on the important 
issues in population health and to allocate resources accordingly.
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Coordination of planning and financing of the different sectors of care 
and public health policies at the regional level
Since the 2000s, emphasis has been on the lack of coordination in the French 
health care system and the anticipated financial (and health) gains from 
improved information, development of joint care protocols and regional 
planning based on the public needs of the local populations. Efficiency gains 
were expected from the merger at the regional level of all institutions involved 
in the planning and financing of health services and public health policies in 
a one-stop shop: the ARS (see section 2.4). Improvement in capacity planning 
and allocation of health care resources were expected to result from the PSRS 
that would lead to a needs-based approach for planning the hospital, ambulatory 
and health and social care sectors (see section 4.2). However, the PSRSs have 
not demonstrated the anticipated results and they will be reformulated in the 
health care reform (see section 6.2).
Each ARS enters into a four-year contract for targets and resources with the 
Ministry in charge of Health, the SHI and the CNSA that establishes objectives 
and resources, which are approved and evaluated by the CNP. The ARSs are 
financed by general government funding (77%), SHI contributions (18%) and 
the CNSA (4%), and the CNP also oversees the distribution of financing among 
the ARSs based on a risk-adjusted allocation formula that accounts for the need 
to reduce health inequalities among the regions. Nonetheless, the real financial 
challenge with respect to the ARSs lies not in their operating budgets but in 
their ability to increase the overall efficiency of the health system to control 
health costs. However, none of the indicators included in the contract for targets 
and resources specifically measures the impact of the ARSs on SHI expenditure 
(Cour des comptes, 2012a).
7.5.2 Technical efficiency
According to the most recent projections of HCAAM, health expenditure will 
outpace growth of the economy until the middle of this century. If no corrective 
measures are taken, the SHI deficit will reach €14 billion in 2020, nearly double 
the €7.7 billion deficit recorded in 2013, and will reach €41 billion by 2040. The 
major drivers of the growth in health spending are the ageing of the population, 
the increased prevalence of chronic diseases, the cost of new technologies and 
the manner in which the health care system is organized. In light of these 
trends, HCAAM has underscored the urgent need to improve the efficiency of 
the system (HCAAM, 2013c).
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The foremost target for efficiency efforts has been the hospital sector. The 
French health care system has long had a hospital-centric, curative orientation. 
The number of full-time beds in France is among the highest in Europe by 
population (see Fig. 4.1a), while the occupation rate is only 67%. Therefore, the 
challenge is to reduce hospital capacity while maintaining a network of hospitals 
that responds to regional needs for emergency services and overall access to 
care. However, the activity-based financing model (T2A; see section 3.7.2) may 
undermine efforts to improve efficiency because tariffs are established based 
on demand that already has been identified as suboptimal.
While average length of stay has steadily fallen since the mid-1990s (see 
Fig. 4.1b), the rate of ambulatory hospitalizations remains far below that of 
neighbouring countries. The estimated savings from a shift to ambulatory 
surgery could amount to €5 billion or 7% of the ONDAM target for hospital 
expenditure. Other efficiency measures include combining certain resources 
across hospitals and redeploying personnel based on actual rather than 
maximum capacity (IGAS, 2012b).
Reducing inefficiency in the hospital sector also involves better organization 
of primary care. For example, fewer patients should be sent directly to emergency 
care as part of the broader effort to avoid unnecessary hospitalizations, but 
this requires ready access to GPs and after-hours care. Multidisciplinary care 
models are seen as one answer to meeting these needs, although expansion has 
been hampered by lack of agreement regarding remuneration and task transfer. 
Moreover, in order to facilitate better coordination across sectors to improve 
both efficiency and quality of care, information technology systems must be 
interoperable and used on a widespread basis. However, this objective remains 
far from being met, particularly with respect to information technology systems 
in doctors’ private offices (see section 4.1.4).
Increasing the market share of generics among prescribed drugs is a key 
efficiency goal. However, the list of substitutable drugs in France is relatively 
limited compared with other European countries (see section 6.1.2). In addition, 
consumer reluctance to embrace generics, compounded by doctors who indicate 
on the prescription that the drug may not be substituted, has further limited 
growth. Incentives aimed at both doctors and pharmacists have been used to 
spur growth of the generic market. For example, the prescription of generic 
statins has generally increased as new generic forms have entered the market. 
However, between 2006 and 2011, a downward trend emerged. Since 2012, 
prescription of generic statins has been among the efficiency indicators for the 
ROSP, and resulted in a 6.9 percentage point increase by March 2013.
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7.6 Transparency and accountability
The transparency of the health system was called into question in the wake of 
the Mediator scandal and resulted in major changes to the regulatory agency 
for health products (now ANSM), including disclosure of direct and indirect 
interests by health professionals providing expert advice within the decision-
making process (see section 6.1.1). Since 2014, a searchable public database 
(www.transparence.sante.gouv.fr) identifies health professionals’ relationships 
with companies marketing drugs and other health products.
Nonetheless, accountability has improved in recent years through monitoring 
of spending and public health objectives under the Social Security Financing 
Laws, as well as through the development of information systems.
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8. Conclusions
In France, the overall health status of the population is good as well as the degree of financial protection provided by the health system. Women live longer and older people remain in better health than in many European 
countries. Patients in France are three times less likely to report forgoing 
care because of long waits than the EU average. Public financing of health 
care expenditure is among the highest in Europe and OOP spending one of 
the lowest.
Nonetheless, major problems include social and geographical inequalities 
in health status and access to care; a relative underdevelopment of preventive 
care compared with acute care; and a lack of coordination between the hospital 
sector, the ambulatory care sectors and the health and social care sectors, in 
particular in caring for patients with chronic diseases but also in developing 
preventive care and intersectoral policies.
Social inequalities remain in terms of health status and access to care. 
Life expectancy at age 35 is seven years lower for working class men and 
three years lower for working class women compared with managers. These 
social health inequalities result not only from risk factors such as alcohol and 
tobacco consumption but also from differences in access to health care, which 
have increased over time. Indeed income-related inequalities in health care 
utilization remain despite universal coverage and relatively low OOP payments. 
This inequity in access is predominant in goods and services for which patients’ 
OOP expenditure is the highest, such as dental care and consultations with 
specialists engaging in extra-billing. Geographical disparities in the density of 
health professionals also affect access to care in some areas of France. While 
the average physician density should provide adequate nationwide coverage, 
certain areas are underserved.
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The significant burden of chronic diseases exacerbated by an ageing 
population and the increasing level of obesity have underscored the need for 
ongoing monitoring and treatment as well as preventive strategies to reduce the 
incidence and burden of chronic diseases such as diabetes. However, the focus 
of the health system has been on acute care rather than long-term chronic care 
and prevention.
In light of these issues, the health care system in France has undergone a 
series of reforms since 2010 to increase equity in access to care for socially 
disadvantaged individuals, those living in underserved geographic areas and 
the most vulnerable populations.
Recent reforms have focused on addressing access barriers to health care 
and improving chronic and long-term care to better meet population needs. 
The level of equity in access has improved for individuals with the lowest 
revenues thanks to expanded eligibility for CMU-C and financial assistance 
to purchase ACS. Third-party payment for beneficiaries of these programmes 
has further reduced the financial barriers to accessing care, although extension 
of third-party payment to all SHI beneficiaries has drawn strong opposition 
by physicians. In addition, the quality of VHI contracts has been an ongoing 
concern, given the importance of VHI in financing health care. A new mandate 
will require all employers to offer and partially finance group VHI contracts 
for employees from 2016.
The so-called medical deserts have been a priority on the political agenda 
for over two decades. However, because French physicians have freedom of 
settlement, it is challenging to address this issue. Coercive measures were 
considered but abandoned because of the significant political power of doctors, 
and financial incentives have been generally unsuccessful. Government reform 
efforts have shifted to multidisciplinary practice models, task transfer and the 
use of information technologies such as tele-health as means of compensating 
for lower physician density, particularly in rural areas. Moreover, promising 
initiatives focusing on improving the workplace quality of life of doctors have 
flourished at the local level.
Measures to improve chronic and preventive care have been implemented, 
and early results show some practice improvements. Physicians have embraced 
P4P, despite initial resistance from their unions, and better monitoring of 
patients with chronic diseases such as diabetes has been documented. However, 
objectives related to prevention, including vaccination and cancer screening, 
have shown mixed results. Financial incentives to improve care coordination by 
GPs are also being tested as part of regional pilot projects designed to improve 
care for frail elderly individuals.
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Indeed, the long-term care reform has been repeatedly delayed by intense 
political and institutional resistance to certain provisions because of the 
financial impact of measures to address financing of care in nursing homes. 
Indeed, while the increasing demand for long-term care remains a major 
concern in the government’s plan, the current government has broadened the 
scope of the policy focus to include identification of risk factors to delay the 
loss of autonomy, to address the ways in which society must adapt to meet 
the needs of an ageing population and to improve support to those who have 
become dependent. However, measures to reduce the financial and care burdens 
on families through public coverage of long-term care for the elderly in order 
to achieve greater equity in access have not been voted upon, despite the fact 
that these issues constitute some of the most pressing challenges to the system.
The future challenges facing the French health care system are underscored 
by the measures planned for the 2015 Health Reform Law: on the one hand, 
improvements in the organization of care to meet the needs of an ageing, 
increasingly chronically ill population while combating inequalities through 
improved efficiency and equity in financing and geographic access; and on the 
other hand, the reform of long-term care to preserve the autonomy of elderly 
individuals and facilitate ageing at home while reducing the financial and care 
burdens on families.
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9.2 Key legal acts
Act on Patients’ Rights and Quality of Care 2002 (Loi n° 2002–303 du 4 mars 
2002 relative aux droits des malades et à la qualité du système de santé): http://
www.legifrance.gouv.fr/affichTexte.do;jsessionid=374371674CC1D73032C707
6155B256C9.tpdjo09v_1?cidTexte=JORFTEXT000000227015&categorieLien
=id 
Employment Protection Law 2013 (Loi n° 2013–504 du 14 juin 2013 relative à 
la sécurisation de l’emploi): http://www.legifrance.gouv.fr/affichTexte.do?cidT
exte=JORFTEXT000027546648&categorieLien=id
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Health Insurance Act 2004 (Loi n° 2004–810 du 13 août 2004 relative à 
l’assurance maladie): http://www.legifrance.gouv.fr/affichTexte.do;jsessionid
=374371674CC1D73032C7076155B256C9.tpdjo09v_1?cidTexte=JORFTEXT0
00000625158&categorieLien=id 
Health Security Act 2011 (Loi n° 2011–2012 du 29 décembre 2011 relative au 
renforcement de la sécurité sanitaire du médicament et des produits de santé): 
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT00002505
3440&categorieLien=id 
Hospital, Patients, Health and Territories Act (HPST Act) 2009 (Loi n° 2009–879 
du 21 juillet 2009 portant réforme de l’hôpital et relative aux patients, à la 
santé et aux territoires): http://legifrance.gouv.fr/affichTexte.do?cidTexte=JOR
FTEXT000020879475&categorieLien=id 
Public Health Act 2004 (Loi n° 2004–806 du 9 août 2004 relative à la politique 
de santé publique): http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JOR
FTEXT000000787078&dateTexte=&categorieLien=id 
Social Security Finance Act 1999 (Loi n° 98–1194 du 23 décembre 1998 de 
financement de la sécurité sociale pour 1999): http://www.assemblee-nationale.
fr/11/budget/plfss1999/sommaire.asp
Social Security Finance Act, annual (Loi de financement de la sécurité sociale): 
http://www.securite-sociale.fr/LFSS-2015 
Universal Health Coverage Act 1999 (Loi n° 99–641 du 27 juillet 1999 portant 
création d’une couverture maladie universelle): http://www.legifrance.gouv.fr/
affichTexte.do;jsessionid=A3CCAE8203E5533B32065650ABF8F31E.tpdjo09v
_1?cidTexte=JORFTEXT000000198392&categorieLien=id
9.3 Useful web sites
Agency for Information on Hospital Care (Agence technique de 
l’information hospitaliere) 
http://www.atih.sante.fr/ 
French Agency for Food, Environmental and Occupational Health 
Safety (Agence nationale de sécurité sanitaire de l’alimentation, de 
l’environnement et du travail; ANSES) 
https://www.anses.fr/en 
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French Biomedicine Agency (Agence de la biomédecine) 
http://www.agence-biomedecine.fr/About-us 
French Blood Agency (Etablissement français du sang)  
http://www.dondusang.net/rewrite/site/39/french-blood-service.
htm?idRubrique=1092
French Chamber of Midwives (Conseil National de l’Ordre des sages-
femmes) 
http://www.ordre-sages-femmes.fr/NET/en/document//bkp/about_us/index.
htm
French Health Products Safety Agency (Agence nationale de sécurité du 
médicament et des produits de santé; ANSM) 
http://ansm.sante.fr/Mediatheque/Publications/Information-in-English 
French Institute for Public Health Surveillance (Institut national de 
veille sanitaire) 
http://www.invs.sante.fr/en 
French Medical Council (Conseil national de l’Ordre des médecins; 
CNOM)  
http://www.conseil-national.medecin.fr/ 
http://www.conseil-national.medecin.fr/node/1357
French Order of Dental Surgeons (Ordre national des chirurgiens 
dentistes) 
http://www.ordre-chirurgiens-dentistes.fr/ 
French Order of Nurses (Ordre national des infirmiers) 
http://www.ordre-infirmiers.fr/ 
Health Emergency Preparedness and Response Agency (L’Établissement 
de préparation et de réponse aux urgences sanitaires; EPRUS) 
http://www.eprus.fr/ 
High Council for the Future of Health Insurance (Haut conseil pour 
l’avenir de l’assurance maladie; HCAAM) 
http://www.securite-sociale.fr/L-actualite-du-HCAAM 
High Council for Public Health (Haut conseil de la santé publique; 
HCSP)  
http://www.hcsp.fr/Explore.cgi/Accueil 
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Institute for Research and Information in Health Economics  
(Institut de recherche et information en économie de la santé) 
http://www.irdes.fr/english/home.html
Ministry in charge of Health 
http://www.sante.gouv.fr/
National Agency for the Quality Assessment of Health and Social Care 
Organizations and Services (Agence nationale de l’evaluation de la 
qualite des établissements et services sociaux et medico-sociaux) 
http://www.anesm.sante.gouv.fr/ 
National Agency to Support the Performance of Health and Health 
and Social Care (Agence nationale d’appui à la performance des 
établissements de santé et médico-sociaux; ANAP) 
http://www.anap.fr/accueil/ 
National Chamber of Pharmacists (Ordre national des pharmaciens)  
http://www.ordre-pharmacien.com/
National Health Authority (Haute Autorité de Santé; HAS) 
http://www.has-sante.fr/portail/jcms/r_1455134/fr/about-has 
National Health Conference (Conference nationale de santé)  
http://www.sante.gouv.fr/notre-composition.html 
National health strategy (Strategie nationale de santé)  
http://www.sante.gouv.fr/planification-nationale-et-regionale-en-sante.html 
National Institute for Cancer (Institut National du Cancer) 
http://www.e-cancer.fr/en 
National Institute for Prevention and Health Education (Institut national 
de prévention et d’éducation pour la santé; INPES) 
http://www.inpes.sante.fr/ 
Radioprotection and Nuclear Safety Institute (Institut de 
Radioprotection et de Sécurité Nucleaire; IRSN) 
http://www.irsn.fr/EN/Pages/home.aspx 
Social health insurance 
http://www.ameli.fr/#
Social security (La sécurité sociale)  
http://www.securite-sociale.fr/Information?type=part 
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9.4 HiT methodology and production process
HiTs are produced by country experts in collaboration with the Observatory’s 
research directors and staff. They are based on a template that, revised 
periodically, provides detailed guidelines and specific questions, definitions, 
suggestions for data sources and examples needed to compile reviews. While 
the template offers a comprehensive set of questions, it is intended to be used in 
a flexible way to allow authors and editors to adapt it to their particular national 
context. The most recent template is available online at: http://www.euro.who.
int/en/home/projects/observatory/publications/health-system-profiles-hits/
hit-template-2010.
Authors draw on multiple data sources for the compilation of HiTs, ranging 
from national statistics, national and regional policy documents to published 
literature. Furthermore, international data sources may be incorporated, such as 
those of the OECD and the World Bank. The OECD Health Data contain over 
1200 indicators for the 34 OECD countries. Data are drawn from information 
collected by national statistical bureaux and health ministries. The World Bank 
provides World Development Indicators, which also rely on official sources.
In addition to the information and data provided by the country experts, 
the Observatory supplies quantitative data in the form of a set of standard 
comparative figures for each country, drawing on the European Health for All 
database. The Health for All database contains more than 600 indicators defined 
by the WHO Regional Office for Europe for the purpose of monitoring Health 
in All policies in Europe. It is updated for distribution twice a year from various 
sources, relying largely upon official figures provided by governments, as well 
as health statistics collected by the technical units of the WHO Regional Office 
for Europe. The standard Health for All data have been officially approved 
by national governments. With its summer 2007 edition, the Health for All 
database started to take account of the enlarged EU of 27 Member States.
HiT authors are encouraged to discuss the data in the text in detail, including 
the standard figures prepared by the Observatory staff, especially if there are 
concerns about discrepancies between the data available from different sources.
A typical HiT consists of nine chapters.
1. Introduction: outlines the broader context of the health system, including 
geography and sociodemography, economic and political context, and 
population health.
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2. Organization and governance: provides an overview of how the health 
system in the country is organized, governed, planned and regulated, as 
well as the historical background of the system; outlines the main actors 
and their decision-making powers; and describes the level of patient 
empowerment in the areas of information, choice, rights, complaints 
procedures, public participation and cross-border health care.
3. Financing: provides information on the level of expenditure and the 
distribution of health spending across different service areas, sources of 
revenue, how resources are pooled and allocated, who is covered, what 
benefits are covered, the extent of user charges and other out-of-pocket 
payments, voluntary health insurance and how providers are paid.
4. Physical and human resources: deals with the planning and distribution of 
capital stock and investments, infrastructure and medical equipment; the 
context in which IT systems operate; and human resource input into the 
health system, including information on workforce trends, professional 
mobility, training and career paths.
5. Provision of services: concentrates on the organization and delivery 
of services and patient flows, addressing public health, primary care, 
secondary and tertiary care, day care, emergency care, pharmaceutical 
care, rehabilitation, long-term care, services for informal carers, palliative 
care, mental health care, dental care, complementary and alternative 
medicine, and health services for specific populations.
6. Principal health reforms: reviews reforms, policies and organizational 
changes; and provides an overview of future developments.
7. Assessment of the health system: provides an assessment based on the 
stated objectives of the health system, financial protection and equity 
in financing; user experience and equity of access to health care; health 
outcomes, health service outcomes and quality of care; health system 
efficiency; and transparency and accountability.
8. Conclusions: identifies key findings, highlights the lessons learned 
from health system changes; and summarizes remaining challenges and 
future prospects.
9. Appendices: includes references, useful web sites and legislation.
The quality of HiTs is of real importance since they inform policy-making 
and meta-analysis. HiTs are the subject of wide consultation throughout the 
writing and editing process, which involves multiple iterations. They are then 
subject to the following.
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•  A rigorous review process (see the following section).
•  There are further efforts to ensure quality while the report is finalized that 
focus on copy-editing and proofreading.
•  HiTs are disseminated (hard copies, electronic publication, translations 
and launches). The editor supports the authors throughout the production 
process and in close consultation with the authors ensures that all stages 
of the process are taken forward as effectively as possible.
One of the authors is also a member of the Observatory staff team and 
they are responsible for supporting the other authors throughout the writing 
and production process. They consult closely with each other to ensure that 
all stages of the process are as effective as possible and that HiTs meet the 
series standard and can support both national decision-making and comparisons 
across countries.
9.5 The review process 
This consists of three stages. Initially the text of the HiT is checked, reviewed 
and approved by the series editors of the European Observatory. It is then 
sent for review to two independent academic experts, and their comments 
and amendments are incorporated into the text, and modifications are made 
accordingly. The text is then submitted to the relevant ministry of health, or 
appropriate authority, and policy-makers within those bodies are restricted to 
checking for factual errors within the HiT.
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The Health Systems in Transition profiles
A series of the European Observatory on Health Systems 
and Policies
The Health Systems in Transition (HiT) country profiles provide an analytical 
description of each health care system and of reform initiatives in progress or 
under development. They aim to provide relevant comparative information to 
support policy-makers and analysts in the development of health systems and 
reforms in the countries of the WHO European Region and beyond. The HiT 
profiles are building blocks that can be used:
•  to learn in detail about different approaches to the financing, organization 
and delivery of health services;
•  to describe accurately the process, content and implementation of health 
reform programmes;
•  to highlight common challenges and areas that require more in-depth 
analysis; and
•  to provide a tool for the dissemination of information on health systems 
and the exchange of experiences of reform strategies between policy-
makers and analysts in countries of the WHO European Region.
How to obtain a HiT
All HiTs are available as PDF files at www.healthobservatory.eu, where you 
can also join our listserve for monthly updates of the activities of the European 
Observatory on Health Systems and Policies, including new HiTs, books in 
our co-published series with Open University Press, Policy briefs, Policy 
summaries, and the Eurohealth journal.
If you would like to order a paper copy of a HiT, 
please write to:
info@obs�euro�who�int
The 
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Health Systems and Policies
are available at
www.healthobservatory.eu
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